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Summary 
 
High-risk human papillomaviruses (HPVs) are causative agents of cervical cancers. 
Expression of high-risk HPV E6 and E7 viral oncogenes is closely associated with the 
malignant transformation of infected keratinocytes. High-risk HPV E7 oncoprotein has 
been well studied for its ability to subvert repressive function of all pRB family 
members, thereby inducing potent transcriptional activation of S-phase genes. On the 
other hand, our group demonstrated for the first time that E7 functions prominently in 
transcriptional activation of mitotic genes in high-risk HPV-associated cervical cancer 
cells but the molecular mechanism by which E7 stimulates expression of mitotic genes 
has not been elucidated so far. Therefore, in this thesis, we first attempted to verify the 
impact of E7 on cell cycle regulatory program by conducting both siRNA-mediated 
gene depletion of E7 in HPV16-positive cervical cancer cell line and E7-overexpression 
studies in primary human fibroblasts. Transcriptome analyses in cervical carcinoma 
cells revealed a group of mitotic genes that is modulated by E7 independently of tumor 
suppressor pRB. Majority of these genes were not controlled directly by pRB-E2F 
regulatory axis. Instead, they were previously identified as direct targets of transcription 
factors B-Myb and FoxM1 whose expression is E2F-regulated and elevated in a variety 
of tumors. We have confirmed the biological functions of B-Myb and FoxM1 in 
cervical cancer cells via gene silencing assays. In light of previous reports showing the 
importance of E7, B-Myb and FoxM1 in regulation of mitotic genes, primary fibroblasts 
were co-transduced with retroviruses carrying E7 and B-Myb or FoxM1 respectively to 
ascertain if any synergistic crosstalk exists between them. This data uncovered that E7 
works in concert with B-Myb or FoxM1 to induce expression of endogenous mitotic 
genes and cell cycle in a cooperative manner. To further delineate how E7 participates 
in regulation of mitotic gene expression, a ChIP approach was employed to map in vivo 
  viii 
E7-DNA interactions. Strikingly, E7 was found bound to B-Myb- and FoxM1-
responsive promoters and this finding led us to investigate the possible association of 
E7 with transcriptional regulatory machinery controlling mitotic genes, including B-
Myb, FoxM1 and LIN9. Results obtained from a series of CoIP experiments showed 
that E7 associate with B-Myb, FoxM1 and LIN9, a member of MuvB subcomplex. It is 
conceivable that recruitment of E7 to promoters of mitotic genes further augments 
transactivation capacity of B-Myb and FoxM1, leading to aberrant expression of mitotic 
genes and chromosomal abnormalities. Collectively, our findings propose a novel pRB-
independent function of E7 in promoting oncogenic transformation, and shed light on 
the involvement of B-Myb/FoxM1/MuvB activator complex in cervical carcinogenesis. 
Dissecting the mechanism of E7-mediated transactivation of mitotic genes may help to 
identify novel therapeutic targets for combating HPV-associated carcinoma, for instance 
disruption of interaction between E7 and B-Myb/FoxM1/MuvB activator complex 
could probably aid in controlling malignant progression in conjunction with other 
conventional therapies.  
(464w) 
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Chapter 1: Introduction 
 
1.1 The biology of HPV 
1.1.1 HPVs and disease 
 
Human papillomaviruses (HPV) are icosahedral, non-enveloped particles, 
containing a small circular double stranded DNA that belong to the Papillomaviridae 
family. HPV infect proliferating basal epithelial tissues of specific anatomical location 
such as skin, mucosa of oral or genital area including uterine cervix. The viral infection 
may contribute to a wide variety of diseases and cancers, for example genital warts 
(condyloma accuminata), psoriasis, Epidermodysplasia Verruciformis (EV)-associated 
skin tumors, oropharyngeal cancers, genital adenocarcinoma, squamous cell carcinoma 
including vulvar and cervical carcinoma (uterine cervix) and etc.  
Currently more than 100 different types of HPVs have been characterized and 
HPV can be phylogenically classified into two main genera: Alpha and Beta according 
to the infected target cell types. HPV genotypes belonging to Alpha Papillomaviruses 
family are characterized by the ability to infect mucosal or anogenital epithelial cells 
whereas Beta Papillomaviruses share a tropism for the cutaneous epithelium. Genital 
HPV types are typically transmitted through sexual contact. The outcome of HPV 
infection at genital areas can lead to pathological changes ranging from benign lesions 
(such as condylomas/warts) for low-risk HPV types such as HPV6 and HPV11, to 
neoplasia and carcinoma for high-risk HPV types such as HPV16 and HPV18.  High-
risk HPVs are the main etiological agents of cervical cancer, which is the second most 
common cancer affecting women worldwide (World Health Organization, 2005) 
(Figure 1). The significance of HPV infection in cervical cancer was demonstrated in an 
epidemiological survey that showed the presence of their genome in more than 99% of 
these cancers, 70% of which were accounted for by high-risk HPV16 or 18 
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(Walboomers et al., 1999). HPV16 is the most frequent high-risk HPV type associated 
with cervical carcinoma whereas HPV18 is the most prevalent type to induce aggressive 
neoplastic progression such as in adenocarcinomas (Bosch et al., 1995). Cervical 
infection by HPVs is very common and the life-time risk of infection is about 80% in 
female population. The incidence of malignant progression is however not very high, 
about 1%, due to the protective immune response by which most infections are resolved 
efficiently (Parkin et al., 2005).   
Currently two prophylactic HPV vaccines have been developed for prevention 
of HPV infection and HPV-associated diseases especially cervical cancer. The 
recombinant vaccine produced by Glaxo Smith Kline (GSK) successfully elicits 
protective immunity against high-risk HPV16/18 whereas Merck generated a 
quadrivalent vaccine, Gardasil, which exhibits additional protection against benign 
condylomas caused by low-risk HPV6/11.  Recently, starting in 2004 or 2005, HPV 
vaccines have been widely accepted and implementation of HPV vaccination 
programme has been shown to increase worldwide, especially in developed countries 
with excellent results showing protection against HPV infection and subsequent cancer 
in an almost 10 years of retrospecific studies. In addition, it has been reported that the 
global vaccination against most prevalent high-risk type of HPV can theoretically result 
in 10-15% decrease in cancer risk within the female population (Zur Hausen, 2000). 
Nevertheless, so far these vaccines have no known therapeutic effect against pre-
existing HPV infection and are not designed to treat patients with HPV-associated 
disease, particularly cervical cancer. Furthermore the cost-effectiveness of the 
prophylactic vaccines needs to be re-evaluated before the vaccine can be applied 
globally and made to be available to women in developing countries. Currently HPVs of 
high-risk group inducing cervical cancer is yet a leading cause of cancer death in 
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women worldwide and therefore further investigation of the viral life cycle, host 
immune evasion following viral infection, mechanism underlying viral oncogenesis is 
crucially important in the development of efficient cancer therapy and drug treatment 













Figure 1. World age-standardized incidence rates of cervical cancer. 
Worldwide incidences of cervical cancer per 100,000 females (all ages), age-
standardized to the WHO standard population (Adapted from epidemiological study of 
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1.1.2 HPV genome and virus life cycle 
 

















HPVs infect the active proliferating cells of the basal layer of epithelial tissues 
through micro abrasions via interaction with attachment molecules followed by 
endocytosis. After gaining access to basal keratinocytes, HPV genomes are maintained 
in episomal form and the viral early genes (E) are expressed (Table 1). Following viral 
genome replication and mitotic division of infected cells, daughter cells migrate towards 
the epithelial surface to undergo stratification and differentiation. Within stratified 
upper layers of the epithelia, late viral genes (L) responsible for viral encapsidation are 
expressed for the formation of viral particles. The viral life cycle is inextricably coupled 
 
Viral proteins Molecular weight  Function 
Early genes (E) 
E1 68-85 kDa Helicase function;  
Essential for viral DNA replication  
E2 48 kDa Viral transcription factor;  
Essential for viral replication and control of 
gene transcription;  
Genome segregation and encapsidation; 
Control of the cell cycle and apoptosis 
E3 Unknown Function not known;  
present in only a few HPVs 
E1-E4 10-44 kDa Binding to keratins protein and results in 
disruption of cytoskeletal structure of the cell  
E5 14 kDa Interaction with EGF/PDGF receptor 
Transforming protein in some PVs 
E6 16-18 kDa Interaction with several cellular proteins; 
High-risk type E6 causes degradation of p53 
and activates telomerase 
E7 <10 kDa Interaction with several cellular proteins; 
Binding to pRB and pocket proteins to 
induce transactivation of E2F-dependent 
transcription 
E8-E2C 20 kDa Long distance transcriptional and replication 
repressor protein (only in some HPV types) 
Late genes (L) 
L1  57 kDa Major capsid protein 
L2 43-53 kDa Minor capsid protein 
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to the differentiation of epithelial cells and HPVs do not lead to lysis of infected host 
cells (Figure 2). Viruses exploit the host replication machinery for the viral genome 
amplification and the transforming activities of E6 and E7 oncoproteins retain the 
replicative ability of differentiated keratinocytes.  Mature progeny virions are released 
after assembly with the shedding of terminally differentiated surface epithelium 
















Figure 2. Schematic diagram of the morphological differences between normal and 
infected cervical epithelium.  
(A)  Representation of normal epidermis, nuclei are shown in blue.  
(B) Representation of HPV-infected epithelium of low-grade precancerous lesions 
indicated with differential expression of viral early genes. Here it was shown that viral 
replication is tightly coupled to normal stratification of keratinocytes (Adapted from 
Bellanger et al., 2011).  
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1.1.3 Malignant progression of infected keratinocytes 
 
The integration of high-risk HPV viral genome into host chromosome is found 
in a vast majority of high-grade squamous cells lesions and cervical carcinoma (Klaes et 
al., 1999) (Figure 3). This integration disrupts the coding region of HPV E1 and E2 
viral genes, which are the key regulators for DNA replication and viral genome 
expression. In addition, a prominent role of HPV E2 is to transcriptionally repress the 
expression of the E6 and E7 oncogenes, hence loss of E2 expression induces 







Figure 3. Integrated form of high-risk HPV18 viral genome.  
In most cancer cells, HPV viral genome is found in the integrated form. E2 ORF is 
disrupted as a result of integration, thereby leading to deregulated expression of E6 and 
E7 oncoproteins. 
 
In addition, compelling evidences have highlighted that the uncontrolled 
expression of E6 and E7 is the pre-requisite for the neoplastic progression of HPV-
infected cervical keratinocytes. This integration event therefore disrupts expression of 
some viral early genes, thereby impairing the productive life cycle of HPV but 
selectively triggering malignant transformation of cells constitutively expressing E6 and 
E7 (reviewed in Doorbar, 2006). This also causes progressively histological changes 
ranging from CIN1 (mild dysplasia) to CIN2 (moderate dysplasia) to CIN3 (high-grade 
dysplasia) to cancer then invasive carcinoma (zur Hausen, 2002) (Figure 4). As a 
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Figure 4. Disease progression from low-grade squamous intraepithelial lesion (LSIL), 
high-grade squamous intraepithelial lesion (HSIL) to cervical carcinoma (CaCx).  
The capacity of infected host to produce viruses is inversely correlated with clinical 
severity of disease. Following integration event, E6 and E7 oncoproteins are aberrantly 
expressed due to the loss of E2, a transcriptional repressor bound to LCR promoter. As 
a result, productive viral life cycle is markedly impaired and no virions can be found in 
cervical cancer. Expression of E4 is only found in differentiated cells (as shown in 
green) whereas cells undergoing active proliferation are E7-positive and labeled with 
red dots (Adapted from Doorbar et al., 2006).  
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1.1.4 Transcriptional regulation of viral oncogenes 
 
The HPV genome is a double-stranded circular DNA of approximately 8 Kbp in 
size. It encodes eight open reading frames (ORFs) comprised of the coding regions for 
early genes (E1, E2, E4, E5, E6 and E7), late genes (L1 and L2), and a non-coding Long 
Control Region (LCR) (Figure 5). The LCR is a transcriptional regulatory region 
containing the viral origin of replication and HPV early promoter, which governs viral 










Figure 5. Schematic representation of the HPV16 viral genome. 
 
High-risk HPV viral oncogenes are transcribed from the early promoter, P105, 
contained in the HPV18 LCR, in HeLa cells and the polycistronic mRNA can give rise 
to both E6 and E7 transcripts by alternative splicing. The gene expression of viral 
oncogenes is activated by binding of cellular transcription factors to an upstream 
enhancer core (reviewed in Thierry, 2009) which lies between nucleotide sequences 
7510 and 7740 of the HPV18 LCR with an overall length is around 230 bp. During the 
past two decades, many researchers have identified the trans-acting cellular factors 
implicated in the long control region (LCR) transcriptional activity of high-risk HPV16 
and HPV18 notably. A wide spectrum of transcription factors, including Sp1, AP-1, 
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NF1, KRF-1, Oct-1, Nucleolin, HMG-I(Y) has been reported to bind to cis-regulatory 
elements for transcriptional modulation of E6 and E7 promoter in HPV-associated 
cervical cancer cells (Figure 6) (Garcia-Carranca et al., 1988; Gloss et al., 1989; Offord 
et al., 1990; Mack et al., 1991; Hoppe-Seyler et al., 1992; Thierry et al., 1992; 
Bouallaga et al., 2000; Grinstein et al., 2002). Among these candidate proteins, AP1, 
which is also known as a heterodimer of two proto-oncogenes, Jun and Fos, has been 
suggested to be the major determinant in the stimulation of E6 and E7 transcription in 
HPV18-positive keratinocytes (Thierry et al., 1992).  
The functional significance of interplay between enhancer sequences and host 
cell factors has been well studied. Bouallaga et al. (2000) demonstrated that binding of 
the architectural protein HMG-I(Y) to the enhancer is required for the formation of high 
order nucleoprotein complex, which is named enhanceosome, on HPV18 enhancer site 
(Carey et al., 1998). This three-dimensional structure is tissue-specific, active mainly in 
human epithelial cells and keratinocytes and is responsible for the active recruitment of 
transcription factors to the LCR promoter. Notably, an abundant phosphoprotein, 
Nucleolin has been proposed as therapeutic target protein for HPV-18 positive cervical 
cancer patient due to its novel role of acting as a potentially specific activator of HPV18 
oncogene transcription (Grinstein et al., 2002). 
On the other hand, some regulators that act on the LCR of HPV18 and HPV16 
have been found to exert significant repressive effect on transcriptional activity of 
HPV18 LCR by interfering with the interaction between activator proteins and their 
corresponding binding sites in the LCR. For instance, reintroduction of the viral 
transcriptional repressor E2 protein into HeLa cells, a HPV18-associated cervical 
carcinoma cell line, consequently leads to down regulation of transcription of E6 and E7 
oncogenes and subsequent suppression of cell growth (Dowhanick et al., 1995; 
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Desaintes et al., 1997). It has also been shown that the phenomenon of G1-arrest, 
senescence and apoptosis induced by E2 in HPV-positive cervical carcinoma cell lines 
can be attributed to the reactivation of p53 target genes and repression of E2F-
responsive mitotic or S-phase genes due to E6/E7 repression (DeFilippis et al., 2003; 
Desaintes et al., 1997; Goodwin et al., 2000; Hwang et al., 1996; Thierry et al., 2004; 
Teissier et al., 2007). Also, there has been growing interest in identifying the molecules 
or compounds that are able to repress activity of key activator, such as AP-1, in order to 
develop the therapeutic treatment for HPV-associated malignant lesions or cervical 
carcinoma. For instance, recent findings showed that heparin disrupts the interaction 
between AP1 and its DNA binding sites and consequently renders it unable to stimulate 
transcriptional activity of the HPV18 LCR efficiently (Villanueva et al., 2006).  
Nevertheless these promoter and enhancer studies implied that the number and 
diversity of cellular factors that contribute to the transcriptional regulation of HPV18 or 
HPV16 oncogenes are probably not entirely discovered. Therefore we cannot rule out 
the possibility that there are a variety of cellular proteins having crucial importance for 
transcriptional modulation of E6 and E7 oncogenes, which remained to be identified. As 
an example, our group has recently demonstrated that E2F5, a typical cell cycle 
transcriptional repressor, stimulates E7 gene expression in HPV18-associated cervical 
cancer cells. We concluded that this repressor-activator switch accounts for aberrant 
expression of HPV oncogenes and higher transforming potential of HPV18 among other 












Figure 6. Schematic representation of the HPV18 long control region (LCR).  
Putative binding sites for cellular and viral proteins were represented along the LCR of 
HPV18, which is composed of three functionally distinct regions: a proximal region, 
containing the early promoter P105 that is devoid of intrinsic transcriptional activity; an 
upstream tissue-specific enhancer of 230 nucleotides between nucleotides 7510 and 
7740 and a 5' region dispensable for the P105 transcriptional activation (Adapted from 
Thierry, 2009).  
 
1.1.4.1 Transcriptional repressor E2 
 
The viral protein E2 has a molecular weight of approximately 50 kDa and 
consists of a N-terminal transactivation domain (TAD) and a carboxy-terminal DNA-
binding domain (DBD). E2 proteins form homodimers and act as transcriptional 
repressor through interaction of E2 DBD with four palindromic E2-binding sites within 
the LCR of HPV16 or HPV18 viral genomes. On the other hand, E2 is able to form a 
complex with E1 via N-terminal TAD, thus allowing them to work cooperatively for 
viral genome replication (Figure 7). During malignant progression, E6 and E7 viral 
oncoproteins are aberrantly expressed due to the integration of the HPV DNA into host 
genome by which E2 ORF is disrupted (Figure 8). Therefore E2 expression is virtually 
absent in most cervical cancer cell lines (reviewed in Thierry, 2009 and Bellanger et al., 
2011). On the other hand, our lab showed for the first time the immunohistochemistry 
(IHC) staining of clinical specimens ranging from low-grade (CIN1) to high-grade 
(CIN2/3) and malignant cervical carcinoma using our in-house HPV16 E2 antibodies. 
Interestingly, IHC staining of CIN1 samples revealed that E2 is expressed in the 
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intermediate and upper layers but not in the basal layers and staining of E2 coincides 
well with the differentiation marker K13 and amplification of viral genome. For CIN2 
and CIN3 sections, the expression of E2 is restricted to the upper layers and it is 
mutually exclusive with staining pattern of p16INK4a (also known as cyclin-dependent 
kinase inhibitor 2A), p63, or Ki67. Currently, p16INK4a is employed as a surrogate 
marker for E7 expression but only high-grade lesions and cervical carcinoma display 
elevated E7 expression. Our data indicated that E2 staining allows clear discrimination 
between normal epithelium and infected low-grade precancerous lesions, raising the 
possibility that E2 could be developed as a diagnostic marker for HPV infections at 
early stages (Xue et al., 2010).  
Notably, reintroduction of E2 into HPV-associated cervical carcinoma cells 
gives rise to suppression of E6- and E7-stimulated transformation, leading to a strong 
cell cycle arrest at G1 phase and cellular senescence. In addition, previous microarray 
studies from our group demonstrated that majority of p53 and/or p63 target genes was 
found to be activated whereas repression of cell cycle genes, including mitotic genes 
and E2F-regulated S-phase genes was detected in HeLa cells, a HPV18-associated 
cervical adenocarcinoma cell line, upon E2-mediated repression of E6 and E7 
respectively (Teissier et al., 2007; Thierry et al., 2004) (Figure 8). Taken together, all 
these findings strongly suggest that E2 plays a role as a tumor suppressor protein in 
HPV-positive cervical cancer cells.  
Despite anti-proliferative properties of E2, our group reported that E2 possess 
the abilities to interfere with genomic integrity through inhibitory interaction with 
Anaphase-Promoting Complex (APC), which is an E3 ubiquitin ligase responsible for 
degradation of substrates involved in the metaphase-anaphase transition (Bellanger et 
al., 2005). We found that E2-expressing cells exhibit chromosomal abnormalities such 
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as aneuploidy and supernumerary centrosomes and hence these cells are more prone to 
develop cancer (Bellanger et al., 2005).  Apart from inactivation of APC, Bellanger et 
al. also uncovered a novel relationship between E2 and Skp2 oncogene. Deregulation 
expression of Skp2 is always associated with a wide variety of cancers because Skp2 is 
capable of inducing aberrant proliferation by targeting p21 and p27, CDK inhibitors, for 
SCF
Skp2
-mediated polyubiquitination followed by proteasomal degradation. Our lab was 
the first to show the stabilization of Skp2, also known as a substrate of APC, through 
E2-mediated sequestration of two APC co-activators, Cdh1 and Cdc20 (Bellanger et al., 
2005; Bellanger et al., 2010). This paper also revealed a negative feedback loop 
between E2 and Skp2 owing to the fact that E2 itself is marked for degradation by Skp2 
(Bellanger et al., 2010). In agreement with our studies, there is growing number of 
papers highlighting a role of E2 in the early stages of malignant transformation. For 
instance researchers proved the ability of E2 to drive skin tumor formation in HPV8 E2 
transgenic mice (McLaughlin-Drubin and Munger, 2008; Pfefferle et al., 2008).  
Collectively, we do not exclude the possibility that E2 plays a pivotal role in 
cancer initiation, although concurrently it displays characteristics of a tumor-suppressor 
protein through reversal of transforming phenotypes caused by E6 and E7 oncoproteins 


















Figure 7. Schematic diagram of E2 protein structure.  
N-terminal module is connected with C-terminal DNA binding domain via a flexible 
hinge region. Interaction between E1 and E2 is mediated through transactivation 
domain of E2 whereas C-terminal end is required for formation of E2 homodimer and 







































Figure 8. Schematic representation of p53- and pRB-regulated pathways in the absence 
or presence of E2 in HPV-positive cervical carcinoma cells.  
(A) LCR promoter governs expression of E6 and E7. Degradation of p53 and pRB 
accounts for major transforming activities of E6 and E7 respectively. (B) 
Reintroduction of E2 into HPV-associated cervical cancer cells represses transcription 
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1.1.5 HPV oncoproteins 
 
Owing to integration of viral genome into host genome, there is no viral early 
gene found to be expressed in cervical cancer cells except E6 and E7 oncogenes. 
Following the disruption of E2 ORF, E6 and E7 are highly expressed in cervical 
carcinoma and playing pivotal roles in cervical carcinogenesis.  The best characterized 
transforming properties of E6 and E7 oncogenes are their capacity to abrogate the tumor 
suppressor function of two key cell-cycle checkpoint proteins, p53 and pRB 
respectively (Figure 9). Besides, It was documented that E6 and E7 oncoproteins are 
capable of promoting deregulated proliferation, cellular immortalization and malignant 
transformation in transfected keratinocytes, notably by P. Howley’s group in the 1990s 
(Munger et al., 1989).  
Interestingly, recent works suggested that HPV E5 might have oncogenic 
function in early stage of transformation despite the absence of E5 in cervical cancer 
cells. This is further supported by increasing reports showing the ability of E5 to 
interact with a wide spectrum of host proteins. In addition, BPV E5 was described as 
one the most prominent oncoproteins in the BPV-mediated cellular transformation. 
However, up-to-date, the role of E5 in cervical carcinogenesis is much less defined than 
that of E6 and E7. In light of these new findings revealing oncogenic potential of E5, 
more studies needed to be done to have a deeper understanding of how E5 contributes to 





















    











































Key oncogenic activities of E6 and E7 
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1.1.5.1 E5 
 
E5 is a relatively small protein of only 83 amino acids and approximately 10kD 
in size. E5 possesses a hydrophobic domain at its N-terminal end and hence it is 
primarily localized in membrane compartments of endoplasmic reticulum (ER), nuclear 
envelope and Golgi apparatus (GA). E5 proteins can only be detected in precancerous 
cervical lesions including low-grade squamous intraepithelial lesions (LSILs) and high-
grade SILs (HSILs), however its expression is diminished or absent in invasive 
squamous cervical carcinoma due to a disruption of E5 ORF following integration of 
HPV viral DNA into host genome (reviewed in Ganguly et al., 2012). Therefore E5’s 
role in cervical carcinogenesis remained subtle. Notwithstanding, recent findings 
showing the ability of E5 to interact with a wide spectrum of host proteins have shed 
light on oncogenic potential of E5 during early stages of cellular transformation.  
The acquisition of extensive proliferative capacity is known as hallmark of 
cancer. E5 is capable of stimulating cellular proliferation through dysregulation of 
EGFR signaling pathway. It was shown that E5 binds vacuolar proton-ATPase (V-
ATPase) to impinge on receptor internalization and endosomal acidification, leading to 
increased expression of EGFR at plasma membrane (Straight et al., 1995). Besides, 
MAPK signaling cascade, the main downstream component of EGFR pathway, can be 
activated by E5 in an EGFR-independent manner. The EGFR-independent activation is 
mediated by recepter tyrosin kinase and protein kinase C (PKC) (Crusius et al., 1997; 
Gu et al., 1995). 16E5 stimulates expression of c-fos and c-jun via MAPK activation, 
thereby resulting in a strong driving force for cell cycle progression and elevation in 
expression of viral oncogenes E6 and E7. In addition to MAPK activation, E5 possesses 
the ability to augment cell proliferation by enhancing ET-1-induced G protein-coupled 
endothelin receptor (ETA) pathway activation (Venuti et al., 1998). To further promote 
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cell growth, E5 is able to overcome cell cycle arrest mediated by p21CIP1 and p27KIP1 
through repression of the p21 promoter and destabilization of p27 proteins (Tsao et al., 
1996; Pedroza-Saavedra et al., 2010). Upon infectious insults, cells appear to be more 
prone to cell death but E5 contributes to evasion of apoptosis using a mechanism 
distinct from E6. It renders infected keratinocytes insensitive to ligand-mediated, 
extrinsic apoptosis by decreasing expression of Fas ligand and disrupting the formation 
of death-inducing signaling complex provoked by TRAIL (Das et al., 2000; Kabsch et 
al., 2002). E5 can also protect infected cells against anti-viral defense mechanism via 
down-regulation of several proteins related to ER stress, like cyclooxygenase-2 (COX-
2), XBP-1 and IRE1a. This inhibition of ER stress pathway prevents cellular anti-viral 
response such as apoptosis in order to support viral replication and persistence (Tardiff 
et al, 2004). E5 further abrogates apoptotic response in infected keratinocytes by 
inducing a marked decrease in Bax proteins as a result of sequential activation of 
EGFR, MAPK, COX-2 and PGE2 expression. It is noteworthy that EGFR-MAPK 
signaling cascade and stimulation of COX-2 and PGE2 were reported to be involved in 
angiogenesis (Oh et al., 2009). E5 is also found to account for the upregulation of 
VEGF expression. Taken together, these articles strongly suggest a role of E5 in 
exacerbating angiogenesis.  
Some research findings also demonstrated that E5 is an important oncoprotein to 
evade immuno-surveillance for establishment of persistent HPV infection in human 
keratinocytes. Down-regulation of major histocompatibility (MHCII) complex on cell 
surface in response to interferon gamma (IFN-γ) treatment was observed in E5-
expressing keratinocytes (Zhang et al., 2003). Furthermore E5 impinges on CD1d 
trafficking in ER and renders it more susceptible for ubiquitin-mediated proteolysis 
(Miura et al., 2010).  
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Collectively, E5 is not only an accessory protein to aid in E6- and E7-driven 
carcinogenesis, but rather a dominant player in the initiation of malignant 
transformation. Therefore more studies need to be carried out to gain further insights 
into deregulated cellular pathways involving E5 in order to unveil novel oncogenic 
















Figure 10. Oncogenic properties of E5. 
Besides E6 and E7, E5 also contributes to transforming capacity of HPV through 
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1.1.5.2 E6 
 
HPV16 E6 consists of 151 amino acids and its protein size is approximately 
18kDa. E6 has two zinc finger domains comprising four C-X-X-C motifs. The 
sequences required for the interaction with protein bearing LXXLL motif lies within the 





Figure 11. Schematic structure of HPV16 E6 proteins.  
E6 associates with E6AP via second zinc finger domain whereas interaction between 
PDZ proteins and E6 requires C-terminal end of E6 (Adapted from McLaughlin-Drubin 
et al., 2009). 
 
The best-known binding target of E6 is E6AP (E6-Associated Protein), a cellular 
E3 ubiquitin-ligase, and their association is also LXXLL motif-dependent. High-risk E6 
protein targets the degradation of the p53 tumor suppressor through E6AP by forming a 
tripartite complex that ubiquitinates p53 and flags it for degradation by the proteasome 
(Huibregtse et al., 1993a; Huibregtse et al., 1993b; Scheffner et al., 1993; Werness et 
al., 1990). High-risk viruses exploit this mechanism to counterbalance the activation of 
p53 as a consequence of the upregulation of p14ARF by E7 (Figure 14). As a result, E6 
renders severely damaged cells unresponsive to p53-induced apoptosis and growth 
arrest. E6 enables the infected cells to bypass the G1/S and G2/M checkpoints and leave 
them to proceed in the cell cycle unchecked, thereby leading to accumulation of 
genomic defects. Besides, E6 is capable of inhibiting p53-mediated transactivation in an 
E6AP-independent manner. It was documented that p53 requires p300-mediated 
acetylation to exert regulatory effect on its target genes and therefore sequestration of 
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p300 away from p53 by E6 significantly impairs transactivation activity of p53. 
Additionally, E6 further impinges on transcriptional program governed by p53 through 
targeting TIP60, a chromatin-modifying factor necessary for activation of p53-
responsive apoptotic genes, for ubiquitin-mediated proteolysis (Jha et al., 2010; Sun et 
al., 2010).  
Nevertheless E6 is able to exhibit potent anti-apoptotic properties independently 
of p53. For instance, direct binding of E6 with pro-apoptotic proteins, Bak, 
accompanied by destabilization of Bak confers resistance to apoptosis (Thomas and 
Banks, 1999). E6 interferes not only with Bak-mediated intrinsic apoptotic signaling, 
but also with extrinsic apoptotic stimuli triggered by tumor necrosis factor (TNF), TNF-
related apoptosis inducing ligand (TRAIL) or Fas ligand (Fas-L) (Filippova et al., 2002; 
Filippova et al., 2004; Garnett et al., 2006). E6 binding to TNF-receptor 1 (TNFR-1) 
abrogates the interaction between TNFR-1 and TNFR-associated death domain 
(TRADD) adaptor protein, thus impeding TNF-elicited cell death (Duerksen-Hughes et 
al., 1999). Moreover, FADD adaptor molecule and executioner caspase, caspase-8, 
which are important mediators downstream of all death receptors, are described as 
substrates for E6- and ubiquitin-dependent proteolytic system (Filippova et al., 2007; 
Garnett et al., 2006). In addition, E6-induced NF-kB activation has been shown to 
increase expression of an inhibitor of apoptosis (IAP) proteins, cIAP2 (James et al., 
2006b). Overall, E6 can markedly attenuate multiple death signaling pathways by 
different means in order to provide strong cytoprotective effects on HPV-infected 
keratinocytes.  
Besides its anti-apoptotic effects, E6 can interfere with signal transduction 
pathway involved in cell adhesion by interacting with several cellular proteins 
expressing PDZ motifs via C-terminal PDZ-binding domain and directs them for 
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ubiquitin-mediated proteolysis (Kiyono et al., 1997; Lee et al., 1997; Lee et al., 2000; 
Nakagawa and Huibregtse, 2000; Watson et al., 2003). These PDZ proteins include 
human homologues of Drosophila melanogaster disc large and scribble tumour 
suppressors (hDlg and hScrib), post-synaptic density protein 95 (PSD95), multiple PDZ 
domain-containing protein 1 (MUPP1), membrane-associated guanylate kinase (MAGI- 
1, -2, -3), GAIP-interacting protein c-terminus (GIPC), PALS-1 associated tight 
junction protein (PATJ), protein tyrosine phosphatase N3 and protein tyrosine 
phosphatase N13 (PTPN3 and PTPN13) (reviewed in Beaudenon and Huibregtse, 
2008). This oncogenic function accounts for invasiveness of HPV-associated cervical 
carcinoma by inducing extracellular matrix remodeling and loss of cell polarity. 
Recently, Hoover et al. discovered a novel relationship between E6 and activation of 
mitogen-activated protein kinase (MAPK) cascade (Hoover et al., 2009), which is 
triggered by E6-dependent destabilization of PTPN13 (Jing et al., 2007; Spanos et al., 
2008a). PTPN3 acts as a negative regulator of growth factor receptor signaling pathway 
and its main function is to remove phosphate groups from tyrosine residues on proteins. 
Hence E6 causes deregulated MAPK activity, promoting aberrant cell growth and 
malignant transformation (Spanos et al 2008b).  
Another important role of E6 is its ability to activate telomerase activity but the 
underlying mechanism remains under debate. Telomerase is composed of two subunits, 
the catalytic protein component, termed telomerase reverse transcriptase (TERT) and 
the telomerase RNA component (TERC), which serves as a template for extension of 
the telomere repeats. E6 has been reported to up regulate human telomerase reverse 
transcriptase (hTERT) transcription via two E-box cis-elements (Gewin and Galloway, 
2001; Liu et al., 2005; Oh et al., 2001; Veldman et al., 2001). Interestingly, this E6 
function also relies on E3 ubiquitin ligase activity of E6AP because it was demonstrated 
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that E6 and E6AP are implicated in degradation of NFX1-91, a transcriptional repressor 
of hTERT (Gewin et al., 2004; Xu et al., 2008). This prevents the shortening of 
telomeres with each successive cell division, thereby allowing cells to overcome 
replicative senescence and achieve limitless replicative potential (Fehrmann and 
Laimins, 2003). However, E6 has to work in cooperation with E7 in order to induce cell 
immortalization. 
Furthermore, E6’s abilities to bind and target E6-targeted protein 1 (E6TP1), 
tuberin and G protein pathway suppressor 2 (Gps2) for proteosomal degradation were 
shown to give rise to an aberrant G protein-coupled receptor signaling pathway (Gao et 
al., 2002; Gao et al., 1999; Lee, Wooldridge, and Laimins, 2007; Lu et al., 2004; 
Degenhardt and Silverstein, 2001b).  Previous studies also revealed that aberrant 
overexpression of E6 and E7 can result in chromosomal abnormalities. For instance 
high-risk HPV18 E6 has been reported to associate with minichromosome maintenance 
7 (MCM7), a component of MCM subcomplex involved in regulation of DNA 
replication, and subsequently induce degradation of MCM7 via ubiquitin-mediated 
proteolysis in an E6AP-dependent manner (Kukimoto et al., 1998; Kuhne and Banks, 
1998). In addition to the perturbation of DNA replication, E6 is able to impede single-
strand DNA break repair by interacting with X-ray repair complementing defective 
repair in Chinese hamster cells 1 (XRCC1) and O(6)-methylguanine-DNA methyl- 
transferase (MGMT) (Iftner et al., 2002; Srivenugopal and Ali-Osman, 2002). These 
three proteins that are key players in ensuring chromosome integrity and E6 abrogates 
their functions to induce accumulation of genomic instability, thereby contributing 
towards malignant progression.  
Evasion of interferon (IFN) signaling pathway is a common strategy adopted by 
viruses like HPV to avoid immune clearance and maintain viral persistence. E6 was 
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found to attenuate the expression of Type I IFN via direct association with Tyrosine 
Kinase 2 (Tyk2) of Janus Kinase (Jak) - signal transducers and activators of 
transcription (STAT) pathway and IFN regulatory factor-3 (IRF-3) by which the signal 
transduction and induction of IFN-β are abrogated (Li et al., 1999; Ronco et al., 1998).  
Interestingly, apart from p53, high-risk HPV E6 was reported to account for 
degradation or inactivation of two p53 homologues, p63 and p73 (Ben Khalifa et al., 
2011; Park et al., 2001). Our lab demonstrated for the first time that E6 can shorten the 
half-life of TAp63β isoform of the p63 transcription factor in HPV-positive cervical 
cancer cells, in turn, dampening the expression of TAp63β-regulated genes which are 
closely linked to cell adhesion pathway (Ben Khalifa et al., 2011). Our findings together 
with previous reports showing E6-mediated degradation of PDZ proteins indicated a 
pivotal role of E6 in disrupting focal adhesion and consequently trigger anchorage-
independent growth of cervical cancer cells.  
In summary, E6 is capable of causing a wide spectrum of cellular perturbations 
such as inhibition of apoptosis, disruption of cell adhesion, telomerase activation, 
abrogation of anti-viral immune response, genomic instability, p53 inactivation, 
aberrant GPCR-mediated signal transduction and epithelial dedifferention (Figure 12). 
  















Figure 12. Association of E6 with host cellular proteins perturbs a multitude of cellular 
processes. 
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1.1.5.3 E7 
 
E7 proteins consist of 98 amino acids (aa) but SDS–polyacrylamide gel 
electrophoresis usually gives an apparent molecular weight of 18 kD which is bigger 
than expected (~11kD), probably owing to its high content of acidic residues (Smotkin 
and Wettstein, 1986; Armstrong and Roman, 1993). E7 is composed of three functional 
domains, Conserved Region 1 (CR1), CR2 and CR3 (Figure 13). Notably, CR1 and 
CR2 are commonly present in both E1A of adenovirus and large T antigen of simian 
virus 40 (SV40) (Phelps et al., 1992; Phelps et al., 1988). CR1 domain is responsible 
for pRB-independent cellular transformation whereas E7 possesses a Leu-X-Cys-X-Glu 
(LXCXE) motif, a pRB-binding site, within CR2 domain (Figure 13). Nevertheless it 
was documented besides LXCXE motif, CR1 and CR3 are also involved in E7-
dependent destabilization of pRB-related p107 and p130 proteins (reviewed in 
Klingelhutz and Roman, 2012) (Figure 13). It is interesting to note that structure of CR3 
region of E7, which is a unique fold that has not been found in cellular proteins so far, is 









Figure 13. Schematic representation of E7 structure.  
(A) LXCXE motif is required for the interaction between E7 and pocket proteins 
whereas CR1 domain in E7 is involved in Cul2-dependent ubiquitin-mediated 
proteolysis of pRB (Adapted from McLaughlin-Drubin et al., 2009).   
(B) Crystal structure of CR3 region of HPV1A E7. HPV1A E7 forms homodimer via 
CR3 domain and the bound zinc atoms are labeled in red (Adapted from Liu et al., 
2006). 
A B 
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E7 induces aberrant cell proliferation by subverting the repressive function of 
hypo-phosphorylated pRb proteins and disrupting E2F-Rb complexes. E7 can target 
pRb and its related pocket protein family members, p107 and p130 for ubiquitin-
mediated proteolysis mainly through LXCXE motif within CR2 (Zhang et al., 2005; 
reviewed in McLaughlin-Drubin et al., 2009) and liberates E2F transcription factors to 
activate transcription of S-phase genes for cell growth and proliferation. In normal cells, 
cell cycle restriction point, also known as G1/S transition state, is under the surveillance 
of tumor suppressor retinoblastoma protein, pRb. During early G1 phase, in the absence 
of growth-stimulating factors, pRb is in a hypo-phosphorylated form and actively 
sequesters E2F activators to repress the expression of E2F responsive cellular genes. 
Upon sequential phosphorylation by Cdk4,6/cyclin D, Cdk2/cyclin E and Cdk2/cyclin 
E, hyper-phosphorylated-pRb is non-functional and thereby leads to trans-activation of 
E2F target genes to induce cellular proliferation and S-phase entry. However pRb is 
able to regain its tumor suppressor function to mask transcriptional activation domains 
of E2F activators via dephosphorylation in late M phase. In high-risk HPV-infected 
cervical keratinocytes, E7 inactivates pRb directly and render the cells unresponsive to 
external growth stimuli, thereby attenuating the fine regulatory pathways in cell cycle. 
Despite having the same sequence motif LXCXE within conserved region 2 (CR2) 
domain, HPV16 E7 but not Ad E1A or SV40 TAg, is capable of inducing proteasomal 
degradation of pRB and this oncogenic function of E7 relies on E3 ubiquitin ligase 
activity of Cullin 2-containing SKP-CUL-F-box protein (SCF) complex (Huh et al., 
2007).   
The oncogenic function of E7 to deregulate multiple cellular pathways of 
differentiation, proliferation, growth arrest, apoptosis and mitosis is not solely 
dependent on the binding to pRb proteins but also mediated by interaction with 20 or 
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more different nuclear and cytoplasmic target proteins. A plethora of E7 interaction 
partners have been identified, including cyclin A, CDK2, cyclin-dependent kinase 




, transcriptional coactivators CBP/p300, pCAF, 
TBP and chromatin remodeling enzymes, for example histone deacetylases and histone 
acetyl transferases, transcription factors such as E2F1, E2F6 and MPP2 (also known as 
FoxM1), nuclear mitotic apparatus protein (NuMA), γ-tubulin, IFN regulatory factor 1 
(IRF1), p600 and etc (Dyson et al., 1992; Tommasino et al., 1993; Avvakumov et al., 
2003; Bernat et al., 2003; Brehm et al., 1999; Funk et al., 1997; Huang et al., 2002; 
Hwang et al., 2002; McLaughlin-Drubin et al., 2008; Lüscher-Firzlaff et al., 1999; 
Nguyen and Munger, 2009; Nguyen et al., 2007; Barnard and McMillan 1999; Huh et 















Figure 14. Interactions between E7 and cellular proteins. 
E7 interacts with a plethora of cellular proteins and perturbs numerous cellular 
processes thereby promoting oncogenic transformation (Adapted from Moody and 
Laimins, 2010). 
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E7 is known as a potent inducer of proliferation owing to its multitude of 
abilities to attenuate cell cycle controls and augment expression of genes necessary for 
cell cycle progression. For instance E7 retain proliferative capacity of infected 





, which act as negative regulators of cell cycle and key downstream mediators of 
cell cycle arrest in response to differentiation signals, p53 activation upon DNA 
damages and TGF-β induced growth inhibition.  
An important hallmark of epithelial-mesenchymal transition (EMT) is down-
regulation of E-cadherin and this molecular characteristic is commonly observed in a 
wide variety of human solid tumors, including cervical carcinoma. The ability of E7 to 
activate DNMT1 (DNA methyltransferase I) via direct interaction, contributes to 
repression of E-cadherin in transformed keratinocytes (Burgers et al., 2007; Caberg et 
al., 2008). Consequently to the loss of cell-cell adhesion molecules such as E-cadherin, 
E7 expression increases tumor cell migration, invasion and metastatic potential. 
Nevertheless detachment of epithelial cells from extracellular matrix triggers caspase-
mediated apoptotic program, also known as anoikis, to prevent anchorage-independent 
growth and metastatic formation (Frisch and Screaton, 2001). A pRB-binding factor as 
well as an E3 ubiquitin ligase, which is a component of the N-end rule pathway, p600, 
is involved in the acquisition of resistance to anoikis, a pre-requisite for cancer 
progression (Tasaki et al., 2005). It was demonstrated that E7 also binds p600 and 
hence this interaction accounts for E7-mediated anchorage-independent growth, thereby 
promoting cellular transformation (DeMasi et al., 2007; Huh et al., 2005).  
Interestingly, a wide spectrum of chromatin-associated proteins and transcription 
regulators were previously documented as binding partners for E7. For example, 
Lüscher-Firzlaff et al. showed that co-recruitment of both E7 and FoxM1 to FoxM1-
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responsive elements augmented transactivation capacity of FoxM1 based on their 
results obtained from in vitro luciferase reporter assays (Lüscher-Firzlaff et al., 1999). 
E7 also associates with E2F1 to transactivate promoters of S-phase genes in a pRB-
independent manner (Hwang et al., 2002). Besides acting as a co-activator, E7 can also 
negatively impact on activity of transcription factor E2F6 by direct binding. E2F6 is 
known as an important component of polycomb group protein (PcG)-containing 
repressive complex and hence overexpression of E7 severely impaired formation of 
E2F6-associated PcG repressive bodies (McLaughlin-Drubin et al., 2008).  
In addition to interacting with transcription factors, E7 is able to modulate 
expression of cellular genes through chromatin remodeling. Histone deacetylases 
(HDAC) is described as a chromatin-modifying enzyme responsible for the removal of 
acetyl groups from lysine residues of histones, which in turn renders chromatin less 
accessible to transcription factors. Previous studies revealed that E7 can interact directly 
with Mi2, a constituent of HDAC NuRD complexes to de-repress transcription of genes 
favouring cell growth (Brehm et al., 1999). A recent work demonstrated that E7 binds 
and sequesters HDAC away from hypoxia-inducible factor 1 (HIF-1) and this 
association releases HIF-1 from HDAC inhibition, allowing HIF-1-driven 
transcriptional activation of pro-angiogenic genes, such as vascular endothelial growth 
factor (VEGF), carbonic anhydrase 9 (CA9), thrombospondin-1 (TSP1) and 
phosphoglycerate kinase 1 (PGK1) (Bodily et al., 2011).  
Furthermore E7 is involved in induction of two histone demethylases, KDM6A 
and KDM6B. Increased expression of KDM6A and KDM6B leads to drastic reduction 
in histone H3 lysine 27 trimethylation (H3K27me3), which is an epigenetic mark 
required for the recruitment of Polycomb Repressive Complex (PRC) to inactivate 
transcription of target genes (McLaughlin-Drubin et al., 2011; Schwartz et al., 2007). 
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PRC negatively regulate the expression of p16INK4A, a CDK4/6 inhibitor, and 
Homeobox (HOX) genes which are always associated with angiogenesis, epithelial-to-
mesenchymal transition (EMT) and carcinogenesis (Serrano et al., 1997; Shah et al., 
2010). Therefore E7-induced diminished H3K27me3 signals further supports aberrant 
proliferation and cellular transformation. 
Like E6, E7 is similarly essential for evasion of host immune-surveillance 
through attenuation of IFN- or TNF-dependent-signaling. This activity is mediated by 
association of E7 with IFN regulatory factor 1 (IRF-1) and consequently E7 abrogates 
IRF-1-dependent expression of anti-viral genes implicated in anti-viral response, 
including IFN, monocyte chemotactic protein-1 (MCP1), antigen peptide transporter 1 
(TAP1) (Park et al., 2000; Um et al., 2002). Besides impinging on IFN-mediated anti-
viral response, E7 is also capable of rendering HPV-infected kerationcytes resistant to 
tumor necrosis factor hypoxia inducible factor  (TNF-). TNF is produced by 
cytotoxic T cells and it potently stimulates apoptosis for elimination of virus-infected 
cells. Thompson et al. demonstrated that E7 perturbs TNF-mediated pro-apoptotic 
signaling and caspase 8 activity in order to protect HPV-infected cells from TNF-
induced killing (Thompson et al., 2001).   
Altogether, these studies revealed that the multitude of E7 protein partners, 
which are independent of pRb, allows it to regulate many important cellular processes, 
including proliferation, senescence, DNA damages and host immunity. Besides, recent 
research depicted that E7 also play a critical role in inducing chromosomal aberration 
and aneuploidy (Duensing et al., 2000; Pett et al., 2004; Winkler et al., 1984).  It has 
been noted that these oncogenic effects are necessary but not sufficient to trigger the 
progression to invasive cervical carcinoma. The accumulation of secondary genetic 
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changes throughout the persistent infection period is the key event to trigger HPV-
mediated oncogenesis.  
A series of recent papers have demonstrated that E7 abrogates mitotic spindle 
checkpoint through direct protein-protein association with centrosomal proteins and 
kinetochore complexes. For instance E7 causes delocalization of dynein from mitotic 
spindles and this activity is mediated through binding to nuclear and mitotic apparatus 
protein-1 (NuMA) (Nguyen and Munger, 2009). NuMA and dynein are key players in 
maintaining epithelial polarity and hence it was speculated that the interaction of E7 
with NuMA/dynein networks is able to perturb normal stratification process of 
epithelium, favouring expansion of infected basal cells for viral genome amplification 
and persistence of infection. In addition to NuMA, it was documented that the 
association of E7 with γ-tubulin via sequences that overlap with LXCXE motif, 
accounts for a dramatic reduction in the amount of γ-tubulin recruited to mitotic 
spindles, thereby leading to centrosomal abnormalities. Lately, Korzeniewski et al. 
identified Polo-like kinase 4 (PLK4) as a transcriptional target gene of high-risk HPV 
E7 (Korzeniewski et al. 2011). PLK4 plays a pivotal role in ensuring proper centriole 
amplification because elevated expression of PLK4 mRNA is always associated with 
centriole overduplication. It was also suggested that E7 may also contribute to post-
transcriptional modification of PLK4 by which stability of PLK4 proteins is enhanced, 
resulting in centriole multiplication. Collectively, these E7-mediated events account for 
genomic instability that predisposes to the development of cancer. 
The central role played by E7 in cell cycle progression and malignant 
transformation points that the novel factors that regulate the transforming activity of E7 
deserve scrutiny in attempts to develop specific therapeutic means to combat cervical 
cancer. 
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1.2 Cell cycle regulatory network 
1.2.1 Transcriptional regulation of G1/S genes 














Figure 15. Schematic representation of the E2F family 
 
All E2F transcription factors are pivotal for controlling the expression of genes 
required for cell-cycle entry and DNA synthesis (Dyson, 1998). There are eight E2F 
family member genes that have been identified so far (Figure 15). E2F member proteins 
can be further divided into three subgroups according to their transcriptional roles on 
target gene promoters. E2F transcriptional activators include E2F-1, E2F-2, E2F-3 and 
this subgroup is highly expressed during late G1 and early S phase. While another 
subgroup comprising E2F-4 and E2F5, act primarily as transcriptional repressors and 
their expression is constitutive throughout the cell cycle. The function of a third 
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target genes in the absence of pRb binding. E2Fs 1-6 require the formation of 
heterodimers with DP transcription factor and this interaction can enhance the DNA 
binding affinity of E2F subunit. In addition, most of E2F transcription factors are 
negatively regulated by binding to pocket proteins (Figure 16). Transcriptional 
activators such as E2F-1, E2F-2, E2F-3 form a complex with pRb during G1-phase 
whereas repressor complexes between E2F-4, E2F-5 and p107 or p130 are 
predominantly found in quiescent and early G1-phase cells (Figure 17) (Lees et al., 
1993; Zhu et al., 1993; Cobrinik et al., 1993). Upon pocket protein binding, the 
transcriptional activation domains at the carboxyl terminus of E2Fs 1-5 are blocked and 
it allows the recruitment of a variety of chromatin modifier proteins and remodeling 
factors to the promoters of E2F-responsive genes.  
The classification of E2F family proteins is highly controversial since some 
investigations have shown that E2F proteins may function beyond their transcriptional 
properties. For example, a novel role of typical transcriptional repressors, E2F-4 and 
E2F5, has been described in which they are able to interact with a number of cellular 
factors and co-activators to up-regulate transcription of E2F target genes when being 




Figure 16. Selective E2F binding to pRb pocket protein family proteins. 
 

















Figure 17. Dynamic changes in the composition and location of E2F complexes 
throughout the cell cycle. 
E2F4 and E2F5 are the most prominent form of E2F found in G0 and early G1 phase, 
and in these cells most E2F-binding sites appear to be occupied by complexes that 
repress transcription. Cell cycle entry correlates with the loss of the repressor complexes 
and the accumulation of free E2F activators. On some promoters, gene induction 
appears to be due to the loss of repression. In other cases, E2F activator complexes are 
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1.2.1.2 E2F-regulated S-phase genes 
 
Each E2F-inducible promoter contains one or more E2F consensus recognition 
sites which is derived as [T/C]TT[C/G][G/C]C G[C/G] (Slansky et al., 1993). Most of 
E2F members can bind to E2F-responsive element but may not exert same degree of 
transcription abilities. Recently, several research groups have performed microarray 
analyses, ChIP-on-chip and ChIP-sequencing to identify novel gene targets of E2F to 
unravel the mechanism by which E2F transcription factors control cell cycle 
progression and oncogenesis.  
Majority of E2F target genes are negatively regulated by DREAM repressor 
complex, which is composed of E2F4 or E2F5 with p107 or p130, during quiescence. 
When cells enter G1 phase, hypo-phosphorylated form of pRB binds and blocks 
transactivation domain of transcription activators E2F1, E2F2 and E2F3. Upon 
mitogenic stimulation, pRB is sequentially phosphorylated by CDK4,6/cyclin D and 
CDK2/cyclin E complexes, thereby allowing E2F1,2,3 to transactivate genes required 
for G1/S transition, DNA replication as well as cellular proliferation (Figure 18). The 
following E2F-target genes have been studied in this project for the understanding of 
transcriptional modulation of S-phase genes under oncogenic effect of E7.  
Figure 18. Representation of 
experimentally derived position 
weight matrices (PWMs) of E2F 
transcription factors in promoters 
of genes expressed in different 
cell cycle phases. 
Putative binding sites of E2F are 
highly enriched in promoters of 
genes expressed in G1/S and S-
phase. In contrast, transcriptional 
regulatory regions of late cell 
cycle genes contain no or very 
few E2F-responsive elements 
(Adapted from Elkon et al., 
2003). 
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Cyclin E1 (CCNE1) and Cyclin E2 (CCNE2) 
Cyclin E forms a complex with Cdk2 and the accumulation of this protein can be seen 
during late G1 phase. Cdk2/CyclinE complex is involved in the phosphorylation of the 
gate keeper protein, pRb and it can actively promote cell cycle progression (Koff et al., 
1992). Cyclin E is over-expressed in many tumors and hence it has been described as an 
oncogene. 
 
Minichromosome maintenance deficient 6 (MCM6) 
Minichromosome maintenance deficient 6 (MCM6) plays critical role in the initiation of 
DNA replication. MCM6 is recruited to replicon together with MCM2, 4 and 7 and 
leads to formation of MCM complex, thereby acting as helicase to unwind double-
stranded DNA (Ishimi, 1997). In addition, it enables formation of replication forks and 
promotes the recruitment of other essential components of pre-replication complex. 
DNA replication is well controlled in the cell and hence kinase activity of Cdk2 is 
responsible for the regulation of functional activity of MCM complex. 
 
DNA polymerase α (POLA) 
DNA polymerase α (PolA) is an enzyme involved in the polymerization of nucleotide 
subunit alongside a DNA template. In the presence of a cofactor, magnesium ion, it is 
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1.2.2 Transcriptional regulation of mitotic genes 
 
Promoters of genes with peak expression at different cell cycle phases have been 
previously screened for enrichment of E2F binding sites. This study revealed that E2F 
transcription factors are not involved directly in transcriptional program controlling 
expression of mitotic genes owing to the absence of E2F-responsive elements within the 
promoters of genes expressed in G2 and M phase (Elkon et al., 2003) (Figure 18). B-
Myb and FoxM1, whose expression is governed by the E2F-pRB regulatory axis, 
exhibit dominant activator role in the transcription of mitotic genes (Figure 19). This 
was further supported by a very recent work showing that consensus binding sites of B-
Myb and FoxM1 are highly enriched in transcriptional regulator regions of mitotic 
genes. In that paper, Sadasivam and colleagues also postulated a new model in which 
MuvB core serves as a platform for sequential recruitment of B-Myb and FoxM1 in 
order to regulate periodic expression of mitotic genes (Sadasivam et al., 2012) (Figure 
19). 
Figure 19. Schematic 
representation of cell 
cycle regulatory network.  
During G0 and G1 phase, 
E2F-regulated genes are 
repressed by mammalian 
DREAM repressor 
complex followed by 
pRB-mediated inhibition 
of E2F1,2,3 activity. 
Upon mitogenic 
stimulation, pRB is hyper-
phosphorylated and 
degraded, resulting in 
transactivation of S-phase 
genes, including B-Myb 
and FoxM1, which in turn 
stimulate expression of 
mitotic genes from late S 
until G2 phase.   
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1.2.2.1 B-Myb and mammalian DREAM complex 
 
B-Myb belongs to the Myb family of transcription factors that is composed of 
three members named A-Myb, B-Myb and c-Myb. All three proteins share similar 
structural features including a N-terminal DNA-binding domain comprised of three 
helix-turn-helix repeats and a C-terminal end encompassing both regulatory and 
transactivation domains. They are all capable of binding to the identical sequence-
specific Myb binding site (MBS; C/TAACNG) but each of them exhibits distinct 
pattern of expression and functions (Biedenkapp et al., 1988; Howe et al., 1991). Both 
A-Myb and c-Myb have been described to display a more restrictive expression pattern 
in comparison to B-Myb (Golay et al., 1991; Reiss et al., 1991; Lam et al., 1992; 
Kamano et al., 1995). A-Myb is primarily expressed in reproductive and hematopoietic 
tissues and was proved to be pivotal for spermatogenesis and mammary gland 
development (Toscani et al., 1997). On the other hand, c-Myb, a cellular homologue of 
avian myeloblastosis virus oncogene (v-Myb), is predominantly detected in immature 
hematopoietic cells. Expression of c-Myb is inversely correlated with maturation of 
hematopoietic cells and it acts as a switch between hematopoietic stem cell renewal and 
differentiation (Westin et al., 1982; Mucenski et al., 1991).  
On the contrary, B-Myb is found in virtually all mitotically active cells (Oh et 
al., 1999). B-Myb promoters harbour canonical E2F binding sites where repressive 
p107/E2F complexes are recruited in G0 and early G1 phase (Lam and Watson, 1993; 
Lam et al., 1995). Subsequently derepression of B-Myb promoter occurs at boundary of 
G1/S upon activation of G1 Cdks or infection by DNA tumour viruses. For instance, 
high-risk HPV16 oncoproteins E7 as well as adenovirus E1A were implicated in 
dysregulation of B-Myb expression through subversion of pRB/p107/p130-mediated 
suppression of cell cycle progression (Lam and Watson, 1993; Lam et al., 1994). On the 
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other hand, DiMaio’s group has recently discovered that pRB exerts inhibitory effect on 
B-Myb expression at post-transcriptional level via upregulation of miR-29 and miR-30, 
the two microRNAs responsible for B-Myb repression through binding to 
complementary sequences on B-Myb mRNA during senescence (Chang et al., 2008; 
Martinez et al., 2011).  
In addition, DNA binding affinity and transactivation ability of B-Myb is 
regulated by phosphorylation in a cell-cycle dependent manner. During late G1 and S 
phase, transcriptional activity of B-Myb is further enhanced by phosphorylation and it is 
speculated that Cdk2/cyclinA is the dominant kinase responsible for modification of 
different Thr and Ser residues located within C-terminal end of B-Myb (Robinson et al., 
1996; Sala et al., 1997; Ziebold et al., 1997; Johnson et al., 1999). B-Myb is primarily 
distributed within nuclear compartment due to the presence of two nuclear localization 
signals (NLS) in its C-terminal tail but its intracellular localization is unaffected by 
post-translational modification (Takemoto et al., 1994).  It is notable that 
Cdk2/cyclinA-mediated phosphorylation is a key event to liberate B-Myb from 
sequestration by Cyclin D1 or transcriptional co-repressor complex formed by SMRT 
and N-CoR (Horstmann et al., 2000; Li et al., 2002), hence facilitating the association 
of B-Myb with a variety of co-activators, such as CREB-binding proteins (CBP), p300 
and poly (ADP-ribose) polymerase (PARP) protein (Bessa et al., 2001; Schubert et al., 
2004; Santilli et al., 2001).  These protein-protein interactions led to chromatin 
remodeling and CBP-dependent acetylation of B-Myb by which transactivation 
properties of B-Myb is further increased (Johnson et al., 2002). Furthermore B-Myb 
promoter is self-regulated and B-Myb itself is capable of establishing a positive 
feedback loop to promote expression and accumulation of active, phosphorylated B-
Myb (Sala et al., 1999).  Therefore phosphorylation marks at C-terminal end is also 
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vital for protein turnover of B-Myb because it accounts for physical interaction with 
Skp2, a F-box component of the Skp1-Cul1-F-box protein (SCF) E3 ubiquitin ligase, 
thereby targeting B-Myb for ubiquitin-mediated proteosomal degradation (Charrasse et 


















Figure 20. Regulation of B-Myb activity.  
B-Myb activity is inhibited by binding of Cyclin D or N-CoR repressor in G1 phase. 
Upon mitogenic stimulation, B-Myb is released from this repressive complex, and 
subsequently being phosphorylated by CDK2/cyclin E,A complexes. Hyper-
phosphorylated form of B-Myb abrogates cell cycle arrest imposed by p107 through 
impeding the interaction between CDK2/cyclin complexes and p107, thus further 
promoting CDK2/cyclin-mediated activation of B-Myb proteins. Association with co-
activator PARP and concurrent acetylation by CBP augments transactivation capacity of 
B-Myb during S phase. Protein levels of B-Myb are reduced when cells progress into 
late S phase due to the proteasomal degradation mediated by SCF
Skp2 
ubiquitin ligase 
(Adapted from Joaquin and Watson, 2003). 
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B-Myb plays a crucial role in transactivating expression of numerous genes 
actively involved in cell cycle progression. Nevertheless B-Myb can also downregulate 
expression of human c-erbB2 (Her2) by impeding the binding of TFIID to TATA-box 
sequence which overlaps with B-Myb binding sites (MBS) on human c-erbB2 promoter 
(Mizuguchi et al., 1995). Another example of gene repressed by B-Myb is p16INK4a, a 
cyclin-dependent kinase 4/6 inhibitor. B-Myb is bound to p16INK4a promoter via MBS 
which acts as a negative cis-regulatory sequence located upstream of transcription 
initiation site of p16INK4a. Consequently, B-Myb-mediated repression of p16INK4a 
impacts on cell cycle regulation and induction of cellular senescence (Huang et al., 
2011). However, promoter of B-Myb-responsive genes does not necessarily require 
MBS for the recruitment of B-Myb. For examples, promoters of DNA polymerase 
alpha, B-Myb itself and fibroblasts growth factor 4 (FGF4) do not contain any MBS 
(Watson et al., 1993; Sala et al., 1999; Johnson et al., 2002).  Promoter occupancy by 
other co-activators assists the recruitment of B-Myb in order to stimulate expression of 
genes lacking MBS, in particular, B-Myb acts as a positive regulator on B-Myb 
promoter through Sp1 (Sala et al., 1999). Sp1-binding site is known as a common cis-
acting element found in promoters of many genes and therefore it was conceivable that 
B-Myb could be implicated in transcriptional regulation of a large number of genes. 
Previous report has demonstrated that B-Myb works in conjunction with E2F1-3 
activators to transactivate G2/M genes (Zhu et al., 2004). However, the presence of E2F 
binding sites and this co-operative behavior is specific for regulation of Cyclin B1, 
Cyclin A2 and Cdc2 (Zhu et al., 2004).  
More recently, it was shown that majority of genes required for G2/M phase of 
cell cycle is modulated by the multiprotein complex LINC/DREAM containing B-Myb. 
During cell cycle progression into mitosis, B-Myb displaces p130, E2F4 and DP1 from 
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MuvB core repressor complex and form multisubunit Myb-MuvB (MMB) activator 
complex to potently activate transcription of genes expressed in M phase (Pilkinton et 
al., 2007). In mammalian cells, MuvB core comprises 5 MuvB-like proteins, namely 
LIN9, LIN37, LIN52, LIN54 and RBBP4 (Figure 21A), among which, LIN9 
component is a crucial regulator for cell cycle gene transcription and a major control for 
G1/S and G2-M transition. It is important to highlight that LINC or DREAM is 
evolutionary highly conserved. The multisubunit DREAM complex termed Drosophila 
RB, E2F and MuvB complex is originally isolated from D. melanogaster and 
C.elegans and it is involved in developmental gene repression. A conserved DREAM 
complex has also been
 
identified in mammalian cells and its mammalian orthologues 
include pRB-related pocket protein p130, E2Fs and B-Myb respectively (Korenjak et 
al., 2004) (Figure 21B).  In addition to its role to stimulate expression of late genes with 
peak expression during G2 and M phase, B-Myb also augments cell viability by acting 
as a positive regulator of anti-apoptotic genes, such as Bcl2, survivin and clusterin 






























Figure 21. Dynamic compositions and roles of MuvB core during cell cycle 
progression.  
(A) Mammalian MuvB subcomplex consists of LIN9, LIN37, LIN52, LIN54 and 
RBBP4. (B) MuvB core forms a repressor complex with E2F4 or E2F5 and p130 to 
negatively regulate transcription of E2F-regulated genes during G0 whereas MuvB 
serves as a platform to recruit B-Myb and FoxM1 sequentially for transactivation of 
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Our present knowledge regarding the biological function of B-Myb is limited to 
its role as a transcription factor, however, compelling data implied that B-Myb may 
associate directly with several cell cycle regulatory proteins, for examples Cyclin D1, 
Cyclin A1, p107 and p57KIP2, to promote cell growth (Horstmann et al., 2000; Müller-
Tidow et al., 2001; Joaquin et al., 2003; Sala et al., 1996). B-Myb is able to outcompete 
the binding of Cdk2/Cyclin to the N-terminal end of p107 and results in bypass of G1 
arrest induced by p107 (Joaquin et al., 2002) (Figure 20) whereas p57KIP2 binds DNA 
binding domain of B-Myb to abrogate its transactivation potential (Joaquin et al., 2003). 
In addition, recent report revealed that B-Myb interferes with chromosomal stability 
through direct association with clathrin and filamin, the two key components within the 
mitotic spindle (Yamauchi et al., 2008).  
Given the fact that B-Myb is a dominant player in cellular proliferation, 
transcription regulatory network governing apoptosis, G2/M transition and mitosis, it is 
expected that B-Myb overexpression is of prognostic significance in patients with breast 
cancer, hepatocellular cancer, cervical cancer, melanoma, neuroblastoma etc. 
Interestingly, researchers revealed a crosstalk between B-Myb and p53 signaling 
pathway in hepatocellular carcinoma cells (HCC) in which functional activity of 
LIN9/B-Myb is determined by p53 status. p53 is often referred to as the major guardian 
of genome because of its ability to halt cell cycle progression or execute apoptosis in 
response to cellular stress or DNA damages. In addition to these well-established 
tumour suppressive roles, p53 also interferes with formation of LIN9/B-Myb complex. 
Upon activation of p53 pathway, p21 serves as an inhibitor of cyclin-dependent kinases 
in G1 phase and allows accumulation of under-phosphorylated, active form of p130, 
thereby promoting assembly of the LIN9/p130 repressive complex (Calvisi et al., 2011). 
, In addition, however, B-Myb is able to counteract tumour suppressive properties of 
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p53 and it was accounted for by its ability to overcome p53-mediated cell cycle arrest in 
human glioblastoma cell line, although the underlying mechanism remained largely 
unknown (Lin et al., 1994).   
On the contrary, in HCC harbouring p53 mutants, DNA-damaging agents failed 
to restrain cell growth through the p53-p21 axis. As a result, tumour bearing p53 
mutations favor formation of LIN9/B-Myb complex and are unable to impede cell cycle 
progression. Not only liver tumours, breast cancer cells harbouring mutant p53 also 
exhibit high levels of LIN9/B-Myb complex because their association is greatly 
stabilized in the absence of an intact p53 pathway (Mannefeld et al., 2009). Therefore 
overexpression of B-Myb is pivotal especially in tumours where p53 is mutated for a 
mechanism conferring resistance to DNA-damaging chemotherapeutic drugs (Calvisi et 
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1.2.2.2 FoxM1 
 
FoxM1, previously named HFH-11B, Trident and WIN, is a member of 
Forkhead Box (Fox) transcription factor family characterized by an evolutionarily 
conserved winged-helix DNA binding domain. Currently Fox family comprises more 
than 50 mammalian proteins that are actively involved in transcriptional modulation of 
cellular genes. FoxM1 protein is exclusively expressed in actively dividing cells and is 
barely detected in terminally differentiated cells. Expression of FoxM1 is mainly 
regulated via the E2F-pRB axis. FoxM1 exists in three alternatively spliced isoforms, 
termed FoxM1A, FoxM1B and FoxM1C (Korver et al., 1997; Yao et al., 1997; Ye et 
al., 1997) (Figure 22). These splice variants show tissue-specific expression and are 
functionally different, for instance FoxM1A, lacking full-length transactivation domain, 
is transcriptionally inactive whereas FoxM1B and FoxM1C can transcriptionally 
activate a wide spectrum of target genes via binding to FoxM1 recognition site, 
A(C/T)AAA(C/T)AA (Ye et al., 1997; Wierstra et al., 2006) (Figure 22).  Among these 
three isoforms, FoxM1B whose mRNA expression is regulated in a cell-cycle 










Figure 22. Schematic representation of three FoxM1 isoforms identified in human. 
FOXM1 gene located in human chromosome 12p13.3 (Genomic Contig; GenBank 
accession no. NT 009759) comprises at least seven exons (I-VII) plus two alternatively 
expressed exons (A1, A2). Exon A1 encodes a 15 amino-acid insertion within the C-
terminal part of the DNA binding-domain (DBD), and Exon A2 represents a 38 amino-
acid insertion within the C-terminal transactivation domain (TAD) of the protein. 
Differential splicing of these exons generate three encoding FoxM1 isoforms, named 
FoxM1A, C and B. 
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FoxM1 is a potent transcription activator controlling expression of genes 
implicated in execution of G1/S transition, G2/M transition and mitotic entry, including 
cyclin D1, S-phase kinase-associated protein (Skp) 2, Cks1, Cyclin B1, Polo-like kinase 
(Plk) 1, Cdc25B, Aurora kinase B, survivin, never in mitosis gene a (NIMA)-related 
kinase 2 (NEK2), centromere-associated protein (CENP)-A, CENP-B and CENP-F 
(Wang et al., 2005; Wang et al., 2002; Kim et al., 2006; Costa et al., 2005; Li et al., 
2008; Chan et al., 2008; Laoukili et al., 2005). For instance, CDC25B is a phosphatase 
required for dephosphorylation of Cdk1 on residues Tyr15 and Thr14 and Cdk1 can 
therefore be activated upon removal of these phosphorylation marks to facilitate cell 
cycle entry into mitosis (Draetta et al., 1997; Nilsson et al., 2000). On the other hand, 
CENP-F is a vital molecule for spindle assembly checkpoint because gene knockdown 
of CENP-F gives rise to defects in chromosomal aggregation (Liao et al., 1995; 
Laoukili et al., 2005).  
In addition, FoxM1 can further promote cell cycle progression through up-
regulation of Skp2 and Cks1, genes encoding the substrate recognition subunits of 
Skp1-Cullin 1-F-box (SCF) ubiquitin ligase complex which target cyclin-dependent 
kinase inhibitor (CDKI) proteins, such as p27Kip1 and p21Cip1 for proteasomal-
mediated degradation pathway (Wang et al., 2002).  
FoxM1 expression is tightly coupled to cell cycle progression. Promoter of 
FoxM1 is regulated by E2F and hence FoxM1 is expressed upon mitogenic stimulation 
in G1 phase. Additionally, transcriptional activity and intracellular localization of 
FoxM1 is determined by post-translational modification. In G1 and S phases, FoxM1 is 
predominantly localized in cytoplasm and its trans-activation function is suppressed by 
pRB binding to the FoxM1 protein. As a result of pRB hyperphosphorylation by 
Cdk4/Cyclin D during late G1 phase, FoxM1 is released from pRB-mediated inhibition 
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(Major et al., 2004; Wierstra et al., 2006). Subsequently FoxM1 proteins shuttle into the 
nucleus upon phosphorylation by Cdk2/Cyclin E, Mitogen-activated protein kinase 
(MAPK) signaling pathway or Checkpoint kinase (Chk) 2 prior to entry into G2 and M 
phases.  The binding of LXL motif at residues 639-641 by Cdk2-cyclin E or cyclin A in 
G1/S phase and Cdk1-cyclin-B during G2/M phase allows efficient phosphorylation at 
Thr596 of FoxM1 carboxyl-terminal region. This is a crucial step to recruit CREB-
binding protein co-activator complex and enable subsequent Plk-1-mediated 
phosphorylation (Major et al., 2004; Myatt et al., 2007; Luscher-Firzlaff et al., 2006; 
Ma et al., 2005, Fu et al., 2008). Concurrently FoxM1 also associates with general 
transcriptional machinery and co-factors including TBP, TFIIB, TFIIAα/β, TFIIAγ and 
TAF1, to enhance its transcriptional activity (Wierstra et al., 2006). Chk2 activation 
triggered by DNA damage response also causes phosphorylation of FoxM1 on Ser361, 
thereby contributing to further accumulation and stability of transcriptionally active 
FoxM1 (Tan et al., 2007). FoxM1 becomes dephosphorylated and is targeted for 
ubiquitin-mediated proteosomal degradation by Cdh1, which is known as a substrate-
specific activator subunit of the anaphase promoting complex/cyclosome during late M 
phase and early G1 phase of the next cell cycle (Laoukili et al., 2008; Park et al., 2008) 
(Figure 23).  Notably, mechanism underlying FoxM1-driven transactivation has been 
further characterized by a recent publication which uncovered a novel relationship 
between FoxM1 and LIN9/B-Myb complex. This finding demonstrated that FoxM1 is 
recruited to the promoters of mitotic genes together with B-Myb and MuvB core 
complex in a sequential manner and it is a critical event for controlling cell cycle 
































Figure 23. Cell cycle-dependent regulation of FoxM1 expression and activity.  
 
However compelling data have demonstrated that cellular functions of FoxM1 
are not restricted to cell cycle regulation. FoxM1 can affect a plethora of cellular 
pathways, including DNA damage repair, cell migration, reactive oxygen species (ROS) 
production, proliferation, apoptosis and senescence.   
FoxM1 plays an important role in DNA damage response and it is implicated in 
transcriptional activation of DNA repair genes such as XRCC1 and BRCA2, the latter 
of which is responsible for double-strand break repair via homologous recombination. 
Besides, as I mentioned earlier, FoxM1 is stabilized by Chk2-mediated phosphorylation 
in response to DNA damage. Therefore gene ablation of FoxM1 impairs DNA damage 
repair and increases DNA break events.  However, FoxM1 expression is inversely 
correlated with that of p53 because FoxM1 is repressed by p53 for the long-term 
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maintenance of G2 arrest (Barsotti et al., 2009). Not only p53, another tumour 
suppressor protein p19Arf can also exert suppressive effect on FoxM1-regulated genes 
through direct interaction with FoxM1 by which FoxM1 is delocalized to the nucleolus 
(Kalinichenko et al., 2004). Conversely DNA damage response stimulates protein 
expression of FoxM1 in tumours where p53 is absent or mutated. It was demonstrated 
that FoxM1 rendered cancer cells with mutant p53 insensitive to DNA-damaging 
chemotherapeutic agents including Herceptin, paclitaxel, doxorubicin and cisplatin via 
suppression of JNK-dependent apoptosis and activation of anti-apoptotic Bcl-2 
expression (Halasi et al., 2012). In addition, high FoxM1 expression is also associated 
with disease progression and poor prognosis in a variety of solid tumours, such as 
pancreatic carcinomas, head and neck squamous carcinomas, cervical carcinoma, 
hepatocellular carcinomas (HCC), basal cell carcinoma, glioblastomas, breast cancer, 
colon carcinomas, non-small cell lung cancers (NSCLC) and prostate cancer (Wang et 
al., 2007; Gemenetzidis et al., 2009; Chan et al., 2007; Kalinina et al., 2003; Teh et al., 
2002; Liu et al., 2006; Madureira et al., 2006;Yoshida et al., 2007; Kim et al., 2006; 
Kalin et al., 2006).  Therefore several reports suggest that administration of FoxM1 
inhibitors together with conventional DNA-damaging agents could potentially improve 
outcome of current cancer treatment.   
Apart from DNA damage pathway, oncogene-induced ROS elevation also leads 
to up-regulation of FoxM1 expression that in turn counteracts damaging effect of ROS 
by activating expression of anti-oxidant genes, such as Superoxide Dismutase 
(MnSOD), Catalase, and Peroxiredoxin 3 (PRDX3). Perturbation of ROS homeostasis 
by FoxM1 further promotes cell viability and increases resistance to oxidative stress-
mediated apoptosis (Park et al., 2009).   
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Furthermore FoxM1 is found to be linked to activation of PI3K/Akt signaling 
pathway by regulating NEDD4-1 level in glioblastoma cell lines.  Tumour suppressor 
PTEN is a major brake in Akt pathway and an E3 ligase, NEDD4-1 has recently been 
shown to negatively regulate protein level of PTEN through ubiquitin-mediated 
proteolysis. In addition to abrogation of apoptosis induced by DNA-damaging drugs 
and oxidative stresses, FoxM1 impinges on Akt signaling pathway to promote survival 
of malignant tumour cells, thereby exacerbating cancer progression (Dai et al., 2010).  
Interestingly, mounting evidences have suggested that FoxM1 contributes to 
induction of cancer stem cell phenotype which is mainly characterized by acquisition of 
epithelial-mesenchymal transition phenotype, unlimited self-renewal capacity, increased 
cell motility and invasiveness. In pancreatic cancer cell lines, ectopic expression of 
FoxM1 alone is sufficient to induce expression of cancer stem cell markers, EpCAM 
and CD44, and promotes epithelial to mesenchymal transition. Researchers 
demonstrated that FoxM1 reduces the expression of microRNA let-7a, let-7b, let-7c, 
miR-200b and miR-200c, leading to the activation of mesenchymal markers such as 
ZEB-1, ZEB-2 and vimentin (Bao et al., 2011).  This paper also indicated that FoxM1 
directly activates Sox2 and Bmi1 in neuroblastoma cells. It is noteworthy that Sox2 
expression in conjunction with Oct4, Nanog, Klf4 can reprogram a somatic cell from 
differentiated state to stem-like pluripotent state and these proteins also act 
cooperatively to drive tumour progression (Bao et al., 2011).  
FoxM1 is also responsible for increased cell migration. FoxM1 perturbs 
microtubule dynamics through stimulation of stathmin, a microtubule-destabilizing 
protein.  Both studies in glioma and pancreatic cancer model showed that FoxM1 is able 
to actively induce invasiveness via up-regulation of angiogenesis factors for examples 
vascular endothelial growth factor VEGF and matrix metalloproteinase genes MMP-2, 
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MMP-3. All these pro-metastatic events are inter-connected and largely dependent on 
FoxM1 expression (Zhang et al. 2008; Wang et al., 2003; Chetty et al., 2009; Ahmad et 
al., 2009). In addition, a recent evidence unveils a direct role of FoxM1 in formation of 
premetastatic niche by showing recruitment of FoxM1 to the promoters of lysyl oxidase 
(LOX) and lysyl oxidase-like 2 (LOXL2), resulting in high expression of genes required 
for promoting metastasis (Park et al., 2011).     
Teh and his group recently studied the effect of ectopic expression of FoxM1 on 
keratinocyte stratification in three-dimensional organotypic epithelial co-culture model. 
They reported that FoxM1 markedly represses mRNA expression of differentiation 
markers and promotes expansion of epithelial progenitor cells. It is believed that FoxM1 
predisposes epithelial cells to undergo hyper-proliferation through deregulation of 
keratinocyte differentiation and plays a critical role during initial stage of malignant 
transformation (Gemenetzidis et al., 2010). Taken together, these findings strengthen 
the role of FoxM1 in cancer progression and shed lights on potential involvement of 

























Figure 24. Biological functions of FoxM1.  
FoxM1 is described as a proto-oncogene owing to its ability to deregulate a wide range 
of biological processes in mammalian cells such as cell cycle progression, cell 
proliferation, apoptosis, cell differentiation, DNA damage repair, angiogenesis, 
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1.2.2.3 Mitotic genes 
 
In present study, seven mitotic genes, which are implicated in spindle assembly 
checkpoint (SAC), centrosomal duplication, kinetochore localization and chromosomal 
segregation, have been selected to facilitate the characterization and identification of E7 
as a novel co-factor in regulation of mitotic gene expression. Among the seven genes 
described below, Aurora kinase B (AURKB), Cyclin B1 (CCNB1) and Centromere 
Protein A (CENPA) has been previously reported as B-Myb- or FoxM1-responsive 
targets (Wang et al., 2005; Osterloh et al., 2005). Majority of mitotic genes harbour 
more B-Myb and FoxM1 binding sites than E2F-responsive elements (Sadasivam et al., 
2012).  Exceptionally, two genes with peak expression in G2 and M phase, CDK1 and 
cyclin B1, which contain consensus E2F binding sites instead of cis-elements for B-
Myb and FoxM1, are found to be regulated in E2F-dependent manner (Zhu et al., 
2004). Interestingly, B-Myb can also be recruited to these promoters and work co-
operatively with  E2F transcription factors to stimulate expression of CDK 1 and cyclin 
B1(Zhu et al., 2004).  
 
Aurora Kinase B (AURKB) 
AURKB belongs to aurora kinase family, which comprises three related 
serine/threonine kinases involved in regulation of mitosis. It serves as a key component 
within chromosomal passenger protein complex. The roles of AURKB in mitosis have 
been clearly established and it was reported that AURKB is indispensable for 
cytokinesis, chromosomal segregation, microtubule-kinetochore attachment and etc. 
Two interaction partners of AURKB, INCENP and survivin, were demonstrated to 
stimulate kinase activity of AURKB, which in turn leads to phosphorylation of a wide 
range of substrates, including centromeric proteins centromere protein A (CENP-A), 
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INCENP, survivin, the mitotic checkpoint proteins BubR1 and Mad2, the cytoskeletal 
proteins myosin II regulatory light chain, vimentin, desmin, and histone H3 (Carvajal et 
al., 2006). Notably, deregulated expression of AURKB gives rise to aneuploidy owing 
to asymmetric distribution of genomic material from parent to daughter cells during 
mitosis. Therefore, high expression of AURKB is consistently associated with a variety 
of tumours, which also exhibits genomic instability. 
 
Budding Uninhibited by Benzimidazoles 1 (BUB1) 
BUB1 is a serine/threonine kinase critical for formation of spindle assembly 
checkpoint (SAC), which inhibits cell cycle progression from metaphase into anaphase 
in the presence of defects in mitotic spindle. Upon activation of SAC, BUB1 renders 
Cdc20 inactive through direct binding and phosphorylation, thereby dampens activity of 
APC/C (anaphase promoting complex), an E3-ubiquitin ligase controlling degradation 
of key mitotic proteins for metaphase-anaphase transition (Tang et al., 2004). Besides, 
Mad1 is another known substrate of Bub1 and it was reported that Bub1-mediated 
phosphorylation abrogates interaction between Mad1 and Mad2. Consequently Mad1-
free Mad2 is capable of sequestering Cdc20 from recognizing its substrates (Yu et al., 
2002). BUB1 acts as master regulator of SAC because it is also important for 
recruitment of checkpoint proteins, such as Mad1, Mad2, BubR1, CENP-E and PLK1 to 
the kinetochore (Sharp-Baker et al., 2001). In addition to the well-studied roles in SAC 
activation, BUB1 shares similar function with AURKB to ensure correct alignment of 
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Cyclin B1 (CCNB1) 
CCNB1 primarily associates with CDK1 during mitosis and this interaction 
allows activation of CDK1, in turn, phosphorylates a plethora of mitotic proteins to 
promote the cell cycle progression into mitosis. CCNB1-CDK1 is mainly responsible 
for chromosomal condensation, breakdown of nuclear lamina and mitotic spindle pole 
assembly. CCNB1 is actively shuttled from cytoplasm into nucleus when cells enter late 
prophase. Kinases such as Polo-like kinase and CDK1 account for phosphorylation of 
CCNB1, resulting in inactivation of nuclear export signal of CCNB1 and accumulation 
of CCNB1 in nucleus during mitosis (Yu et al., 2008). Recent finding revealed that 
CCNB1 could be found on unattached kinetochore with help from Hec1 and Mad2 
proteins and plays a role in chromosome alignment. Furthermore a large number of 
kinetochore proteins as well as SAC components were reported as substrates of 
CCNB1-CDK1, indicating the ability of CCNB1 to interfere with SAC checkpoint 
signaling when it is localized to unattached kinetochere (Chen et al., 2008).   
 
Centromere Protein A (CENPA) 
CENPA is known as a histone H3 variant, which is capable of replacing 
conventional histone H3 at specific domain of the centromeric chromatin. The 
incorporation of nucleosomes containing CENP-A into centromeric chromatin serves as 
epigenetic mark, which generates unique centromere identity, and contributes to proper 
kinetochore assembly, centromere activity, chromosome stability and cell viability. It 
has been demonstrated that HJURP (Holliday Junction Recognition Protein) is required 
for loading of new CENP-A into centromeric chromatin from late telophase until next 
G1 phase, thereby allowing the distribution of these pre-existing nucleosomes 
containing CENP-A to sister chromosome during DNA replication (Foltz et al., 2009). 
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Besides, CENP-A acts as structural foundation for assembly of kinetochore, a 
macromolecular protein complex, which helps in forming a bridge between spindle 
microtubule and centromeric chromatin. Given the central role of CENP-A in 
kinetochore assembly and centromere activity, a research study revealed that auto-
antibodies against endogenous CENP-A and CENP-B could result in autoimmune 
diseases for examples limited systemic sclerosis or scleroderma and mitotic or 
centromere dysfunction (Russo et al., 2000).  
 
Extra Spindle Pole Bodies 1 (ESPL1) 
ESPL1 gene encodes separase, a proteolytic enzyme involved in cleavage of 
cohesion subunit SCC1. Prior to anaphase onset, cohesin physically connects sister 
chromatids and proteolytic activity of separase is inhibited by securin. Interaction with 
securin is critical for functional conformation of separase despite blocking the access of 
substrates to active sites of separase. Upon completion of chromosome alignment, 
securin is ubiquitinated and directed for proteasomal degradation by APC/C. The 
release of separase from inhibitory complex leads to cohesin destruction and separation 
of sister chromatids in metaphase (Sullivan et al., 2001). While the proteolytic function 
of separase is well characterized, no one has described to date the protease-independent 
role of separase. Recent findings reported that separase is able to associate with both 
CDK and CCNB1, raising possibility that separase has a second role in driving the cell 
cycle progression (Gorr et al., 2005). 
 
Polo-like Kinase 4 (PLK4) 
PLK4 is the most divergent member of polo-like family serine/threonine protein 
kinases because it exhibits least homology among other members in the family. PLK4 
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possesses a C terminal end containing signals for centriolar localization of PLK4, which 
is not found in other PLK members. Therefore it is predominantly found in centrioles 
and has a vital role in centriole duplication. The protein expression of PLK4 is 
temporally controlled because either overexpression or depletion of PLK4 can result in 
abnormalities in centriole number. In agreement with it, PLK4 is a low abundance 
protein and rapidly marked by SCF/Slimb-E3 ubiquitin ligase for proteosomal 
degradation.  In addition to its established role in centriole duplication, recent studies 
discovered that PLK4 is involved in cellular proliferation, exit from cytokinesis and cell 
cycle regulation. For instance, PLK4 is able to activate two mitotic proteins, such as 
CDC25C phosphatase and RhoA guanine exchange factor (GEF) by phosphorylation to 
ensure proper progression through mitosis (Sillibourne et al., 2010).  
  
Spindle Pole body Component 25 (SPC25)   
SPC25 is a component of NDC80 complex comprising NDC80/HEC1, CDCA1, 
SPC24 and SPC25. Heterodimerization between HEC1-CDCA1 and SPC24-SPC25 
through coiled-coil domain of each subunit is a prelude for the formation of 4-subunit 
NDC80 complex. SPC25 is localized to kinetochore from prometaphase to anaphase 
and it also contributes to the targeting of Mad1 and Hec1 to kinetochores (McCleland et 
al., 2004). On the other hand, NDC80 complex functions as an important regulator for 
chromosome movement, kinetochore microtubule attachment and spindle checkpoint 
activity. The attachment of microtubule to kinetochore is necessary for proper 
chromosomal alignment and mitotic progression (Ciferri et al., 2007). It was 
demonstrated that depletion of SPC25 of NDC80 complex impeded proper chromosome 
segregation, leading to genomic instability (McCleland et al., 2004). 
 
 
  61 
1.3 Rationale of study 
 
Our present knowledge regarding the function of E7 is limited to its role as a potent 
inducer of S-phase genes. However our group previously reported for the first time that 
E7 could also exert profound effect on transcriptional regulation of genes necessary for 
mitotic entry based on the observation showing massive repression of mitotic genes 
upon gene knockdown of E7 in HPV-associated cervical cancer cell lines (Thierry et al., 
2004; Teissier et al., 2007). We herein aim at dissecting the mechanism by which E7 is 
able to elicit activation of mitotic genes. By dual silencing of pRB and E7 in an HPV16-
associated cervical carcinoma cell line, Caski, in parallel with gene knockdown of pRB 
in primary human fibroblasts, we determined that transcriptional modulation of mitotic 
genes is not dependent on a regulatory axis containing E2F and pRB, in striking contrast 
to that of S-phase genes. In light of recent identification of the roles of B-Myb and 
FoxM1 in cell cycle regulation, our present study confirmed that B-Myb, FoxM1 
together with E7 are pivotal for G2/M gene expression as well as mitotic progression in 
cervical cancer cell line. Next we employed retroviral-based transduction system to 
investigate whether possible co-operation or synergism, if any, exists between E7 and 
master regulators of mitotic genes, B-Myb and FoxM1 to regulated cellular endogenous 
G2/M genes. In this report, we described for the first time that E7 works in concert with 
B-Myb and FoxM1 to co-operatively activate mitotic genes as well as the recruitment of 
E7 to the promoters of B-Myb- or FoxM1-regulated genes was also demonstrated by 
ChIP-qPCR assays. It then posed interesting mechanistic question of how E7 is capable 
of interacting with G2/M gene promoters to stimulate gene expression because E7 lacks 
both DNA binding domain and transactivation domain. Our results obtained from CoIP 
experiments uncovered novel association between E7, B-Myb and FoxM1. Morever, we 
could demonstrate an interaction between E7 and LIN9, one of the components of the 
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MuvB subcomplex recently shown to serve as a platform for sequential recruitment of 
B-Myb and FoxM1 for activation of mitotic genes. We also revealed that FoxM1 binds 
to this complex, which has since been confirmed in a recent publication (Sadasivam et 
al., 2012).  
Furthermore, we directly showed a robust activation of mitotic pathway by E7 in 
comparative analyses of global gene expression profiles both in Caski cells and in E7-
transduced primary human fibroblasts demonstrating that the intersection subset is 
highly enriched for mitotic genes. Collectively, we proposed a novel, pRB-independent 
mechanism for E7 to activate mitotic genes and mitosis through direct interaction with 




Chapter 2: Materials & Methods 
 
Cell culture 
HeLa, Caski, SiHa, U2OS, 293T cells and primary human skin fibroblasts were grown 
in Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin-streptomycin at 37
o




Vectors expressing B-Myb or FoxM1B were constructed by amplifying the 
corresponding DNA fragments from pBABE-B-Myb and pSIN-CMV-FoxM1B 
respectively (kind gifts from Dr Perou and Dr Teh) (Thorner et al., 2009; Teh et al., 
2002). The full length, wild type HPV16 E7 and HPV16 E7 mutant ∆21-24 were 
subcloned from pLXSN-16E7 and pLXSN-16E7∆21-24 (generously provided by Dr 
Galloway) (Halbert et al., J Virol 1992) into mammalian expression vector pXJ-Flag 
(obtained from Dr Manser) (Manser et al., 1997). In co-immunoprecipitation 
experiments, HA-tagged human p130 was a generous gift from Dr Roman (Zhang et al., 
2006) whereas GFP-tagged human LIN9 was kindly given by Dr Colamonici (Pilkinton 
et al., 2007). 
 
Plasmid Transfection   
For either transient gene expression or gene knockdown experiments, cells were 
transfected with FuGENE HD (Roche) and respective plasmids constructs. These 
experiments were conducted according to manufacturer’s recommendations. 106 cells 
were seeded in 10cm dish one day before transfection so that cell density at the time of 
transfection should reach at least 70% confluence. We prepared transfection mix using a 
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DNA (g) to FuGENE HD (l) ratio of 1:2.5 in OptiMEM (Invitrogen) to a total 
volume of 1ml for transfection in 10cm dish of HeLa and U2OS cells. After half an 
hour of incubation at room temperature, 1ml of transfection mix was added dropwise to 
cells and antibiotic-free medium was used to bring the final volume up to 8ml. Cells 




Small-interfering RNA (siRNA) duplexes were designed for each gene of interest. The 
sequences for siRNA used for transfections are listed below. Caski cells and SiHa cells 
were treated with Dharmafect I (Thermo Scientific) as manufacturer’s instructions.  
Caski cells were grown to 50% confluence in antibiotic-free DMEM supplemented with 
10% FBS. To perform Dharmafect transfection on 6cm dish of Caski cells, 200 pmol of 
siRNA and 6 μl of transfection reagent were added to DMEM to make up a final 
volume of 100 μl. Each tube was incubated for 5 min at RT before adding the 
transfection reagent into the tube containing siRNA. Following 20 min incubation of 
transfection mix at room temperature, antibiotic-free medium was used to bring the 
final volume up to 1ml. Transfection mix was added dropwise to 3ml of antibiotic-free 
culture medium. 
pSUPER plasmids were used together with transfection reagent Fugene HD (Roche) for 
gene depletion of HPV18 E7 in HeLa cells. Cells were transfected with pSUPER-based 
vector for two days prior to harvesting to achieve optimal shRNA expression and gene 
silencing efficiency. Sequences of respective siRNA or shRNA constructs were 
























E6/E7 HPV18  Forward 5’-GATGGAGTTAATCATCAACTT-3’ 
 
Reverse 5’- GTTGATGATTAACTCCATCTT-3 
 
hLIN9 Forward 5’- GAGGAAGAGAGAUCAGCAUUAAATT-3’ 
 




Retroviral Production and Transduction  
Retroviruses were produced in 293T cells by co-transfection of pSIN- or pBABE-based 
vectors and retroviral packaging components including Gag-Pol gene-expressing 
plasmids pUMVC and VSV-g envelope gene-expressing constructs pVSVG using 
calcium phosphate transfection method.  Media was changed 6 to 8 hours after 
transfection and we collected the virus supernatants at 48 and 72 hours post 
transfection. Supernatants were then filtered through 0.45 µM cellulose acetate filter 
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and viruses were pelleted by centrifugation at 19500 rpm for 1 hour at 4°C. The final 
pellet was resuspended with sterile HBSS buffer for further applications.  
Primary human fibroblasts were transduced with retroviral vectors carrying B-Myb, 
FoxM1B, HPV16 E7, HPV16 E7 mutant ∆21-24 or empty vector in the presence of 
8µg/ml of polybrene and were harvested 72 hours post infection for real-time PCR or 
western blots to confirm gene expressions.  
 
Real-time PCR 
RNA was extracted using RNeasy Mini Kit (Qiagen) according to manufacturer’s 
instructions. Reverse transcription was performed using 0.5 µg of total RNA, random 
hexamer primers and the SuperScript II reverse transcription kit (Invitrogen). Newly 
synthesized single-stranded cDNA, 4 µM specific primers and SyberGreen PCR Master 
Mix (Applied Biosystems) were used for each PCR reaction. It was conducted with 
cycling condition of 2’ at 50 oC, 10’ at 95 oC and 40x (15” at 95 oC, 1’ at 60 oC) on real 
time PCR machine MX3500 (Stratagene). Each quantitative PCR was done in duplicate 
for each primer set. Relative transcript amounts were calculated by the ΔCT method 
with GAPDH as reference gene. The sequences of the primers used are listed in below. 
Primer   Sequence 
MYBL2 Forward 5’-AGCTGCACTACCAGGACACAGATT-3' 
Reverse 5’-TGACCTTGCACTTGCTATCCCTCT-3' 
FOXM1 Forward 5’-CCAGGTGTTTAAGCAGCAGA-3’  
Reverse 5’-TCCTCAGCTAGCAGCACCTTG-3’  
hLIN9 Forward 5’-GCGCGGCTCGTTCAAG-3' 
Reverse 5’-GACAAGGGCTTTTGCTGAAGAG-3' 
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AURKB Forward 5’-TTCAATCTGTCGCCTGATGG-3’ 
Reverse 5’-ATACAAACACACGCACCCGA-3’ 
BUB1 Forward 5’-GAG TGA TAT CTT CAG CTT GTG-3’  
Reverse 5’-AAC AACCTGCTCAACATCAAC-3’   
CCNB1 Forward 5’-ATCAGCATGGCAGTGGTGAG-3’ 
Reverse 5’-AGGCAGGACAGATAGCTGGTG-3’ 
CCNE1 Forward 5’-TGACCGTTTTTTTGCAGGATC-3’ 
Reverse 5’-TCCTGTCGATTTTGGCCATT-3’ 
CCNE2 Forward 5’-TCACCTTTGCCTGATTTAAG-3’ 
Reverse 5’-CATGAACATATCTGCTCTCC-3’ 
CDC25B Forward 5’-GGGCAAGTTCAGCAACAT CGT GGA-3’ 
Reverse 5’-GTAGCCGCCTTTCAGGATATACATCC-3’ 
CENPA Forward 5’-TCAGAGTAGCCTCACCATTAGTGG-3’ 
Reverse 5’-AGCTACACATCCGTTGACAAGC-3’ 
CENPF Forward 5’-TTGTAAAGAAAGGGTTTGC-3’ 
Reverse 5’-CCAGCTGTTGGT TTGGAGG-3’ 
MCM6 Forward 5’-AACCAATCGTGACACAGGAGC-3’ 
Reverse 5’-TCATTGGTCAGGTTTGGCG-3’ 
NEK2 Forward 5’-CAGCTCTGTGTCTCTCTACCG-3’ 
Reverse 5’-AAGCAGGCAGATCCTGG-3’ 
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PLK1 Forward 5’-CACAGTGTCAATGCCTCCAA-3’ 
Reverse 5’-TTGCTGACCCAGAAGATGG-3’ 
POLA Forward 5’-TCCTCCGGCTTCCCCTC-3’ 
Reverse 5’-GCCCTGTGATGACCCCTTAG-3’ 
ESPL1 Forward 5’-GAATGAGGCAGTAGGACGTCTACA-3’ 
Reverse 5’-TGGCTATTGCTTGGTACTGTCAG-3’ 
PLK4 Forward 5’-AGCTTGAAAGAGGAGATAAAAATGTATATG-3’ 
Reverse 5’-ATGACCCTCATTAGCATGGTCC-3’ 
SPC25 Forward 5’-AAAGTACGGACACCTCCTGTCAG-3’ 
Reverse 5’-CCTTGTAGGTATCTCTTAGTCCCGC-3’ 
pRB Forward 5’-AGACCCAGAAGCCATTGAAATC-3’ 
Reverse 5’-CAAAGTGTATTTAGCCGGAGATAGG-3’ 
E7 HPV16 Forward 5’-GCTCAGAGGAGGAGGATGAAATAG-3’ 
Reverse 5’-CCGAAGCGTAGAGTCACACTTG-3’ 
E7 HPV18 Forward 5’-CCCCAAAATGAAATTCCGGT-3’ 
Reverse 5’-GTCGCTTAATTGCTCGTGACATA-3’ 






Microarray hybridization and analysis  
For Affymetrix microarray analysis, a total of 200 ng of RNA for each experiment was 
amplified, terminally labeled and used for hybridization according to the manufacturer’s 
instructions (Affymetrix). The high density microarrays used in this study were the 
Human Gene 1.0 ST array from Affymetrix, including 28,869 well-annotated genes 
with 764,885 distinct probes (expressed sequence tags) and 384 controls (calibration 
and negative control spots). The microarrays were washed and stained using Fluidics 
Station (GenChip) and scanned using a GeneArray 25000 Scanner. Data collected from 
each hybridization experiment were analyzed and statistical analyses carried out using 
Partek Genomics Suite software.  
Illumina Human HT-12V4 expression BeadChips were employed for genome-wide 
expression profilings of E7 or BMyb-transduced fibroblasts. Microarrays were 
performed by the microarray facility at Biopolis Shared Facilities (A-star, Singapore). 
Data collected from each hybridization experiment were analyzed and statistical 
analyses carried out using Partek Genomics Suite software.  
 
PCR arrays 
1µg of total RNA from each sample was converted into cDNA with RT
2
 First Strand 
Kit (SA Biosciences). Next cDNA was mixed with an-instrument-specific and ready-to-
use RT
2
 SYBR Green qPCR Master Mix (SA Biosciences). 25 µl of this mixture was 
added to each well of the Human Cell Cycle PCR Array plate containing the pre-
dispensed gene-specific primer sets plus control sets. It was conducted with cycling 
condition as recommended by manufacturer on real time PCR machine MX3500 
(Stratagene). Fold changes in gene expression for pair-wise comparison using the ΔΔCT 
method was calculated and normalized against housekeeping genes. 
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Cell cycle synchronization  
Caski and SiHa cells were arrested at G1/S boundary after adding 2.5mM thymidine to 
the medium for 24h. These cells were then released for 2 hours to enable cell cycle 
entry into S phase. 2.5mM thymidine and siRNA transfection mix were added to the 
medium again and incubated for 24 hours. Synchronized cells were harvested at 0h, 6h 
and 13h post release from thymidine treatment and fixed in 70% ethanol. Then the cells 
were stained with 20µg/ml propidium iodide and 10µg/ml RNase for DNA content 
analyses. Cell cycle analyses were performed using an LSR-II flow cytometer (BD 
Biosciences).  
 
Cell proliferation analyses 
Primary human fibroblasts were infected by retroviruses expressing HPV16 E7 or 
empty vector for 24 hours and then seeded on 96-well E-plate (Roche). Cell growth was 
monitored and recorded hourly by xCELLigence System (Roche) for 5 days. We 
calculated doubling time based on the slope of the growth curve using RTCA software 
(Roche).  
 
Chromatin immunoprecipitation  
HeLa cells were grown to 70-80% confluence and were ready to be treated after 24 h 
transfection. Cells were then cross-linked with 1% formaldehyde for 10 min at room 
temperature. Fixation reaction was stopped by glycine (0.1M) and cells were harvested 
and processed for cell lysis. Isolated nuclei were pelleted by centrifugation and 
resuspended in digestion buffer. The chromatin material was sheared to generate DNA 
fragments with size ranging from 200bp to 600bp by adding enzymatic shearing 
cocktail. Immunoprecipitations were done with mouse monoclonal anti Flag M2 
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antibodies and protein A/G agarose beads for overnight incubation after pre-clearing the 
sheared chromatin with salmon sperm DNA and beads. Immunoprecipitates were 
washed sequentially with 1ml of low salt washing buffer, high salt washing buffer, LiCl 
washing buffer and TE buffer. Beads were then eluted with elution buffer (Tris pH8 
100mM, 1% sodium dodecyl sulfate). Chromatin was reverse-crosslinked with 5M 
NaCl and digested with Proteinase K overnight at 65
o
C to remove all residual proteins. 
DNA was extracted and purified by phenol chloroform method. The precipitated DNA 
samples were then subjected to quantitative real-time PCR by using the primer sets 
listed in the table below. 
Promoter primer   Sequence 
Promoter GAPDH Forward 5’-GTCTGCCCTAATTATCAGGTCCAG-3’  
Reverse 5’-AGGTCACGATGTCCTGCAGC -3’  
Promoter AURKB  Forward 5’-GCAACGAAAGGTCTATTGGTGG-3’ 
Reverse 5’-TCTAACTTCTCTGCCCGATGGAG-3’ 
Promoter BIRC5  Forward 5’-GGAGGAAGAAGCAGAGAGTGAATG-3’ 
Reverse 5’-CTGGGATTACAGATGTGAGCCAC-3’ 
Promoter CDC25B  Forward 5’-AAGAGCCCATCAGTTCCGCTTG-3’ 
Reverse 5’-CCCATTTTACAGACCTGGACGC-3’ 
Prom ESPL1 Forward 5’-GACTAAGCGACAGGTAGCTGAGAAA-3’  
Reverse 5’-TTGCTGCTCTGCGCGTTA-3’  
Prom SPC25  Forward 5’-AAAGAACTACGAATCCCAGAATGC-3’  
Reverse 5’-TCTCCTTGACAGGATTGGTTGA-3’  
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Immunofluorescence and Time-lapse Microscopy 
U2OS cells were grown on coverslips in 6 well dishes and were transfected with vectors 
carrying N-terminal Flag-tagged HPV16 E7, B-Myb and/or FoxM1. One day after 
transfection, cells were fixed in 2% paraformaldehyde (PFA) overnight at 4
o
C after 
washing twice with 1X phosphate-buffered saline (PBS). Cells were then permeabilized 
with 0.1% Triton for 30 mins. Cells were then incubated with primary antibodies for 1h 
at room temperature at the following dilutions: anti-Flag M2 at 1:200 (M2, Sigma), 
anti-B-Myb at 1:50 (sc-724, Santa Cruz), anti-FoxM1 at 1:100 (sc-502, Santa Cruz). 
Lastly respective secondary antibodies (AlexaFluor 488-conjugated anti-mouse 
antibodies and AlexaFluor 598-conjugated anti-rabbit antibodies, Invitrogen) and DAPI 
were mixed and applied to coverslips for 1 hour. Pictures were taken with the Applied 
Precision DeltaVision Deconvolution microscope system and images analyzed using 
SoftWoRx v4.0.0. 
For time-lapse microscopy, primary human fibroblasts cells were infected with 
retroviral constructs carrying HPV16 E7 or empty vector and next day we plated these 
cells on 2-well Lab-Tek™ II Chambered Coverglass (Thermo Fisher Scientific) in 
complete DMEM with 2.5mM thymidine for 24 hours. Fibroblasts were released from 
thymidine block for 4 hours and the culture medium was then changed to DMEM 
without HCO3
2- 
half an hour before time-lapse imaging. Pictures were taken with the 
Applied Precision DeltaVision Deconvolution microscope system as described above at 
10-minute intervals from 4-52 hours post release from thymidine treatment. Images 





Immunoprecipitation and immunoblot 
For immunoprecipitation experiments, cells were lysed with ML buffer (300mM NaCl, 
0.5% NP-40, 20mM Tris-HCl (pH 8.0), 1mM EDTA) supplemented with one Complete 
EDTA-free protease inhibitor cocktail tablet (Roche) per 50ml lysis buffer. The 
supernatant were collected after centrifugation at 13,000 rpm for 20 min. Protein 
concentration were determined by BCA method (Pierce, Thermo Scientific). Samples 
containing 500 µg to 1 mg of proteins were mixed with 30 µl Protein A/G Agarose 
beads (Santa Cruz) and 2 µg of either anti-Flag M2 antibody (Sigma) or anti-Myc 
antibody (sc-789, Santa Cruz) and incubated for 5 hours at 4
o
C with constant rotation. 
Immunocomplexes were washed three times with ML buffer and subjected to 
immunoblot analysis. Protein samples were denatured by boiling in 4X sample buffer 
(Bio-Rad) mixed with 1 volume of XT reducing agent (Bio-Rad) and separated on 4-
12% Bis-Tris SDS-PAGE (sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis) gels (Invitrogen). Following transfer, the nitrocellulose membranes 
were saturated with 5% milk in PBS-Tween. Blots were probed sequentially with 
primary and secondary antibodies at the following dilutions: rabbit polyclonal anti-Flag 
at 1:2000 (F7425, Sigma), anti-B-Myb at 1:500 (sc-724, Santa Cruz Biotechnology), 
anti-FoxM1 at 1:1000 (sc-502, Santa Cruz Biotechnology), anti-p130 at 1: 500 (sc-317, 
Santa Cruz Biotechnology), anti-pRB at 1:2000 (9307, Cell Signaling), anti-HPV16 E7 
(8C9) at a 1:150 dilution (Zymed/Invitrogen) and anti-HPV16 E7 (ED17) at a 1:200 
dilution (Santa Cruz Biotechnology), anti-GFP at 1:5000 (TP401, Torrey Pines 
Biolabs), HRP-conjugated anti-Myc at 1:500 (sc-40 HRP, Santa Cruz Biotechnology), 
anti-mouse at 1:10000, anti-rabbit at 1:10000. Detection of proteins was done by 
incubation with ECL substrate (Amersham Bioscience) for 5 min and 
chemiluminescence was visualized by STORM imaging system.  
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Chapter 3: Results 
 
3.1 HPV16 E7 causes dysregulation of cell cycle genes in cervical 
cancer cell lines 
Our group has previously demonstrated the roles of HPV viral oncogenes E6 and E7 in 
transcriptional regulation of cell cycle genes via re-introduction of E2 into HPV18-
associated cervical carcinoma cell line, HeLa cells, by which the viral promoter 
directing expression of E6 and E7 is repressed (Teissier et al., 2007; Thierry et al., 
2004; Figure 8). It is noteworthy that the number of mitotic genes was evidently great 
among all the modulated genes and strikingly many of them do not harbour any 
consensus E2F binding sites. We then sought to determine if the abilities of E6 and E7 
to deregulate the cell cycle genes are conserved within high-risk genotypes, HPV16 and 
HPV18. Caski cells, the HPV16-positive cervical cancer cells, were treated with 
recombinant adenoviruses expressing either GFP-tagged HPV18 E2 or GFP alone (as 
control) and subsequently subjected to Affymetrix microarray analyses of gene 
expression profile. Upon E2-mediated repression of E6 and E7, a total of 360 genes 
were found repressed (Appendix I). The list of E2-repressed genes was then analyzed 
using Ingenuity Pathway Analysis Software to identify related functional network and 
gene ontology. We found 190 genes responsible for cell cycle progression, among 
which the majority (134) were mitotic genes and approximately 17% (60) of them were 
genes involved in G1/S transition (Figure 25A).  
The results of gene expression microarrays were confirmed by pre-designed 
cataloged PCR arrays for cell cycle regulatory pathway. It has to be noted that 
expression of viral oncogene E6 and E7 was depleted efficiently using an RNAi 
approach instead of E2-mediated repression, prior to PCR arrays experiments. It has to 
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be highlighted that both E2 and E6/E7 siRNA approaches result in concurrent depletion 
of E6 and E7 since they are translated from a single polycistronic mRNA (Figure 8). It 
is therefore impossible to achieve individual silencing of E6 or E7 in HPV-associated 
cervical cancer cells as discussed in our previous article (Teissier et al., 2007).  
We then compared the expression profile of 84 cell cycle genes between HeLa 
and Caski cells. Numerous cell cycle genes were found to be significantly differentially 
expressed after gene silencing of E6 and E7 in high-risk HPV16-associated cervical 
carcinoma Caski cells (Figure 25B and Table 2). Approximately 30% of the repressed 
genes were common to both Caski and HeLa cells whereas 25% of the repressed genes 
in Caski cells were also identified as being repressed genes in the Affymetrix 
microarrays. Collectively, both microarray and PCR arrays analyses strongly suggested 
a central role of E6 and E7 in cell cycle control and more specifically in mitosis. We 
anticipated that E7 is more prominent than E6 in activation of cell cycle genes, a 
hypothesis which is supported by a previous work from our lab that reported that 
stabilization of p53 alone upon silencing of E6AP was not sufficient to induce a strong 
modulation of mitotic genes in HeLa cells (Teissier et al., 2007). In order to 
discriminate between the effect of E6 and E7 on cell cycle regulation in the present 
study, we used the same approach, i.e. gene knockdown of E6AP, to rescue p53 protein 
levels in Caski cells but it did not give rise to substantial effect on cell cycle gene 
expression. We concluded that modulation of mitotic genes was mainly accounted for 
by E7 activity. On the other hand, it is noteworthy that both Caski and HeLa cells 
behaved similarly upon repression of endogenous viral oncogenes, thus indicating that 





















Figure 25. HPV16 E7 induces cell cycle dysregulation. 
(A) Microarray analyses were performed to measure gene expression changes after gene 
knockdown of HPV16 E6 and E7 in Caski cells expressing the E2 repressor. A total of 
360 genes were down-modulated >2-fold by E2-mediated E6/E7 repression compared 
with control cells in four different replica experiments with p-value <0.01, among 
which 190 genes were involved in cell cycle regulation. These cell cycle-associated 
genes were further categorized into S-phase and mitotic genes by Ingenuity Pathway 































(B) PCR array analysis for expression profile of 84 cell cycle genes in HeLa and Caski 
cells treated with E7 siRNA for 2 days. In Caski cells transfected with siRNA targeting 
E7, 45 genes are down-regulated whereas only 5 genes are up-regulated. 33 out of 84 
genes are repressed while 12 genes are activated in siE7-treated HeLa cells. 
B 
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Table 2. Table showing lists of genes repressed or activated in PCR array 
 
Caski (si16E7 vs ctrl) HeLa (pSUPER18E7 vs ctrl) 
Repressed Activated Repressed Activated 
ANAPC2 CCND1 ANAPC2 BAX 
BCL2 CCND2 BCL2 CCND1 
BIRC5 CCNG1 BIRC5 CCNG1 
BRCA1 CDKN1A BRCA1 CCNT2 
BRCA2 NBN BRCA2 CDK6 
CCNB1  CCNB1 CDKN1A 
CCNB2  CCNB2 CDKN2B 
CCNC  CCNE1 CUL3 
CCNG2  CCNF GADD45A 
CDC16  CDC2 SERTAD1 
CDC2  CDC20 TFDP2 
CDC20  CDK2 UBA1 
CDC34  CDKN2A  
CDK2  CDKN3  
CDK4  CHEK1  
CDK5R1  CHEK2  
CDK5RAP1  CKS1B  
CDK6  CKS2  
CDKN3  DDX11  
CHEK1  GTSE1  
CHEK2  KNTC1  
CKS1B  KPNA2  
CKS2  MAD2L1  
CUL1  MCM2  
DDX11  MCM3  
DNM2  MCM4  
E2F4  MCM5  
GTSE1  MKI67  
HERC5  RAD51  
KPNA2  RB1  
MAD2L1  RBBP8  
MAD2L2  RBL1  
MCM3  RPA3  
MCM4    
MCM5    
MKI67    
PCNA    
RAD1    
RAD51    
RAD9A    
RBL1    
SKP2    
TFDP1    
TFDP2    
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3.2 Induction of mitotic genes by HPV16 E7 is a pRB-independent 
event 
Next we sought to understand whether E7-driven modulation of cell cycle genes was 
solely dependent on pRB-E2F axis in our assays. We used a siRNA approach to silence 
pRB in Caski cells in the presence or absence of E7 siRNA (Figure 26A). Three of the 
repressed mitotic genes identified by microarray (CENPA, ESPL1 and SPC25; 
Appendix I) were comparably repressed by E7 silencing, but not by pRB silencing 
(Figure 26B). Furthermore, if E7 stimulates cell cycle genes dominantly through 
degradation of pRB, disruption of pRB and E7 in tandem should rescue the activity of 
mitotic genes, which is not what we observed (Figure 26B). In contrast, dual silencing 
of E7 and pRB efficiently relieved the repression of S-phase genes, CCNE2 and MCM6 
(Figure 26C), thus confirming that E7 regulates mitotic and S-phase genes by different 
pathways in HPV-positive cervical carcinoma cells. Astonishingly, all these findings 
shed light on a novel pRB-independent function of E7 in the transcriptional regulation 



















Figure 26. HPV16 E7 activates mitotic genes transcription in pRB-independent manner. 
(A) Bar chart here showed knockdown efficiency of HPV16 E7 and/or pRB siRNA in 
Caski cells upon siRNA transfection for 40h. Data shown are derived from three-
independent experiments and are presented as the mean±sd 
(B) Quantitative real-time PCR analyses of the expression profiles of mitotic genes 
CENPA, ESPL1 and SPC25 in Caski cells following HPV16 E7 and/or pRB siRNA 
treatment for 40h. Data shown are derived from three-independent experiments and 
are presented as the mean±sd. 
(C) Quantitative real-time PCR analyses of S-phase genes CCNE2 and MCM6 in Caski 
cells following siRNA silencing of HPV16 E7 and/or pRB for 40h. Data shown are 













3.3 Transcription factors B-Myb and FoxM1 are potent activators of 
mitotic genes in HPV-associated cervical cancer cells 
E7 is able to subvert suppressive role of pRB and results in liberation of E2F 
transcription factors from pRB inhibition. Binding of E2F activators to promoters 
bearing consensus E2F binding sites allows expression of S-phase genes and genes 
governing late cell cycle gene expression, such as B-Myb, FoxM1 and NF-YB. These 
genes are direct E2F targets as well as important transcription activators of mitotic 
genes. Previous report as well as the present work (See Appendix I) also showed that B-
Myb, FoxM1 and NF-YB were markedly down-modulated in E7 knockdown Caski 
cells, implying that B-Myb, FoxM1 and NF-YB could be the key downstream effectors 
in E7-driven stimulation of mitotic genes (Teissier et al., 2007). However the roles of 
B-Myb, FoxM1 and NF-YB remained to be determined in HPV-positive cervical 
carcinoma. We therefore conducted siRNA-mediated depletion assays which efficiently 
reduced both protein and transcript expression levels of these genes in Caski cells, to 
probe the function of B-Myb, FoxM1 and NF-YB in cervical carcinoma cells (Figure 
27A and 27B). Gene knockdown of NF-YB did not significantly alter transcript levels 
of mitotic genes so we decided to focus on B-Myb and FoxM1 in the subsequent studies 
(Figure 27E). Silencing of B-Myb induced marked repression of mitotic genes CENPA, 
ESPL1 and SPC25 in Caski cells (Figure 27C). In contrast, only CENPA gene 
expression was reduced by silencing of FoxM1 (Figure 27C). In light of the growing 
number of studies showing a pivotal role of FoxM1 in execution of mitotic programme, 
we extended our studies to include 5 additional mitotic genes that were reportedly 
activated by FoxM1 (Laoukili et al., 2005; Wang et al., 2005), in order to fully 
characterize the role of FoxM1 in regulating mitotic genes in cervical carcinoma cells. 
Transcription of 3 of these new genes was indeed down-regulated by FoxM1 silencing, 
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namely CDC25B, NEK2 and PLK1, while all other genes were more effectively 
repressed by silencing B-Myb alone (Figure 27D). When both transcription factors were 
silenced together by co-expression of the relevant siRNAs, the level of transcriptional 
repression achieved for these mitotic genes was comparable to that obtained by 
silencing B-Myb alone (Figure 27C). These data indicated a dominant role for 
transcription factor B-Myb in regulating this set of mitotic genes in cervical carcinoma 






































































Figure 27. B-Myb or FoxM1 knockdown dampens mitotic gene expression. 
(A, B) Efficiency of siRNA silencing of FoxM1 and B-Myb in Caski cells as measured 
by Western blot (A) and quantitative real-time PCR (B). Data shown are derived from 
three-independent experiments and are presented as the mean±sd. 
(C) Caski cells were transfected with siRNA targeting B-Myb and/or FoxM1. Cells 
were harvested 40h post transfection and were subjected to real-time PCR analyses 
using primers against mitotic genes including CENPA, ESPL1 and SPC25. Data shown 
are derived from three-independent experiments and are presented as the mean±sd. 
(D) Quantitative real-time PCR analyses were carried out to determine mRNA levels of 
FoxM1 target genes in Caski cells treated with siRNA to silence either B-Myb or 
FoxM1 for 40h. Data shown are derived from three-independent experiments and are 
presented as the mean±sd. 
(E) Graph here showed knockdown efficiency of siRNA against NF-YB and mRNA 
expression of mitotic genes upon silencing of NF-YB in Caski cells. Data shown are 





We then attempted to study whether gene depletion of E7, B-Myb and FoxM1 
would lead to any cell cycle defects. RNAi approach was employed in conjunction with 
thymidine treatment and flow cytometry to measure cell cycle profile of synchronized 
SiHa cells, an alternative HPV16-positive cervical carcinoma cell line, owing to the fact 
that Caski cells cannot be well-synchronized by thymidine treatment. Cells were pre-
incubated with thymidine-containing medium for 24 hours prior to siRNA treatment, so 
that stabilization of pRB following E7-depletion does not interfere with cell cycle 
progression to G2/M upon release from thymidine block. Cells were harvested at 0, 6 
and 13 hours after the release, which corresponded respectively to late G1/S, S/G2 and 
M/G1 phases (Figure 28A). Flow cytometry analyses confirmed that cells were 
synchronized correctly at their respective stages of the cell cycle (Figure 28B). 
Analyses of the cell cycle revealed that E7 induced a G2/M slow down detectable at 13 
hours after release of the thymidine block which was also observed upon silencing of 
FoxM1 or B-Myb (Figure 28B). These experiments showed implication of E7, B-Myb 
and FoxM1 in regulation of the M/G1 boundary in cervical carcinoma cells thus 
confirming the modulation of mitotic genes. We wondered whether modulation of 
mitotic genes by the two transcription factors in SiHa cells would be similar to that 
observed in Caski cells and hence transcription analyses were carried out in SiHa cells. 
E7-, B-Myb- and FoxM1-depleted cells exhibited the exact same phenotype, i.e. 
repression of mitotic genes that probably account for accumulation of cells with 4N 




























Figure 28. B-Myb or FoxM1 knockdown induces G2/M cycle arrest and repression of 
mitotic genes in SiHa cells. 
(A)  Timeline of cell cycle synchronization experiment in SiHa cells.  
(B) FACS profile of SiHa cell grown asynchronously or synchronized by double 
thymidine block and then released at indicated time points (0, 6, 13h). SiHa cells were 
transfected with siRNA targeting HPV16 E7 (16E7), B-Myb and FoxM1 prior to 
thymidine treatment. Flow cytometry analyses of cell cycle profiles 13h after cycle 






















(C) 16E7, B-Myb and FoxM1 were efficiently depleted by respective siRNA 
transfection. Data shown are derived from three-independent experiments and are 
presented as the mean±sd. 
(D)  Real-time PCR analysis of mitotic genes in B-Myb and/or FoxM1-depleted SiHa 











3.4 HPV16 E7 and B-Myb or FoxM1 synergistically activate mitotic 
gene transcription in primary human fibroblasts  
To be able to address direct role of E7 in cell cycle modulation, we constructed 
viral vectors carrying wild type E7 and E7 mutant lacking LXCXE pocket proteins 
binding motif (16E7M) for overexpression study of E7 in primary cells. Efficient 
expression of E7 was verified by qPCR analyses of E7 transcripts in infected cells, and 
the expression conditions were optimized to mimic endogenous levels of expression 
observed in Caski and SiHa cells (where E7 transcripts are expressed at ~16-18 cycles). 
Cells were harvested three days after infection and subjected to real-time PCR analyses 
to investigate expression of 7 cellular genes involved in late cell cycle mitotic control, 
namely AURKB, BUB1, CCNB1, CENPA, ESPL1, PLK4, and SPC25. Indeed, 
expression of full-length E7 causes a drastic induction of mitotic genes whereas E7 
mutant, whose ability to interact and degrade pRB was virtually abolished, was unable 
to elicit comparable level of gene activation (Figure 29A and 30A). From our results, it 
appeared that E7 mutant devoid of pRB binding domain was only capable of inducing 
2- to 3-fold activation of mitotic genes (Figure 29A). Another intriguing observation is 
that E7 mutant retained the ability to destabilize p130 proteins although it is incapable 
of inducing degradation of pRB (Figure 30A). Analysis of four S-phase genes, named 
CCNE1, CCNE2, MCM4 and POLA1, indicated that expression of wild-type E7 
induced a 5-20-fold increase in gene activity, whereas the mutated E7 elicited just a 2-


























Figure 29. Deletion of LXCXE motif abrogates HPV16 E7-mediated activation of cell 
cycle genes.  
(A) Primary human fibroblasts (PHF) were transduced with retroviral vectors encoding 
HPV16 E7 (16E7) or E7M lacking the LXCXE domain (16E7M). After 72h, fibroblasts 
were collected and subjected to qPCR analyses using specific primers for mitotic genes 
as indicated at the bottom of the graphs. Data shown are derived from three-independent 
experiments and are presented as the mean±sd. 
(B) Same experiment as in panel C was repeated using primers for S-phase genes. Data 






On the other hand, we also wished to elucidate further the transcriptional 
program governed by E7 and its putative collaboration with other mitotic transcription 
factors such as B-Myb and FoxM1 which are found to play a active role in mitotic 
genes modulation in cervical carcinoma cells. We therefore performed virus 
transduction to introduce B-Myb or FoxM1 into primary human fibroblasts to facilitate 
the functional study of these two transcription factors and investigate the potential 
cooperation that could exist between E7 and B-Myb or FoxM1 in transactivation of 
promoters of genes expressed in mitosis.  
It is important to highlight that E7-expressing fibroblasts exhibited decreased 
endogenous pRB and p130 pocket proteins, proving functionality of our over-expressed 
E7 in vitro (Figure 30A and 30B). However, protein expression of E7 mutant (16E7M) 
appears to be lower compared with that of wild type E7 because one of the 
commercialized antibodies against E7 (ED17 from Santa Cruz) fails to detect E7 mutant 
in western blot (Psyrri et al., 2004) (Figure 30A). We have also assessed status of 
endogenous pRB proteins in E7- or E7M-transduced fibroblasts and as expected the 
deletion of LXCXE motif completely abolished the ability of E7 to destabilize pRB. 
Expression of exogenous E7, B-Myb and FoxM1 proteins were shown in 
western blots (Figure 30B). Interestingly, a marked reduction in p130 protein levels was 
observed in B-Myb-transduced primary human fibroblasts (Figure 30B) and qPCR 
analyses revealed that B-Myb does not regulate p130 at transcript level (Figure 30C). It 
is plausible that elevated expression of B-Myb out-competed endogenous p130 
efficiently in binding to MuvB complex thereby accelerating degradation of free, 
unbound p130. In addition, high-risk HPV E7 is very efficient in targeting p130 for 
degradation and hence p130 protein was virtually absent in cells co-expressing E7 and 
B-Myb (Figure 30B).  
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Conversely, p130 protein levels seemed to be elevated in FoxM1-expressing 
primary human fibroblasts but transcript levels of p130 were not altered by 
overexpression of FoxM1 (Figure 30B and 30C). Nevertheless FoxM1-mediated p130 
stabilization is unable to counterbalance the efficient degradation of p130 by E7, co-
transduction of E7 and FoxM1 showed a strong decrease in p130 protein levels if 
compared to overexpression of FoxM1 alone (Figure 30B). Further investigations are 

















Figure 30. Status of pRB and p130 in primary human fibroblasts expressing HPV16 E7, 
HPV16 E7LXCXE (16E7M), B-Myb and FoxM1.  
(A) Western blot analysis of 16E7 and 16E7M expression (marked with red asterisk) 
and status of endogenous pRB in infected primary human fibroblasts.  
(B) Western blot analysis showing over-expression of E7, B-Myb and FoxM1 in 























(C) Transcript levels of pRB and p130 were detected by real-time PCR in fibroblasts 
expressing HPV16E7, B-Myb and/or FoxM1. Compensatory up-regulation of pRB 
mRNA level was seen in fibroblasts transduced with HPV16E7 whereas transcript level 
of p130 remained unchanged in response to overexpression of HPV16E7, B-Myb and/or 
FoxM1. Data shown are derived from three-independent experiments and are presented 



























Transduction of B-Myb into primary human fibroblasts led to activation of 
endogenous mitotic genes, albeit with less efficiency than E7 (Figure 31A). Co-
expression of both E7 and B-Myb induced co-operative activation of most of the genes 
studied in this panel (Figure 31A). Co-operative activation of the selected mitotic genes 
was also observed in cells that co-expressed wild type E7 and FoxM1 (Figure 31B).  
In contrast to mitotic genes, the transcription factors B-Myb and FoxM1 were 
poor activators of S-phase genes and did not give rise to co-operative activation when 
co-expressed with wild-type E7 (Figure 32A and 32B). The functional data presented 
here confirmed that B-Myb and FoxM1 are capable of activating mitosis in primary 
human fibroblasts and furthermore we observed that the activation becomes synergistic 
when E7 is co-expressed with one of these transcription factors.   
We were also interested to find out if E7 can activate expression of other cellular 
genes besides genes required for G2/M transition. Hence a panel of p63 target genes 
was assessed by real-time PCR but none of them was responsive to E7, B-Myb or 
FoxM1 overexpression, showing that the molecular cooperation between E7, B-Myb or 
FoxM1 is specific to promoters of genes with peak expression during G2 and M phase 































Figure 31. Co-expression of HPV16 E7 and B-Myb or FoxM1 induces co-operative 
activation of mitotic genes in primary human skin fibroblasts. 
(A) Primary human fibroblasts (PHF) were transduced with B-Myb and viral vectors 
encoding HPV16 E7 (16E7). After 72h, fibroblasts were collected and subjected to 
qPCR analyses using specific primers for mitotic genes as indicated at the bottom of the 
graphs. Data shown are derived from three-independent experiments and are presented 
as the mean±sd. 
(B) Same experiment as in panel C was repeated for FoxM1. Data shown are derived 





















Figure 32. Co-operativity between HPV16 E7 and B-Myb or FoxM1 does not exist in 
transcriptional regulation of S-phase genes and p63 genes.    
(A, B) Primary human fibroblasts (PHF) were infected by retroviruses expressing 
HPV16 E7 (16E7) and B-Myb (A) or FoxM1 (B). After 72h, fibroblasts were collected 
and subjected to qPCR analyses using specific primers for S-phase genes as indicated at 
the bottom of the graphs. Data shown are derived from three-independent experiments 




























(C) The bar graph showed expression profile of p63 target genes. None of these genes 
were modulated by ectopic expression of HPV16E7, B-Myb or FoxM1. Data shown are 

































3.5 HPV16 E7 increases G2/M cell population 
 
As expected from our transcriptional analyses, flow cytometry analyses revealed 
that expression of wild-type E7 together with B-Myb or FoxM1 propelled both the S 
and M phases of the cell cycle in transduced fibroblasts, indicating an acceleration of 
cell division compared with untreated control cells (Figure 33). Furthermore, cellular 
expression of E7 or B-Myb alone moderately increased the cumulative proportion of 
cells in S and G2/M phases (15% and 6% respectively compared with control cells), 
whereas E7+B-Myb induced a synergistic increase in these cell cycle phases (34%), 
thus confirming the co-operative induction of mitosis by E7 and B-Myb (Figure 33). 
Acceleration of the cell cycle was also detected in FoxM1-expressing cells, although 













Figure 33. A marked increase of cell population in S and G2/M was observed in 
primary human fibroblasts co-transduced with HPV16 E7 and B-Myb or FoxM1.  
Flow cytometry analyses of asynchronous primary human skin fibroblasts were 
conducted 72h post infection.  
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Cell cycle analyses showed that ectopic expression of E7 in primary human 
fibroblasts increased significantly the population of cells in S and G2/M phase, showing 
that E7 may plays an active role in promoting cell division. This data prompted us to 
analyse growth properties of the fibroblasts expressing E7 but we did not detect 
increase in cell proliferation despite marked elevation in the S-G2/M phases of the cell 
cycle (Figure 34). E7 overexpression gives rise to activation of p53 pathway, apoptosis 
and oncogene-induced senescence or replicative stress. It is plausible that E7-expressing 
fibroblasts have to overcome oncogenic stress induced by E7 before evolving into 
clones with selective growth advantage. Therefore fibroblasts expressing E7 are unable 
to outgrow control cells in the transient cell proliferation assays (Figure 34). Time-lapse 
imaging of the synchronized E7-transduced cells revealed high levels of mitotic-like 
cells accompanied by cell death that need further investigation to be fully interpreted 
(Figure 34). We noticed that a large fraction of E7-expressing cells failed to undergo 
proper cell divisions while control cells went through mitoses normally (Figure 35). 
Cells experiencing chromosomal aberrations are more prone to cell death and therefore 
it may explain why E7-transduced fibroblasts do not proliferate faster than control cells 
(Figure 34).  
 
Figure 34. HPV16 E7-expressing 
fibroblasts grow slower than control 
cells. 
Bar graph here showed doubling time 
of control and 16E7-transduced 
fibroblasts. Time taken for fibroblasts 
expressing E7 to divide is about two 
times more than that of control cells. 
Data shown are derived from three-
independent experiments and are 























Figure 35. Fibroblasts expressing HPV16 E7 fail to undergo mitoses normally. 
Time-lapse imaging of synchronized primary human fibroblasts expressing empty vector or E7. E7-expressing cells shrank and exhibited 








3.6 HPV16 E7 is recruited to mitotic gene promoters where B-Myb and 
FoxM1 act as transcription factors 
Using UCSC genome browser (genome.ucsc.edu), genomic sequences encompassing 
the transcriptional regulatory regions between -2000bp to +100bp of mitotic genes 
mentioned in previous section (Figure 29A) were extracted. We then proceeded to 
analyze the sequences by TFsearch analysis 
(www.cbrc.jp/research/db/TFSEARCH.html), a publicly accessible computational 
program for prediction of transcription factor binding sites. We found that putative 
binding sites of MYB and FOXM1 are highly enriched within promoter regions of 
mitotic genes included in Figure 29A. On the contrary, promoters of S-phase genes 
harbour more E2F binding sites but less MYB or FOXM1 cis-elements when compared 
with mitotic genes promoters (Figure 36A).  
 Functional data described earlier demonstrated a co-operative activation of 
mitotic genes by HPV16 E7 and B-Myb or FoxM1, and further identified a pRB-
independent role for E7 in the transcriptional control of mitotic genes. These findings 
strongly suggested that E7 either directly interacted with B-Myb or FoxM1 or could 
perhaps form transcriptional complexes with these molecules. Next we sought to 
determine if E7 possesses DNA-binding capacity to interfere directly with 
transcriptional regulatory machinery assembled at promoters of mitotic genes whose 
expression levels were altered in a B-Myb- or FoxM1-dependent manner (Laoukili et 
al., 2005; Wang et al., 2005). We designed primers targeting genomic sequences which 
are in close proximity to MYB or FOXM1 binding sites for chromatin 
immunoprecipitation (ChIP) assay in HeLa cells ectopically expressing Flag-tagged 
HPV16 E7 protein. Anti-Flag M2 antibodies (Sigma) was used to pull down DNA-
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protein complexes containing exogenous E7 proteins owing to unavailability of ChIP-
grade antibodies directed against endogenous HPV16 E7. ChIP coupled with real-time 
PCR analyses confirmed that E7 is actively recruited at the promoters of mitotic genes, 
namely AURKB, CDC25B, ESPL1, SPC25 but not at a control GAPDH promoter 
(Figure 36B). Therefore it was proposed that transcription factors B-Myb and FoxM1, 
which are actively recruited to specific sequences in mitotic gene promoters, were 













Figure 36. HPV16 E7 is recruited to promoters containing MYB and FOXM1 binding 
sites. 
(A) Genomic sequences encompassing transcriptional regulatory regions between  
-2000bp to +100bp were extracted from UCSC genome browser (genome.ucsc.edu) and 
then analyzed using TFsearch (www.cbrc.jp/research/db/TFSEARCH.html), a publicly 
accessible computational program for prediction of transcription factor binding site. The 
mitotic genes analysed harbour more putative binding sites of MYB and FOXM1 on 
average compared to that of E2F. On the contrary, E2F recognition sites often 


























(B) ChIP assays were performed using anti-Flag antibody with extracts from HeLa cells 
ectopically expressing Flag-tagged HPV16 E7. E7 was found to occupy promoters of 
several mitotic genes: AURKB, CDC25B, ESPL1 and SPC25. Relative occupancy 
values were calculated by determining the levels of immunoprecipitated DNA 
compared with that of the input samples, and were normalized to that of GAPDH. 
Histogram depicts fold enrichment of promoter sequences in immunoprecipitates with 
anti-flag antibodies compared with IgG pull-down samples. Data depicted represent the 




3.7 HPV16 E7 interacts with B-Myb and FoxM1 in nucleus 
 
The observation that a small oncoprotein E7 lacking both DNA binding domain and 
transactivation domain is able to associate with promoter of mitotic genes poses 
interesting mechanistic questions. It raised the possibility that the recruitment of E7 to 
target genes could be mediated via its interactions with B-Myb or FoxM1 transcription 
factors.  
We employed protein pull-down assays in HeLa cells co-transfected by vectors 
carrying wild type and mutant E7 lacking the LXCXE motif along with B-Myb or 
FoxM1 overexpression. To confirm the binding capacity of both wild-type and mutated 
E7, we first conducted protein pull-down assays with cell lysates containing E7 variants 
and p130 proteins. We performed IP for E7 and found coprecipitation with p130 but as 
expected the binding was completely abrogated by the deletion of LXCXE motif 
(Figure 37A).  
Next, lysates of HeLa cells expressing N-terminal Flag-tagged full-length or 
truncated E7 and B-Myb or FoxM1 proteins were immunoprecipitated with anti-Flag 
antibodies and immunoblotted with B-Myb or FoxM1 antibodies respectively (Figure 
37B and 37C). We found that wild type E7 was capable of associating strongly with 
both B-Myb and FoxM1. Nevertheless, it is interesting to note that E7 mutant was still 
able to bind B-Myb despite lacking LXCXE domain, in contrast, binding affinity to 
FoxM1 was dramatically diminished upon deletion of pRB binding site (Figure 37B and 
37C).  These data suggest that E7 might form a complex with both B-Myb and FoxM1 

























Figure 37. HPV16 E7 interacts with B-Myb and FoxM1 in nucleus.  
(A) Co-IP assay showed that wild type, full-length HPV16E7 interacts with p130  
whereas truncation of LXCXE domain completely abolishes association with p130.  
(B) Protein extracts from HeLa cells expressing Flag-tagged 16E7 or 16E7 deleted of 
the LXCXE domain (21-24) and B-Myb proteins were immunoprecipitated with Flag 
antibodies and then western blotted for B-Myb. The input controls (I) comprised 2% of 
the lysates used for immunoprecipitation. B-Myb can associate with both wild-type and 
mutant 16E7.  
(C) Same experiment as in (B) but with co-expression of 16E7 and FoxM1, which 




 We wished to examine the subcellular localization of HPV16 E7, B-Myb and 
FoxM1 in order to have a better understanding of where the protein complexes are 
predominantly formed. The immunofluorescent staining was done with antibodies 
specific to these proteins and counterstained nuclei with DAPI after 24 hours of 
transfection into the human bone cancer-derived cell line U2OS cells. Ectopically 
expressed B-Myb and FoxM1 were strictly localized in nucleus while E7 could be 
found throughout the cell although a relatively stronger nuclear staining was always 
seen in E7-expressing cells (Figure 37D). Co-transfection of plasmids encoding E7 and 
B-Myb or FoxM1 did not affect cellular distribution of these three proteins but we 
deduced that E7 interacts with B-Myb and FoxM1 within nuclear compartment due to 
the nuclear localization properties of B-Myb and FoxM1 (Figure 37D). Taken together, 
these data further support our postulation that HPV16 E7 is recruited to mitotic 
promoter in nucleus with assistance of transcription factors B-Myb and/or FoxM1 for 






























(D) E7 proteins are distributed throughout the cell, albeit with stronger staining in 
nucleus whereas the expressions of both B-Myb and FoxM1 are restricted in nuclear 
compartment. Immunofluorescence of U2OS cells co-transfected with E7 and B-Myb or 
FoxM1 revealed that the complexes formed by E7 and B-Myb or FoxM1 were 
predominantly found in nucleus, corroborating previous notion that E7 works in concert 





3.8 HPV16 E7, B-Myb and FoxM1 interact with the h/LIN9 component 
of the Myb-MuvB/DREAM complex  
B-Myb has been described as an important component of Myb-MuvB (MMB) activator 
complex, which is essential for mitotic gene activation during the cell cycle progression 
(Osterloh et al., 2007; Pilkinton et al., 2007b; Schmit et al., 2007) (Figure 21B). 
Therefore identification of B-Myb as a novel binding partner of E7 prompted us to 
investigate possible association between E7 and MuvB subcomplex. LIN9 is one of the 
members of MuvB core and it is regarded as representative of MuvB core in the 
following protein binding assays (Figure 21A). GFP-tagged LIN9 was co-transfected 
together with E7 and E7 mutant lacking pRB-binding motif in HeLa cells to facilitate 
the study of functional interplay between E7 and MMB activator complex. From this 
CoIP experiment we detected an interaction between wild type E7 and human LIN9 
which was strongly reduced in the absence of LXCXE motif (Figure 38A).    
We also confirmed strong binding affinity of B-Myb to human LIN9 proteins by 
CoIP, as well as a reciprocal stabilization of LIN9 and B-Myb proteins (Pilkinton et al., 
2007b) (Figure 38B). The B-Myb-LIN9 interaction served as a positive control in our 
co-immunoprecipitation assays. To ascertain whether there is crosstalk between 
FoxM1- and MMB-dependent gene regulatory networks, we decided to include FoxM1 
in CoIP assay. We co-transfected HeLa cells by FoxM1 and LIN9 constructs and found 
that FoxM1 was successfully co-precipated by LIN9 (Figure 38B). Based on this 
observation, we speculated that the recruitment of FoxM1 to the mitotic genes 
promoters could be mediated through MuvB core, a new finding that was confirmed by 





















Figure 38. HPV16 E7 and FoxM1 interact with the LIN9 component of the 
MuvB/DREAM complex.   
(A) Co-immunoprecipitation assays were conducted in HeLa cells co-transfected with 
HPV16 E7 wild-type or LXCXE deletion mutant (16E7Δ21-24) mutant and GFP-
tagged LIN9, showing that interaction of the wild type E7 with LIN9, reduced for the 
mutant.  
(B) Same experiments as in (A) but conducted in cells co-transfected with GFP-LIN9 
and Flag-tagged B-Myb as a positive control for interaction with LIN9, or with Flag-








The observation showing binding of FoxM1 to LIN9 encouraged us to further 
delineate the inter-relationship between FoxM1 and B-Myb to investigate whether they 
could be part of the same complex. CoIP results uncovered a novel interaction between 
FoxM1 and B-Myb, albeit with rather weak affinity (Figure 39A). This data led us to 
investigate the potential synergistic activity between B-Myb and FoxM1 in stimulating 
expression of mitotic genes. Neither additive nor synergistic effect on endogenous 
mitotic gene expression was observed in primary human fibroblasts transduced with 
both B-Myb and FoxM1 (Figure 39B). Nonetheless it is consistent with earlier findings 
showing the absence of an additive effect upon gene depletion of both B-Myb and 
FoxM1 in Caski cells (Figure 28C). Taken together, these experiments strongly 
suggested that B-Myb, FoxM1 and HPV16 E7 are part of the LIN9/DREAM 
transcriptional activator complex which drives mitotic gene transcription.  
To further understand the importance of MuvB core in mediating recruitment of 
E7 and its association with the DREAM activator complex, we decided to verify 
whether E7 could interact with B-Myb in the absence of LIN9. We have to highlight 
that LIN9 was overexpressed in these experiments in order to assess the silencing 
efficient of siRNA against LIN9 because none of commercially available LIN9 
antibodies could detect endogenous LIN9 proteins by western blot. CoIP experiments 
performed in cells treated by siRNA targeting LIN9 showed that the interaction between 
E7 and B-Myb was not strongly affected by gene depletion of LIN9 (Figure 40). CoIP 
findings described above revealed that LXCXE motif is not required for interaction 
between B-Myb and E7 but mediates the association of E7 with LIN9, indicating that 
E7 probably binds B-Myb and LIN9 via two different interacting domains (Figure 37B 
and 38A). Altogether, we confirmed that E7 is capable of interacting with B-Myb 
independently of LIN9. Additionally, co-precipitation of both LIN9 and B-Myb by E7 
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in the same protein extracts indicates that E7 could be present within B-Myb-MuvB 



















Figure 39. B-Myb and FoxM1 interact but do not activate mitotic genes in co-operative 
manner.  
(A) Proteins were extracted from HeLa cells transfected with Myc-tagged B-Myb and 
HA-tagged FoxM1 before being subjected to immunoprecipitation assay using anti-Myc 
antibodies. Myc-tagged HPV18 E6 was used as a negative control.  
(B) Transcript levels of mitotic genes were assayed by real-time PCR in fibroblasts 
transduced with B-Myb and/or FoxM1. B-Myb and FoxM1 did not modulate mitotic 
genes in a co-operative manner. Data shown are derived from three-independent 



















Figure 40. Silencing of LIN9 does not disrupt binding of HPV16 E7 to B-Myb.  
Cells were treated with siRNA against LIN9 for 24h and were transfected with Myc-
tagged B-Myb, GFP-LIN9 and Flag-tagged E7 HPV16. LIN9 gene silencing resulted in 
decreased B-Myb expression as well as decreased 16E7 binding to B-Myb, but these 
interactions were not abolished. Flag-RFP was used as a negative control and the strong 










Surprisingly, we also noticed that LIN9 itself was regulated in an E7-dependent 
manner and both E7 and B-Myb can up-regulate LIN9 transcript levels, although no 
cooperation was observed between these two proteins (Figure 41). It is conceivable that 
E7 forms a feed-forward amplification loop by driving both B-Myb and LIN9 














Figure 41. LIN9 transcription is activated by both HPV16 E7 and B-Myb in a non-
cooperative manner.  
Real time PCR analyses revealed that endogenous LIN9 is upregulated in E7- and/or B-
Myb-transduced fibroblasts using primers against human LIN9 after 3 days of retroviral 
infection. Data shown are derived from three-independent experiments and are 







3.9 Depletion of pRB and p130 does not modulate mitotic gene 
expression 
Our earlier observation demonstrated that LXCXE motif is required for both E7-driven 
mitotic gene expression and E7 binding to LIN9 (Figure 29A and 38A).  These results 
led us to question whether pRB or pRB-related pocket protein p130, which is a key 
binding partner of MuvB core in mammalian cells (Figure 21B), plays a pivotal role in 
activation of mitotic genes induced by E7. Gene silencing via siRNA against pRB or 
vectors expressing p130 shRNA was carried out in primary human skin fibroblasts and 
pRB- or p130-silenced cells were harvested 2 days post treatment. Knockdown of pRB 
in primary human fibroblasts did not cause any changes in mitotic gene expression, 
while in contrast the S-phase genes were substantially activated in pRB-depleted cells 
(Figure 42A). On the contrary, gene knockdown of p130 led to mild increase in 
transcript level of S-phase genes and substantial elevation of mitotic gene expression. 
This data suggests that a decrease in p130 level promotes formation of MuvB-Myb 
activator complex, resulting in transcriptional upregulation of mitotic genes (Figure 
42B). Depletion of pRB and p130 therefore does not mimic E7-induced stimulation of 
mitotic genes, suggesting that E7 exerts direct regulatory effect on mitotic gene 
promoters independently of pRB or p130.  
This data also corroborates our earlier findings demonstrating that co-depletion 
of pRB and E7 are not sufficient to completely relieve transcriptional repression of 
mitotic genes in Caski cells (Figure 26B). It is possible that direct involvement of E7 in 
MMB-dependent transcriptional regulation of genes governing G2-M transition is more 
important than pRB/E2F regulatory axis to drive cell cycle progression, thereby 
providing an additional different mechanism for acquisition of growth advantage of 


























Figure 42. HPV16 E7 activates mitotic gene expression independently of pRB or p130. 
(A, B) Gene depletion of pRB or p130 was performed on primary human fibroblasts for 
2 days followed by real time PCR analyses. Data shown are derived from three-




3.10 Overlaps between transcriptomes of HPV16 E7- and B-Myb-
expressing fibroblasts are enriched for mitotic genes  
Our findings above depicted E7 as a strong inducer of mitotic genes and showed that E7 
exerts regulatory effect directly on promoters of mitotic genes in collaboration with B-
Myb/FoxM1/MuvB activator complex. To reaffirm the role of E7 in dysregulation of 
cell cycle network, especially the transcriptional program governing mitotic gene 
expression, we decided to perform a genome-wide transcriptomes in human primary 
fibroblasts expressing E7. We generated gene expression profiles from four independent 
replica experiments for each sample using Illumina’s BeadArray Technology. The data 
obtained from microarray analyses corroborate and extend previous notion that a large 
cluster of mitotic genes are potently activated by E7. Notably, LIN9 was found among 
the E7-modulated genes thus confirming our earlier findings (Figure 41). Interestingly, 
comparative analyses revealed a huge overlap of mitotic genes between E7-transduced 
fibroblasts (activated genes) and E6E7-repressed Caski cells (repressed genes), thus 
substantiating our findings of a strong and specific mitotic pathway modulated by E7. 
Venn diagram clearly depicted an overlap of 213 genes, among which 126 are involved 
in cell cycle progression whereas 106 genes are functionally linked to G2-M transition 
as listed in Table 2 (Figure 43 and Table 3).  
On the other hand, we have conducted the transcriptome analyses of B-Myb 
modulated genes in primary human fibroblasts in order to get comparative analyses with 
that of E7. As expected, the B-Myb transcriptome presented a robustly activated mitotic 
pathway that is highly similar to the E7 transcriptome. We compared transcriptome 
analyses of B-Myb and E7 and discovered that the overlapping genes are highly 
enriched for cell cycle genes (159), including 132 genes with known mitosis function 
and 60 genes involved in S-phase (Figure 44 and Table 4). Collectively, microarray 
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analyses strongly corroborate our previous notion that B-Myb and E7 converge and co-
operate to up-regulate common target genes as a consequence of activator complex 
























Figure 43. HPV16 E7 activates large sets of genes controlling mitotic progression. 
Venn diagram showed that a total of 975 genes were activated >2-fold by E7 expressed 
in primary human fibroblasts compared with control cells in four different replica 
experiments with p-value<0.01. Comparison analyses of genome-wide expression 
profiles of E7-depleted Caski cells and E7-transduced primary human fibroblasts 
identified an overlap of 213 genes, among which 106 are mitotic genes whereas there 








Table 3: Lists of M- and S-phase genes within intersect between genes repressed in 
E6E7-depleted Caski cells and genes activated in E7-expressing primary human 
fibroblasts. 
 
Overlap between E2 and E7 








BRCA1 CDC7  






































































































































































Figure 44. Overlap between gene expression profiles of HPV16 E7- and B-Myb-
transduced fibroblasts is highly enriched for mitotic genes. 
Only genes that showed >2-fold of activation between cells expressing E7 and/or B-
Myb and control samples in four independent replicate experiments with p-value<0.01 
were included in the area shaded in light red which is the colour scheme representing B-
Myb. We compared genome-wide expression profiles of genes activated by E7 and B-
Myb. Intersection of these two data sets, which contains common target genes of E7 and 
B-Myb, were further analysed with Ingenuity Pathway analysis and it is highly enriched 
for mitotic genes. As shown in Venn diagram, we found a total of 132 genes involved in 










Table 4: Lists of M- and S-phase genes within intersect between genes activated by E7 
or B-Myb in primary human fibroblasts. 
 
Overlap between E7 and B-Myb 
















































































































































Chapter 4: Discussion and Perspectives 
 
4.1 HPV16 E7 regulates mitotic genes in a pRB-independent manner 
 
pRB, a tumour suppressor protein as well as gatekeeper of G1-S transition, is 
known as the best-characterized target of oncogenic E7. It was documented that HPV16 
E7 interacts with Cullin 2, an E3 ubiquitin ligase and serves as a substrate-specific 
component which mediates efficient targeting of pRB for proteosomal degradation (Huh 
et al., 2007). Nonetheless not only high-risk HPV E7, other viral proteins such as 
adenoviruses E1A and SV40 Large T Antigen also hijack cell cycle regulation 
machinery by inactivating pRB to promote cellular proliferation that favours viral 
genome replication and viability of infected cells and play a critical role in carcinogenic 
progression. The role of E7 in regulation of S-phase genes through pRB/E2F pathway 
has been extensively documented and our results demonstrating robust induction of S-
phase genes by E7 transduction are in line with previous studies as well (Figure 30B, 
43, and Table 3). However a growing number of reports indicated that the ability of E7 
to interact with cellular proteins other than pRB also contributes significantly to its 
transforming capacity (Balsitis et al., 2006). For instance, E7 is able to override cell 
cycle arrest imposed by cyclin/CDK inhibitors, p21CIP1 or p27KIP1 through 
abrogation of the interaction between cyclin E/CDK2 and their inhibitors (Funk et al., 
1997; Zerfass-Thome et al., 1996). This oncogenic property of E7 renders the 
differentiating keratinocytes unresponsive to increased levels of p21 and p27, thereby 
further exacerbating growth of infected cells.  
Our present knowledge regarding the function of E7 is limited to its role as a 
potent inducer of S-phase genes. However our group demonstrated for the first time that 
a large set of mitotic genes was also dominantly regulated by E7 in HPV18-associated 
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cervical cancer cell lines and this observation was then validated in a HPV16-associated 
cervical carcinoma cell line (Figure 25A) (Teissier et al., 2007). It is important to 
highlight that the approach described above resulted in simultaneous silencing of E6 
and E7 due to the fact that both viral genes are encoded by a single polycistronic 
mRNA. Hence we investigated the impact of p53 on cell cycle gene expression using 
RNAi against E6AP, an E3 ubiquitin ligase specifically targeting p53, to restore 
endogenous, wild type p53 expression in Caski cells but it failed to induce substantial 
modulation of cell cycle genes compared to cells co-depleted of both E6 and E7. Based 
on previously published work and current data, we confirmed a vital role of E7 in cell 
cycle dysregulation and uncovered an E7-driven but pRB-independent event required 
for G2/M gene expression (Figure 26B).  
Despite an established role in stimulation of S-phase entry, the contribution of 
E2F activities to activation of genes expressed in mitosis remains controversial. Elkon 
et al. revealed that most mitotic genes do not harbour consensus E2F binding sites 
(Elkon et al., 2003). However, a research report indicated that some important genes 
with peak expression at G2/M such as CDK1 and cyclin B1, contain E2F-responsive 
elements which allows E2F activators to be recruited in conjunction with B-Myb to 
activate their gene expression (Zhu et al., 2004). Interestingly, Sadasivam and 
colleagues have recently performed de novo motif analysis of promoter regions of 
mitotic genes and detected a significant enrichment of B-Myb, FoxM1 and NF-Y 
binding sites instead of E2F-responsive sequences to confirm previously published data 
by Elkon et al. (Sadasivam et al., 2012). B-Myb, FoxM1 and NF-YB whose expression 
is regulated in E2F-dependent manner, are key players in regulation of mitotic genes. 
Moreover, E7 itself is capable of destructing E2F4/p107 repressive complex formed at 
promoter of B-Myb, leading to deregulated overexpression of B-Myb (Lam et al., 
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1994). These evidences led to postulation that B-Myb, FoxM1 and NF-YB act 
downstream of E7/E2F pathway to elicit activation of mitotic genes. We could validate 
this hypothesis by RNA interference to explore biological functions of these three 
transcription factors in regulation of mitotic genes in HPV-associated cell lines. Indeed, 
B-Myb and FoxM1 are important regulators of G2/M genes and neither additive nor 
synergistic effect exists between these two transcription modulators for G2/M gene 
expression in cells experiencing dual silencing or co-expression of B-Myb and FoxM1 
(Figure 27C and 39B). However NF-YB does not appear to be essential for G2/M gene 
expression because none of the selected mitotic genes was markedly regulated upon 
gene knockdown of NF-YB (Figure 27E). Taken together, these data suggest that B-
Myb and FoxM1 are the dominant activators of mitotic gene expression and they could 
converge on the same transcriptional regulatory pathway in cervical cancer cells. 
A wide spectrum of chromatin-associated proteins and transcription regulators, 
for examples E2F1, E2F6, Mi2 (a component of HDAC complex), HAT including p300 
and pCAF, AP1, general transcriptional machinery such as TFIID, were demonstrated 
to be the binding partners of high-risk HPV E7 proteins (Hwang et al., 2002; 
(McLaughlin-Drubin et al., 2008; Brehm et al., 1999; Avvakumov et al., 2003; Bernat 
et al., 2003; Antinore et al., 1996; Mazzarelli et al., 1995; Massimi et al., 1996). For 
example, Lüscher-Firzlaff and his group showed that FoxM1-dependent transactivation 
is enhanced by concurrent recruitment of E7 and FoxM1 to promoter bearing FoxM1-
responsive elements via in vitro luciferase reporter assay (Lüscher-Firzlaff et al., 1999). 
Besides acting as a co-activator, E7 can also exert opposing effect on transcription 
factors exemplified by E2F6, to impinge on transcriptional repression of cellular genes. 
E2F6 is known as an important component of polycomb group protein (PcG)-containing 
repressive complex and hence overexpression of E7 severely impaired formation of 
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E2F6-associated PcG repressive bodies (McLaughlin-Drubin et al., 2008). All these 
findings raise the possibility that E7 itself can be recruited on promoters and act as a co-
regulator for transcriptional modulation of B-Myb- or FoxM1-inducible G2/M genes. 
We examined this possibility by introduction of E7, B-Myb and FoxM1 into primary 
human skin fibroblasts via retroviral-mediated transduction system. Interestingly, co-
operative activation of mitotic genes by E7 plus B-Myb or FoxM1 was detected (Figure 
31A and 31B) while in contrast S-phase genes were not further activated upon co-
expression of E7 with B-Myb or FoxM1 (Figure 32A and 32B). It is important to 
highlight that the co-operative effect was lost when wild-type E7 was replaced by E7 
mutant lacking LXCXE domain. Therefore we do not rule out the possibility that pRB 
and/or pRB-binding motif is essential for co-operation between E7 and B-Myb/FoxM1 
although our earlier findings implied that stimulation of mitotic genes does not entirely 
rely on a regulatory axis containing E2F and pRB (Figure 26B and 42).  
 
4.2 Promoter occupancy by HPV16 E7 
 
Given the reports showing interactions of E7 with multiple chromatin-modifying 
proteins and transcription factors, we have assessed whether E7 could interact with 
regulatory region through chromatin immunoprecipitation (ChIP) assay. The 
precipitated DNA fragments then subjected to real-time PCR analyses using pre-
designed primers against mitotic gene promoters. Prior to primer design, we have first 
conducted analyses for prediction of transcription factor binding motif using a publicly 
accessible computational program, TFSEARCH 
(www.cbrc.jp/research/db/TFSEARCH.html) and our results corroborated recent 
findings indicating that consensus binding sites of B-Myb and FoxM1 are highly 
enriched within transcriptional regulator regions of mitotic genes (Figure 36A; 
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Sadasivam et al., 2012).  It was once again confirmed that B-Myb and FoxM1 rather 
than E2F are dominant regulators for mitotic gene expression. Thus primers used in 
ChIP were designed to amplify genomic regions in close proximity to putative binding 
sites of B-Myb or FoxM1. ChIP for ectopically expressed E7 with a FLAG epitope tag 
at N-terminal end unveiled a novel association of E7 with promoters of selected B-
Myb- or FoxM1-regulated genes, supporting the notion that E7 could be directly 
implicated in regulation of G2/M genes (Figure 36B).  
However, our ChIP data is insufficient to elucidate the precise mechanism by 
which E7 is recruited to G2/M gene regulatory regions. Therefore it is necessary to 
perform genome-wide ChIP-sequencing in order to map E7 binding sites in an 
unambiguous way. We also plan to combine ChIP with cell cycle synchronization 
experiments to address the question whether the recruitment of E7 is regulated in a cell 
cycle-dependent manner as our data strongly suggest. Furthermore, siRNA-mediated 
gene depletion assays should be conducted in conjunction with ChIP to study whether 
B-Myb or FoxM1 serves as an indispensable platform for association of E7 with 
chromatin whereas sequential ChIP using first the B-Myb or FoxM1 antibodies 
followed by the E7 antibodies would enable us to determine whether these three 
proteins can co-occupy target gene promoters. A recent study discussed a co-existence 
of B-Myb and FoxM1 on G2/M gene promoters and it led us to anticipate that E7 could 
be present within this regulatory complex containing both B-Myb and FoxM1 in HPV-
associated cervical cancer cells (Sadasivam et al., 2012; Down et al., 2012).  
 
4.3 Functional association between HPV16 E7, B-Myb and FoxM1 
 
Notwithstanding, E7 is a relatively small protein of approximately 15kDa. It is 
structurally simple and does not contain any DNA binding domain or transactivation 
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domain, which are the common features of most transcription factors in mammalian 
cells. Hence it poses interesting question of how E7 is capable of exerting a regulatory 
effect on transcription of mitotic genes. Additionally, E7, B-Myb and FoxM1 share 
common interaction partners, p300 and CBP that are always found associated with 
transcription factors and act positively on gene expression. These findings encouraged 
us to conduct CoIP assay to investigate the possible binding of E7 to B-Myb and 
FoxM1. In this study, we identified B-Myb as a novel interactor of E7 (Figure 37B) and 
a LXCXE domain-dependent association between E7 and FoxM1 (Figure 37C), which 
is consistent with a previous work done by Lüscher-Firzlaff’s group (Lüscher-Firzlaff et 
al., 1999).  At the end of March 2012, two papers were published on the topic of a new 
functional relationship between B-Myb and FoxM1 within the same MuvB complex 
(Sadasivam et al., 2012; Down et al., 2012). Concurrently, we successfully 
demonstrated that FoxM1 could be co-precipitated by B-Myb, however, neither additive 
nor synergistic effect exists between these two transcriptional modulators for G2/M 
gene expression in cells experiencing dual silencing or co-expression of B-Myb and 
FoxM1 (Figure 39A, 27C, 39B). Our data further elucidated that E7 could not further 
affect or alter the functional relationship between B-Myb and FoxM1 because no 
additive effect was observed upon siRNA-mediated gene silencing of B-Myb and/or 
FoxM1 using a E7-expressing cervical cancer cell line, Caski cells (Figure 27C). B-
Myb and FoxM1 recognize distinct sequence motifs but majority of their target genes 
described to date exhibit similar cellular functions, for instance, regulation of G2/M 
transition, mitosis and cytokinesis. Therefore, it was anticipated that B-Myb pre-
occupies promoters of G2/M genes to induce the local enrichment of p300/CBP, which 
in turn strongly enhances transactivating capacity of FoxM1 and B-Myb itself by direct 
acetylation. Moreover, p300 and CBP causes local nucleosomal modification, thereby 
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allowing DNA to be more accessible for other chromatin-modifying factors and 
transcription factors. On the other hand, FoxM1 binds DNA via AT-rich consensus 
sequences that highly resemble TATA-box but it was reported that FoxM1 interacts 
weakly with its corresponding cis-elements (Littler et al., 2010). We believed that 
binding of B-Myb to its consensus binding sites signals an additional level of specificity 
for FoxM1 recruitment. It was also supported by a recent work showing that promoter 
occupancy by B-Myb is required for subsequent FoxM1 binding to promoters because 
FoxM1 failed to associate with target gene promoters in the absence of B-Myb (Down 
et al., 2012). Interestingly, in addition to B-Myb, another member of Myb gene family, 
C-Myb, possesses the ability to act in synergy with FoxM1 to positively regulate 
proliferation in germinal center (Lefebvre et al., 2010).  Collectively, it is conceivable 
that a novel interplay between B-Myb and FoxM1 ensures temporal specificity and 
transcription efficiency of genes required for mitosis. Thus we can speculate that the 
binding of E7 to their complex is able to further augment transcriptional capacity of B-
Myb and FoxM1, leading to aberrant cell cycle progression and proliferation in cervical 
cancer.  
 
4.4 Role of MuvB core in HPV16 E7-driven stimulation of mitotic 
genes 
B-Myb forms an activator complex, termed Myb-MuvB (MMB) with MuvB 
core for stimulation of G2/M gene expression. MuvB consists of five components, 
namely LIN9, LIN37, LIN52, LIN54, and RBBP4 and it is described as the core 
subcomplex of mammalian DREAM complex (Figure 21A). Besides B-Myb and MuvB 
core components, DP1 (TFDP1), p130 (RBL2), E2F4 and E2F5 can also be found in 
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this DREAM complex. Mammalian DREAM complex composition is highly dynamic 
and regulated in a cell cycle-dependent manner. During G0 or quiescence, MuvB core is 
predominantly associated with E2F4 or E2F5 and p130 to form a repressive complex on 
E2F-regulated promoters but DREAM transcriptional repressor complex disassembles 
owing to degradation of p130 when cells progress into G1 phase. Litovchick and 
colleagues also revealed that more than 800 cell cycle genes were bound by DREAM 
repressor complex during G0 (Litovchick et al. 2007). At late G1 phase, E2F activators 
trigger expression of B-Myb which in turn interacts with MuvB subcomplex to elicit 
activation of genes responsible for G2-M transition. Previously published literature, 
ChIP data, together with observation that majority of mitotic genes were repressed upon 
gene knockdown of B-Myb support the role of B-Myb-MuvB complex as a key 
transcriptional activator of G2/M genes (Osterloh et al. 2007; Knight et al. 2009; 
Sadasivam et al., 2012). Our data further establish this point by showing direct 
activation of mitotic genes by B-Myb and FoxM1 overexpression in primary cells 
(Figure 31A and 31B and 44 and Table 4). 
Given the central role of MuvB core in regulation of cell cycle genes, we have 
examined the possible interaction between E7 and LIN9, the best studied component of 
MuvB complex. As evidenced by our CoIP experiments, LIN9 was co-precipitated by 
E7 although the binding affinity was drastically reduced upon deletion of pRB binding 
domain of E7 (Figure 38A).  Very recently and during the course of the present work, 
role of MuvB core in cell cycle regulation has been further elucidated and it was 
reported for the first time that MuvB core serves as a functional platform for sequential 
recruitment of B-Myb and FoxM1 to mitotic gene promoters (Sadasivam et al., 2012; 
Down et al., 2012). It is noteworthy that the association between FoxM1 and LIN9, 
which is regarded as a representative of MuvB subcomplex, was also identified in our 
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present study (Figure 38B). In light of the findings above, we propose that MuvB core 
functions as a pioneer factor that guides recruitment of E7 to target promoters where B-
Myb and FoxM1 are in close proximity. Conversely, our CoIP experiments showed that 
binding of E7 to B-Myb was unaffected by LIN9-depletion (Figure 40). Thus we 
concluded that LIN9 is not an obligatory factor for the association of E7 with B-Myb. 
Nevertheless we cannot draw the conclusion that E7 binding to target promoters is 
mainly mediated by B-Myb rather than FoxM1 or MuvB core unless similar 
experiments were also conducted for FoxM1 and other MuvB components including 
LIN37, LIN52, LIN54 and RBBP4. While our experiments document the functional 
interaction between E7, LIN9, B-Myb and FoxM1, it is yet unclear how and when this 
multiprotein complex is formed. We cannot exclude the possibility that additional 
interacting partners could also aid in recruiting E7 to G2/M gene promoters. To unravel 
the molecular complexity of this B-Myb-MuvB complex in E7-expressing cervical 
cancer cells, it would be very useful to perform mass spectrometry in combination with 
RNA interference against different constituents of the complex. 
Nor Rashid and colleagues have recently investigated the difference in 
composition of DREAM complex between non HPV- or HPV-associated cervical 
cancer cells. They found that DREAM repressor complex comprising E2F4 or E2F5 
and p130 is readily disrupted and nearly inexistent in Caski or SiHa cells expressing 
HPV16 (Nor Rashid et al., 2011). It is because E7-mediated disassembly of this 
DREAM repressor complex from the S-phase genes is allowing E2F to activate them. 
Concurrently this activity of E7 liberates MuvB core, favouring the formation of Myb-
MuvB complex. Intriguingly, we observed that overexpression of B-Myb induced a 
marked decrease in p130 protein levels (Figure 29A). We deduced from the observation 
that B-Myb outcompetes p130 binding to MuvB complex and consequently induces an 
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acceleration of degradation of unbound form of p130. Taken together, expression of E7 
both disrupts the repressive DREAM complex, thus derepressing S-phase genes (Nor 
Rashid et al., 2011) and interacts with the MuvB activator complex to activate M-phase 
gene in our postulated model (Figure 45).  
 
4.5 Functional similarities between low-risk and high-risk E7 in 
activating mitotic genes 
During keratinocyte differentiation, the cells are maintained in G0 where p130 
levels are elevated to favour the formation of DREAM repressor complex, dampening 
the expression of E2F-responsive genes. Hence the ability of E7 to degrade p130 
counterbalances its upregulation in order to retain proliferative capacity of HPV-
infected keratinocytes despite presence of negative growth signals due to differentiation 
program. It is noteworthy that the property of targeting p130 for proteasomal 
degradation is conserved between low-risk and high-risk E7, implying that this shared 
ability is crucial for viral genome replication and viability of infected cells (Zhang et 
al., 2006).  
Low-risk HPV E7 proteins bind poorly to pRB with affinity that is 
approximately ten-fold weaker than that of high-risk E7, although this interaction is 
inadequate to induce degradation of pRB (Gage et al., 1990; Munger et al., 1989b). 
Apart from the association with pRB or p130, there are some other functional 
similarities between high-risk and low-risk E7. For examples, A 600kD pRB-associated 
factor, p600, has also been identified as a common binding target of both high-risk and 
low-risk E7 and it was documented that E7 works in concert with p600 in a pRB-
independent manner to promote anchorage-independent growth and inhibit anoikis in 
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order to drive cellular transformation (Huh et al., 2005). High-risk and low-risk E7 are 
both capable of up-regulating EZH2 expression (Holland et al., 2008). EZH2 is 
described as a histone methyl transferase and a key component of Polycomb Repressive 
Complex 2 (PRC2). Hence E7-induced overexpression of EZH2 gives rise to increased 
PRC4 complex formation and a change in histone modification, resulting in pro-
proliferative and anti-apoptotic responses (Kuzmichev et al., 2005). These E7 activities 
are conserved across low-risk and high-risk viruses, showing that all these properties 
may contribute significantly to virus life cycle.  
However, despite these common interactions, little functional similarities are 
shared between high-risk and low-risk E7 and low risk HPVs do not cause malignant 
transformation due to the fact that low-risk E7 has very low transforming capacity 
compared with high-risk E7 (Sang & Barbosa, 1992). In contrast to high-risk HPVs, 
low-risk HPV genomes never integrate into host genome and are unable to induce 
tumourigenesis owing to a lack of oncogenic viral genes.  For instance, low-risk HPV6 
and HPV11, are etiologic agents of benign genital warts, which are also called 
condyloma acuminata. Condyloma acuminata are generally characterized by 
hyperproliferation of the keratinocytes located in anogenital area upon low-risk HPV 
infection. Therefore we envisioned that the ability of E7 to induce dynamic changes in 
DREAM complex composition is mainly correlated with the hyperproliferative state of 
condyloma acuminata. We found that low-risk E7 proteins probably bind promoters of 
the MMB complex and associate with LIN9, B-Myb and FoxM1 in the same way as 
observed for high-risk E7 proteins (Toh et al., unpublished data).  
It is therefore plausible that both low-risk and high-risk E7 induce aberrant cell 
cycle progression and proliferation through hijacking MMB activator complex. This 
postulated model is especially crucial for low-risk E7 since it lacks the ability to bypass 
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the pRB-mediated G1/S checkpoint. However, more work needs to be done to verify if 
the interaction with MMB complex is sufficient to cause hyperproliferation of epithelial 
cells infected by low-risk HPVs. Hence samples containing exogenously expressed low-
risk E7 proteins should be included in both chromatin immunoprecipitation (ChIP) and 
CoIP experiments to ascertain whether the novel function of HPV type 16 (HPV16) E7 
described in our current study exists consistently across low-risk and high-risk viruses. 
On the other hand, microarray analyses have been done with both low-risk and high-risk 
E7 and showed activation of many common mitotic target genes (Toh et al., 
unpublished data). These global approaches will allow us to establish the similarities 
and differences between low-risk and high-risk E7 in transcriptional regulation of 
cellular genes and identify novel pathways regulated by E7. In conclusion, it raises the 
possibility that the new function of HPV16 E7 described in this thesis is conserved in 
low-risk HPV11 and HPV6 E7 proteins. This new finding clearly identifies common 
proliferative function that is important for the development of therapeutic intervention 
to combat both HPV-associated diseases and cancers.  
 
4.6 Relationship between HPV16 E7-induced epigenetic aberrations 
and cervical carcinogenesis 
Having established the recruitment of E7 to DNA as well as an interaction with 
transcriptional activator complex in our study, we then could address whether E7 is able 
to induce chromatin remodeling at promoters where E7-associated MMB activator 
complex is formed. Previous studies indicated that E7 is involved in up-regulation of 
two histone demethylases, KDM6A and KDM6B, at the level of transcription. It was 
reported that elevated levels of KDM6A and KDM6B in E7-expressing cells account 
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for a drastic reduction in histone H3 lysine 27 trimethylation (H3K27me3), which is an 
epigenetic mark required for the recruitment of Polycomb Repressive Complex (PRC) 
to transcriptionally silence target genes (McLaughlin-Drubin et al., 2011; Schwartz et 
al., 2007). Notably, PRC-mediated silencing results in repression of p16INK4A, a 
CDK4/6 inhibitor, and Homeobox (HOX) genes whose deregulation is often linked to 
angiogenesis, epithelial-to-mesenchymal transition (EMT) and carcinogenesis (Serrano 
et al., 1997; Shah et al., 2010). Thus abrogation of H3K27me3-mediated gene 
repression by E7 is a critical event in cervical cancer initiation to elicit aberrant 
proliferation and cellular transformation. In addition to the induction of DNA 
demethylases, E7 can directly interact with Mi2, a constituent of histone deacetylases 
(HDAC) NURD complexes.  Sequestration of Mi2 by E7 may cause derepression of 
genes responsible for cell cycle progression, favouring cell growth (Brehm et al., 1999).  
Besides E7, it was suggested that LIN9 induces epigenetic alteration in mouse 
embryonic fibroblasts (MEF) because trimethylation of histone H3 lysine 4 (H3K4me3) 
was dramatically diminished in the absence of LIN9. It is important to highlight that 
H3K4me3 is essentially linked to transcriptional activation, implying that LIN9 
recruitment could be critical to prepare the promoter for transcriptional activation 
mediated by B-Myb and FoxM1. However, to date, no one described the association of 
LIN9 or MMB complex with chromatin modifying enzymes. Altogether, we postulated 
a possible role of E7 and MMB complex in modifying local chromatin structure and this 
activity could be a vital prelude to transactivation of G2/M gene promoters. Recently a 
growing body of evidences established the relationship between epigenetics and cancer 
progression. Generally, in cancer cells, promoters of genes encoding tumour 
suppressors are silenced via hyper-methylation whereas global hypo-methylation occurs 
in early stages of malignancy (Kelly et al., 2010). Therefore new insights into 
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epigenetic status of HPV-associated cervical cancer cells are pivotal for the 
development of epigenetic therapies with specificity to target and reverse E7-induced 
epigenetic aberrations, thereby minimizing adverse drug reactions.  
 
4.7 Self-amplifying feed-forward loop involving HPV16 E7, LIN9, B-
Myb and FoxM1 
The present study reveals an interesting regulatory loop in mitotic gene activation in 
E7-expressing cells. E7 is able to subvert negative growth signals by directing pRB for 
ubiquitin-mediated proteolysis and hence liberating E2F activators, which in turn 
stimulate genes involved in G1-S transition. B-Myb and FoxM1 were previously 
identified as E2F-regulated genes whose expression is markedly upregulated upon E7-
mediated destabilization of pRB. Also, it was documented that E7 directly contributes 
to deregulated expression of B-Myb in cervical cancer cells by disrupting p107/E2F 
repressive complex formed on B-Myb promoter (Lam et al., 1994). It is noteworthy that 
B-Myb binds its own promoter via Sp1-binding sites and acts as a positive regulator to 
self-activate its expression (Nicolaides et al., 1991; Sala et al., 1999). B-Myb forms a 
complex with MuvB core to potently activate genes with peak expression in G2 and M 
phase. A work done by Pilkinton and his group showed that LIN9, a key component of 
MuvB subcomplex, stabilizes the expression of B-Myb post-transcriptionally and a 
similar but reciprocal relationship between LIN9 and B-Myb was also observed in our 
CoIP assay (Pilkinton et al., 2007b; Figure 38B).  
Furthermore, in this report, we demonstrated for the first time that E7 elicited 
elevated expression of endogenous LIN9 at transcription level (Figure 41). Intriguingly, 
transcript levels of LIN9 were also up-regulated by B-Myb (Figure 41) but the 
 137 
observation showing the absence of additive effect upon simultaneous transduction of 
E7 and B-Myb raised the possibility that E7 and B-Myb may converge on a linear 
pathway for transactivation of LIN9 promoter (Figure 41). Taken together, we propose 
that a positive feed-forward regulatory loop involving E7, LIN9, B-Myb and FoxM1 
could further amplify the formation of an activating E7-containing DREAM complex 












Figure 45. Schematic representation of the feedforward loop involving HPV16 E7, 
LIN9, B-Myb and FoxM1. 
 
4.8 Possible impacts of HPV16 E7-MMB interaction on mitosis 
 
E6 and E7 oncoproteins can cooperate to induce cervical carcinogenesis but they are 
insufficient for cellular transformation and additional oncogenic events, such as 
chromosome aberrations, are required to further promote malignant progression. 
Genomic instability is characterized as hallmark of most human malignancies, including 
HPV-associated squamous cervical carcinoma (SCC). A series of recent papers have 
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demonstrated that E7 possesses the ability to impede mitotic spindle checkpoint through 
direct protein-protein interaction with centrosomal proteins and kinetochore complexes. 
For instance the property of E7 to cause delocalization of dynein from mitotic spindles 
is mediated through binding to nuclear and mitotic apparatus protein-1 (NuMA) 
(Nguyen and Munger, 2009). NuMA and dynein are pivotal for establishment of 
epithelial polarity and therefore it was suggested that E7 hijacks NuMA/dynein 
networks in purpose to perturb normal stratification process of epithelium, favouring 
expansion of infected basal cells for viral genome amplification and persistence of 
infection. In addition to NuMA, it was documented that the association of E7 with γ-
tubulin via sequences that overlap with LXCXE motif, accounts for a dramatic 
reduction in the amount of γ-tubulin recruited to mitotic spindles, thereby leading to 
centrosomal abnormalities. The interaction between E7 and γ-tubulin is a pRB-
independent event, although pRB-binding motif of E7 is essential for the binding 
(Nguyen et al., 2007).  
Another study also highlighted that E7 mutant lacking LXCXE motif is not able 
to cause defects in centrosome duplication in pRb−/− p107−/− p130−/− (TKO) MEFs, 
indicating that pRB-binding domain of E7 is crucial for other oncogenic functions, apart 
from mediating interaction with pocket proteins (Duensing and Munger et al., 2003).  
 Similarly, in our report, we revealed that LXCXE motif of E7 is necessary for 
activation of mitotic genes and binding of E7 to LIN9 and FoxM1 but pRB or p130 
pocket proteins are not involved in the incorporation of E7 into MMB complex (Figure 
29A, 37A, 36C and 41). This model is supported by previous findings that documented 
the absence of pRB in both DREAM repressor complex and MMB activator complex 
(Litovchick et al., 2007). By conducting mass spectrometry analysis, researchers 
revealed that MuvB core could associate with p107 but not pRB when p130 expression 
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is greatly diminished upon siRNA treatment (Litovchick et al. 2007; Pilkinton et al. 
2007a; Schmit et al. 2007). Collectively, these data favour the hypothesis that an intact 
LXCXE motif is important to mediate an efficient binding of E7 to LIN9 and 
recruitment to promoters of MMB-regulated genes. Also, these studies raise the 
possibility that this LXCXE motif-dependent mechanism may contribute to E7-induced 
chromosome aberrations in pocket protein-deficient cells.  
In mitosis, transcription of cellular genes is generally repressed and hence 
transcription activators are only allowed to stimulate expression of genes implicated in 
spindle checkpoint, kinetochore assembly and cytokinesis during late S to G2 phase. 
Expression of mitotic genes, such as aurora kinase B (AURKB) and polo-like kinase 4 
(PLK4), has to be regulated in a temporally restricted manner in order to ensure proper 
mitosis and centrosome duplication. For example, deregulated expression of PLK4 
gives rise to abnormalities in centriole number because PLK4 acts as a key regulator of 
centrosome duplication. Therefore MMB activator complex plays a pivotal role in 
regulating mitosis and maintaining genomic integrity. We postulated that the genomic 
instability observed in E7-expressing cells is partly accounted for by the ability of E7 to 
dysregulate MMB-dependent transcriptional program controlling expression of mitotic 
genes. In support with our notion, a recent study indicated that E7-induced 
transcriptional activation of PLK4, which was also identified in the present study, is 
responsible for centriole multiplication (Korzeniewski et al., 2011). Furthermore, 
overexpression of mitotic genes, including AURKB, BUB1, CENPA and PLK4 whose 
expression are robustly activated by E7 in our study (Figure 29A), are always associated 
with a variety of mitotic defects in human cancers and correlate with poor clinical 
prognosis. In line with previous statements, by performing time-lapse imaging, we 
showed that E7-expressing cells failed to undergo cell division normally and seemed to 
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shrink or exhibit necrotic-like morphology repeatedly while control cells went through 
normal mitoses (Figure 35). As expected, cells experiencing mitotic abnormalities were 
more vulnerable to cell death and this may explain why E7-expressing cells cannot 
outgrow control cells in transient proliferation assay (Figure 34). We speculated that 
cells expressing E7 may gradually become resistant to cellular defense mechanism 
against E7-mediated oncogenic activities because we observed that cells that were 
selected to express E7 and resisted to cell death proliferate much faster than normal 
cells after 2-3 passages. However, whether the direct interaction of E7 with the MMB 
activator complex is linked to the E7's reported role in inducing chromosome instability, 
remains to be determined (Duensing and Munger, 2002a, b). We will conduct 
immunofluorescence studies using antibodies against γ-tubulin to indicate localization 
and number of centrosomes to ascertain whether the novel interplay between E7 and 
MMB activator complex gives rise to a more severe genomic instability phenotype. In 
addition, both E7 and B-Myb have been shown to perturb the formation of the mitotic 
spindle (Duensing and Munger, 2002a, b; Yamauchi et al., 2008). Hence we do not rule 
out the possibility that both E7 and B-Myb are localized to mitotic spindle and work in 
cooperation to impinge on spindle assembly checkpoint through direct association with 






























Figure 46: Previously reported and proposed role of HPV16 E7 in cell-cycle 
dysregulation.  
The oncogenic properties of E7 to hijack different transcriptional programs associated 
with cell cycle progression are summarized in this schematic diagram. Previous findings 
demonstrated the abilities of E7 to degrade p130 and pRB and thus leading to 
derepression of S-phase genes. In this report, we have shown that E7 binds G2/M gene 
promoters and interacts with LIN9, B-Myb and FoxM1. This postulated mechanism was 
speculated to account for E7-induced transcriptional activation of mitotic genes.      
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Chapter 5: Conclusions 
 
The impact of E7 on cell cycle progression has historically only been attributed to its 
ability to overcome pRB-mediated G1/S checkpoint, hence stimulating expression of 
genes required for DNA replication and proliferation. Nevertheless, a previous work 
from our lab showing that a cluster of mitotic genes was modulated significantly in an 
E7-dependent manner has led us to investigate the mechanism underlying 
transcriptional activation of mitotic genes in HPV-associated cervical cancer cells. In 
the present study, we unveiled a novel pRB-independent role of E7 in regulating mitotic 
gene expression. We determined that E7 is recruited directly to promoters of B-Myb or 
FoxM1 targets and this is probably mediated through the interactions with B-Myb, 
FoxM1 and LIN9. Notwithstanding, we are uncertain whether E7-driven activation of 
mitotic gene expression gives rise to uncontrolled cell cycle progression because E7-
expressing cells are not able to outgrow control cells in the transient cell proliferation 
assays. It is plausible that cells expressing E7 need to counteract negative growth 
signals induced by oncogenic stress before evolving into clones with selective growth 
advantage. In addition, it remains to be understood if the functional interplay between 
E7 and B-Myb/FoxM1/LIN9 activator complex contribute significantly to chromosomal 
instability, which is commonly associated with precancerous cervical neoplasia.  
Taken together, we concluded that high-risk HPV infection leads to aberrant cell 
cycle progression by interfering with a multitude of host transcriptional regulatory 
machinery. Apart from rendering the cells resistant to cell differentiation cues by 
destabilizing p130, a component of mammalian DREAM repressor complex, in this 
thesis, we postulated that E7 hijacks mammalian DREAM activator complex at G2 
phase as well to further augment transactivation capacity of B-Myb and FoxM1, thereby 
leading to uncontrolled cell proliferation and chromosomal aberrations. Next, this 
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project provides an insight into a novel role and functional significance of mammalian 
DREAM complex during cervical carcinogenesis. Our findings also raise the possibility 
that additional cellular factors may contribute to transcriptional regulation of the mitotic 
genes and hence it is scientifically important to have deeper understanding on 
underlying basis of the highly complex regulatory circuit implicated in activation of 
mitotic gene expression. The combination of the results from these assays showed that 
E7 plays a pivotal role in triggering deregulated cell proliferation of cervical carcinoma 
cells. Further experiments are required to determine whether disruption of its ability to 
bind B-Myb/FoxM1/LIN9 activator complex within transcriptional regulatory region of 
mitotic genes could be developed as a possible anti-tumoural treatment for HPV-
positive cervical carcinoma patients.  
In conclusion, future investigation directed at dissecting the mechanism 
controlling the regulation of cellular gene transcription in E7-expressing cells should 
provide a better understanding of how deregulation of this system leads to malignant 
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Gene ID Entrez Gene Name Fold Change 
ALG10 asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase homolog (S. pombe) -1.978 
ALG10B asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase homolog B (yeast) -1.970 
ANKRD32 ankyrin repeat domain 32 -1.607 
ANLN anillin, actin binding protein -2.322 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B -2.406 
ARHGAP11A Rho GTPase activating protein 11A -3.043 
ARHGAP11B Rho GTPase activating protein 11B -2.445 
ARHGAP19 Rho GTPase activating protein 19 -1.976 
ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 -1.675 
ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6 -1.680 
ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) -1.930 
ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) -2.922 
ATAD2 ATPase family, AAA domain containing 2 -1.994 
ATAD5 ATPase family, AAA domain containing 5 -1.989 
ATL3 atlastin GTPase 3 -1.735 
AURKA aurora kinase A -2.513 
AURKB aurora kinase B -2.400 
BARD1 BRCA1 associated RING domain 1 -1.875 
BIRC5 baculoviral IAP repeat containing 5 -2.555 
BLM Bloom syndrome, RecQ helicase-like -2.385 
BRCA1 breast cancer 1, early onset -2.282 
BRCA2 breast cancer 2, early onset -2.365 
 168 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 -1.833 
BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) -3.201 
BUB1B budding uninhibited by benzimidazoles 1 homolog beta (yeast) -2.696 
C10orf119 minichromosome maintenance complex binding protein -1.616 
C10orf78 SWI5-dependent recombination repair 1 -1.678 
C11orf82 chromosome 11 open reading frame 82 -2.346 
C12orf48 chromosome 12 open reading frame 48 -2.157 
C13orf34 bora, aurora kinase A activator -2.082 
C14orf106 MIS18 binding protein 1 -1.926 
C14orf145 centrosomal protein 128kDa -2.119 
C15orf23 chromosome 15 open reading frame 23 -1.903 
C15orf42 chromosome 15 open reading frame 42 -2.145 
C17orf104 chromosome 17 open reading frame 104 -1.812 
C18orf54 chromosome 18 open reading frame 54 -2.223 
C19orf40 chromosome 19 open reading frame 40 -1.705 
C21orf45 MIS18 kinetochore protein homolog A (S. pombe) -1.656 
C4orf21 chromosome 4 open reading frame 21 -2.007 
C4orf46 chromosome 4 open reading frame 46 -1.614 
C5orf34 chromosome 5 open reading frame 34 -2.164 
C5orf54 chromosome 5 open reading frame 54 -1.735 
C9orf84 chromosome 9 open reading frame 84 -1.990 
CASC5 cancer susceptibility candidate 5 -2.596 
CBX5 chromobox homolog 5 -1.621 
CCDC111 coiled-coil domain containing 111 -1.617 
CCDC150 coiled-coil domain containing 150 -1.913 
CCDC18 coiled-coil domain containing 18 -1.748 
CCDC77 coiled-coil domain containing 77 -1.655 
CCDC88C coiled-coil domain containing 88C -1.831 
CCNA2 cyclin A2 -2.510 
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CCNB1 cyclin B1 -2.666 
CCNB2 cyclin B2 -2.736 
CCNF cyclin F -1.851 
CDC20 cell division cycle 20 homolog (S. cerevisiae) -2.422 
CDC25B cell division cycle 25 homolog B (S. pombe) -1.782 
CDC25C cell division cycle 25 homolog C (S. pombe) -2.199 
CDC45 cell division cycle 45 homolog (S. cerevisiae) -1.926 
CDC6 cell division cycle 6 homolog (S. cerevisiae) -1.653 
CDC7 cell division cycle 7 homolog (S. cerevisiae) -1.775 
CDCA2 cell division cycle associated 2 -2.240 
CDCA3 cell division cycle associated 3 -2.381 
CDCA5 cell division cycle associated 5 -1.998 
CDCA7L cell division cycle associated 7-like -1.639 
CDCA8 cell division cycle associated 8 -2.281 
CDK1 cyclin-dependent kinase 1 -2.952 
CDKN3 cyclin-dependent kinase inhibitor 3 -2.846 
CENPA centromere protein A -2.464 
CENPE centromere protein E, 312kDa -2.735 
CENPF centromere protein F, 350/400kDa (mitosin) -2.871 
CENPH centromere protein H -2.235 
CENPI centromere protein I -2.929 
CENPJ centromere protein J -1.770 
CENPK centromere protein K -2.086 
CENPL centromere protein L -1.902 
CENPN centromere protein N -2.164 
CENPO centromere protein O -1.909 
CENPQ centromere protein Q -1.795 
CEP110 centriolin -1.693 
CEP152 centrosomal protein 152kDa -1.943 
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CEP55 centrosomal protein 55kDa -2.690 
CEP78 centrosomal protein 78kDa -1.715 
CHAF1A chromatin assembly factor 1, subunit A (p150) -1.755 
CIT citron (rho-interacting, serine/threonine kinase 21) -2.491 
CKAP2 cytoskeleton associated protein 2 -2.021 
CKAP2L cytoskeleton associated protein 2-like -2.214 
CKS1B CDC28 protein kinase regulatory subunit 1B -1.927 
CKS2 CDC28 protein kinase regulatory subunit 2 -1.999 
CLSPN claspin -2.069 
CNTLN centlein, centrosomal protein -1.688 
CNTNAP1 contactin associated protein 1 -1.627 
CSNK1G1 casein kinase 1, gamma 1 -1.977 
CTCFL CCCTC-binding factor (zinc finger protein)-like -2.060 
CTDSPL2 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase like 2 -1.680 
CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 -1.600 
DBF4 DBF4 homolog (S. cerevisiae) -1.738 
DBF4B DBF4 homolog B (S. cerevisiae) -1.656 
DCK deoxycytidine kinase -1.625 
DCLRE1A DNA cross-link repair 1A -1.792 
DCLRE1B DNA cross-link repair 1B -1.852 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 -1.742 
DDX12 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 -1.818 
DEPDC1 DEP domain containing 1 -3.476 
DEPDC1B DEP domain containing 1B -2.620 
DHFR dihydrofolate reductase -1.885 
DIAPH3 diaphanous homolog 3 (Drosophila) -2.193 
DLEU2 deleted in lymphocytic leukemia 2 (non-protein coding) -1.631 
DLGAP5 discs, large (Drosophila) homolog-associated protein 5 -2.848 
DNA2 DNA replication helicase 2 homolog (yeast) -1.980 
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DPY19L2P2 dpy-19-like 2 pseudogene 2 (C. elegans) -1.689 
DSCC1 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) -1.876 
DTL denticleless homolog (Drosophila) -1.805 
DUT deoxyuridine triphosphatase -1.608 
E2F2 E2F transcription factor 2 -1.672 
E2F8 E2F transcription factor 8 -1.626 
ECT2 epithelial cell transforming sequence 2 oncogene -1.971 
EME1 essential meiotic endonuclease 1 homolog 1 (S. pombe) -2.027 
EMP2 epithelial membrane protein 2 -1.634 
ERCC6L excision repair cross-complementing rodent repair deficiency, complementation group 6-like -2.615 
ERI1 exoribonuclease 1 -1.631 
ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) -2.276 
ESPL1 extra spindle pole bodies homolog 1 (S. cerevisiae) -2.146 
EXO1 exonuclease 1 -2.227 
EXOSC8 exosome component 8 -1.640 
FAM111A family with sequence similarity 111, member A -1.738 
FAM111B family with sequence similarity 111, member B -1.928 
FAM54A family with sequence similarity 54, member A -2.402 
FAM72D family with sequence similarity 72, member D -3.682 
FAM83D family with sequence similarity 83, member D -2.021 
FANCA Fanconi anemia, complementation group A -1.709 
FANCB Fanconi anemia, complementation group B -2.202 
FANCD2 Fanconi anemia, complementation group D2 -2.433 
FANCE Fanconi anemia, complementation group E -1.645 
FANCI Fanconi anemia, complementation group I -2.217 
FANCM Fanconi anemia, complementation group M -1.789 
FBXO5 F-box protein 5 -2.269 
FIGNL1 fidgetin-like 1 -1.861 
FKBP5 FK506 binding protein 5 -1.836 
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FLJ44896 FLJ44896 protein -1.856 
FOXM1 forkhead box M1 -2.158 
G2E3 G2/M-phase specific E3 ubiquitin protein ligase -1.939 
GAS2L3 growth arrest-specific 2 like 3 -2.723 
GBX1 gastrulation brain homeobox 1 -1.873 
GEN1 Gen endonuclease homolog 1 (Drosophila) -1.928 
GINS1 GINS complex subunit 1 (Psf1 homolog) -1.930 
GINS2 GINS complex subunit 2 (Psf2 homolog) -1.882 
GINS4 GINS complex subunit 4 (Sld5 homolog) -1.758 
GNB4 guanine nucleotide binding protein (G protein), beta polypeptide 4 -1.734 
GPSM2 G-protein signaling modulator 2 -2.022 
GSG2 germ cell associated 2 (haspin) -1.660 
GTSE1 G-2 and S-phase expressed 1 -2.402 
H2AFZ H2A histone family, member Z -1.627 
HAT1 histone acetyltransferase 1 -1.644 
HAUS4 HAUS augmin-like complex, subunit 4 -1.927 
HAUS8 HAUS augmin-like complex, subunit 8 -1.846 
HIST1H1A histone cluster 1, H1a -1.659 
HIST1H1B histone cluster 1, H1b -2.301 
HIST1H1E histone cluster 1, H1e -1.817 
HIST1H2AB histone cluster 1, H2ae -2.299 
HIST1H2AE histone cluster 1, H2ae -1.688 
HIST1H2AI histone cluster 1, H2ag -1.682 
HIST1H2BF histone cluster 2, H2be -2.129 
HIST1H2BH histone cluster 1, H2bh -1.844 
HIST1H2BL histone cluster 1, H2bl -1.645 
HIST1H2BM histone cluster 1, H2bm -2.633 
HIST1H3A histone cluster 1, H3a -1.698 
HIST1H3B histone cluster 1, H3a -2.228 
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HIST1H3D histone cluster 1, H3a -1.799 
HIST1H3F histone cluster 1, H3a -2.159 
HIST1H3G histone cluster 1, H3a -2.301 
HIST1H4B histone cluster 1, H4a -1.716 
HIST1H4C histone cluster 1, H4a -1.826 
HIST1H4L histone cluster 1, H4a -1.719 
HIST2H2AB histone cluster 2, H2ab -1.866 
HIST2H3A histone cluster 2, H3c -1.855 
HIST2H3D histone cluster 2, H3c -1.714 
HJURP Holliday junction recognition protein -2.609 
HMGB2 high mobility group box 2 -2.338 
HMGN2 high mobility group nucleosomal binding domain 2 -1.761 
HMMR hyaluronan-mediated motility receptor (RHAMM) -3.097 
HOOK1 hook homolog 1 (Drosophila) -1.705 
INCENP inner centromere protein antigens 135/155kDa -1.609 
IQGAP3 IQ motif containing GTPase activating protein 3 -2.680 
IRX4 iroquois homeobox 4 -1.670 
ITGB3BP integrin beta 3 binding protein (beta3-endonexin) -1.864 
KCNK5 potassium channel, subfamily K, member 5 -1.625 
KCNS1 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 -1.611 
KIAA0101 KIAA0101 -2.134 
KIAA1524 KIAA1524 -2.362 
KIAA1712 centrosomal protein 44kDa -1.696 
KIF11 kinesin family member 11 -2.661 
KIF14 kinesin family member 14 -2.859 
KIF15 kinesin family member 15 -2.619 
KIF18A kinesin family member 18A -2.012 
KIF18B kinesin family member 18B -1.848 
KIF20A kinesin family member 20A -3.487 
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KIF20B kinesin family member 20B -2.456 
KIF22 kinesin family member 22 -1.806 
KIF23 kinesin family member 23 -2.416 
KIF24 kinesin family member 24 -1.699 
KIF2C kinesin family member 2C -2.622 
KIF4A kinesin family member 4A -3.032 
KIF4B kinesin family member 4B -2.698 
KIFC1 kinesin family member C1 -2.534 
KLHL35 kelch-like 35 (Drosophila) -2.066 
KNTC1 kinetochore associated 1 -1.764 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) -1.871 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) -1.896 
LMNB1 lamin B1 -2.268 
LOC100130433 uncharacterized LOC100130433 -1.683 
LY75 lymphocyte antigen 75 -1.969 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) -2.314 
MASTL microtubule associated serine/threonine kinase-like -2.232 
MCM10 minichromosome maintenance complex component 10 -1.904 
MCM2 minichromosome maintenance complex component 2 -1.616 
MCM4 minichromosome maintenance complex component 4 -1.663 
MCM7 minichromosome maintenance complex component 7 -1.717 
MCM8 minichromosome maintenance complex component 8 -1.727 
MEI1 meiosis inhibitor 1 -2.321 
MELK maternal embryonic leucine zipper kinase -2.285 
MIR15B microRNA 16-1 -2.156 
MKI67 antigen identified by monoclonal antibody Ki-67 -2.610 
MLF1IP MLF1 interacting protein -2.229 
MMP13 matrix metallopeptidase 13 (collagenase 3) -2.365 
MMS22L MMS22-like, DNA repair protein -2.042 
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MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) -2.082 
MNS1 meiosis-specific nuclear structural 1 -2.080 
MOV10L1 Mov10l1, Moloney leukemia virus 10-like 1, homolog (mouse) -2.500 
MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) -1.744 
MTBP 
Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) binding protein, 
104kDa -1.936 
MYBL1 v-myb myeloblastosis viral oncogene homolog (avian)-like 1 -1.683 
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 -1.943 
NCAPD2 non-SMC condensin I complex, subunit D2 -2.184 
NCAPG non-SMC condensin I complex, subunit G -2.595 
NCAPG2 non-SMC condensin II complex, subunit G2 -2.224 
NCAPH non-SMC condensin I complex, subunit H -2.848 
NDC80 NDC80 kinetochore complex component homolog (S. cerevisiae) -3.060 
NEFH neurofilament, heavy polypeptide -1.653 
NEIL3 nei endonuclease VIII-like 3 (E. coli) -2.765 
NEK2 NIMA (never in mitosis gene a)-related kinase 2 -2.865 
NRM nurim (nuclear envelope membrane protein) -1.689 
NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 -1.726 
NUF2 NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) -2.962 
NUP37 nucleoporin 37kDa -1.751 
NUSAP1 nucleolar and spindle associated protein 1 -2.328 
OCLN occludin -1.799 
ODC1 ornithine decarboxylase 1 -2.725 
OIP5 Opa interacting protein 5 -2.029 
OLR1 oxidized low density lipoprotein (lectin-like) receptor 1 -1.645 
ORC1 origin recognition complex, subunit 1 -1.888 
ORC6 origin recognition complex, subunit 6 -1.936 
OTUD7A OTU domain containing 7A -1.936 
OVOS ovostatin 2 -2.490 
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PBK PDZ binding kinase -2.855 
PDZK1 PDZ domain containing 1 -1.793 
PEG10 paternally expressed 10 -2.163 
PER3 period homolog 3 (Drosophila) -1.823 
PHF19 PHD finger protein 19 -1.859 
PIF1 PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae) -1.647 
PKMYT1 protein kinase, membrane associated tyrosine/threonine 1 -2.142 
PLEKHG4 pleckstrin homology domain containing, family G (with RhoGef domain) member 4 -1.661 
PLK1 polo-like kinase 1 -2.835 
PLK4 polo-like kinase 4 -3.187 
POC1A POC1 centriolar protein homolog A (Chlamydomonas) -1.621 
POLA1 polymerase (DNA directed), alpha 1, catalytic subunit -1.642 
POLA2 polymerase (DNA directed), alpha 2 (70kD subunit) -1.607 
POLD1 polymerase (DNA directed), delta 1, catalytic subunit 125kDa -1.639 
POLD3 polymerase (DNA-directed), delta 3, accessory subunit -1.664 
POLE polymerase (DNA directed), epsilon -1.651 
POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit) -1.954 
POLQ polymerase (DNA directed), theta -2.400 
PPIL5 leucine rich repeat protein 1 -1.846 
PRC1 protein regulator of cytokinesis 1 -2.728 
PRIM1 primase, DNA, polypeptide 1 (49kDa) -2.327 
PRR11 proline rich 11 -2.280 
PSIP1 PC4 and SFRS1 interacting protein 1 -1.618 
PSMC3IP PSMC3 interacting protein -1.856 
PSRC1 proline/serine-rich coiled-coil 1 -1.770 
PTTG1 pituitary tumor-transforming 1 -1.869 
RACGAP1 Rac GTPase activating protein 1 -2.419 
RACGAP1P Rac GTPase activating protein 1 pseudogene -1.923 
RAD21 RAD21 homolog (S. pombe) -1.612 
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RAD51 RAD51 homolog (S. cerevisiae) -1.973 
RAD51AP1 RAD51 associated protein 1 -2.360 
RAD54B RAD54 homolog B (S. cerevisiae) -1.700 
RAD54L RAD54-like (S. cerevisiae) -2.113 
RAD9B RAD9 homolog B (S. pombe) -1.946 
RBL1 retinoblastoma-like 1 (p107) -1.992 
RECQL RecQ protein-like (DNA helicase Q1-like) -1.856 
RECQL4 RecQ protein-like 4 -1.656 
RFC3 replication factor C (activator 1) 3, 38kDa -2.029 
RFC4 replication factor C (activator 1) 4, 37kDa -1.866 
RFC5 replication factor C (activator 1) 5, 36.5kDa -1.757 
RIBC2 RIB43A domain with coiled-coils 2 -1.724 
RMI1 RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae) -1.906 
RNASEH2A ribonuclease H2, subunit A -1.831 
RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5 -1.779 
RRM1 ribonucleotide reductase M1 -1.754 
RRM2 ribonucleotide reductase M2 -2.109 
SASS6 spindle assembly 6 homolog (C. elegans) -1.822 
SCLT1 sodium channel and clathrin linker 1 -1.615 
SCYL3 SCY1-like 3 (S. cerevisiae) -2.097 
SFMBT1 Scm-like with four mbt domains 1 -1.742 
SGOL1 shugoshin-like 1 (S. pombe) -2.373 
SGOL2 shugoshin-like 2 (S. pombe) -2.094 
SHCBP1 SHC SH2-domain binding protein 1 -2.493 
SKA1 spindle and kinetochore associated complex subunit 1 -2.472 
SKA3 spindle and kinetochore associated complex subunit 3 -2.330 
SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 8 -1.669 
SLC16A14 solute carrier family 16, member 14 (monocarboxylic acid transporter 14) -1.611 
SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 -1.642 
 178 
SLC29A1 solute carrier family 29 (nucleoside transporters), member 1 -1.644 
SLC41A2 solute carrier family 41, member 2 -1.995 
SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 -1.624 
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 -1.982 
SLFN13 schlafen family member 13 -2.058 
SMC1B structural maintenance of chromosomes 1B -2.829 
SMC2 structural maintenance of chromosomes 2 -2.174 
SMC4 structural maintenance of chromosomes 4 -1.920 
SPAG5 sperm associated antigen 5 -2.629 
SPC24 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) -1.732 
SPC25 SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) -2.467 
STAG3 stromal antigen 3 -3.480 
STIL SCL/TAL1 interrupting locus -2.083 
TACC3 transforming, acidic coiled-coil containing protein 3 -2.115 
TCF19 transcription factor 19 -1.975 
TEX15 testis expressed 15 -1.922 
TIMELESS timeless homolog (Drosophila) -2.168 
TK1 thymidine kinase 1, soluble -1.857 
TLR1 toll-like receptor 1 -1.895 
TMEM194A transmembrane protein 194A -2.152 
TMEM209 transmembrane protein 209 -1.758 
TMEM48 transmembrane protein 48 -1.737 
TMEM56 transmembrane protein 56 -1.614 
TMEM71 transmembrane protein 71 -1.931 
TMPO thymopoietin -1.919 
TOP2A topoisomerase (DNA) II alpha 170kDa -2.345 
TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) -2.236 
TRAIP TRAF interacting protein -1.779 
TRIM59 tripartite motif containing 59 -1.905 
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TRIP13 thyroid hormone receptor interactor 13 -2.110 
TROAP trophinin associated protein (tastin) -2.347 
TTF2 transcription termination factor, RNA polymerase II -1.768 
TTK TTK protein kinase -3.109 
UBE2C ubiquitin-conjugating enzyme E2C -2.398 
UBE2T ubiquitin-conjugating enzyme E2T (putative) -1.963 
UHRF1 ubiquitin-like with PHD and ring finger domains 1 -1.776 
UNG uracil-DNA glycosylase -1.764 
USP1 ubiquitin specific peptidase 1 -1.699 
VIT vitrin -1.600 
VRK1 vaccinia related kinase 1 -1.826 
WDHD1 WD repeat and HMG-box DNA binding protein 1 -1.870 
WDR62 WD repeat domain 62 -1.602 
WDR76 WD repeat domain 76 -2.199 
WEE1 WEE1 homolog (S. pombe) -1.989 
XRCC2 X-ray repair complementing defective repair in Chinese hamster cells 2 -2.479 
ZNF273 zinc finger protein 273 -1.602 
ZNF473 zinc finger protein 473 -1.792 
ZWILCH Zwilch, kinetochore associated, homolog (Drosophila) -1.825 
ZWINT ZW10 interactor -1.829 
 
 
 
 
